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CHAPTER 1 
Introduction 
1.1. Background 
Selective aliphatic C-H functionalization under mild conditions is a significant 
challenge in the scientific community, and is still an active area of research due to its 
importance in the chemical industry.1,2 Natural abundance of hydrocarbons, mainly 
alkanes, in the form of natural gas and oil, make such transformations of great interest. 
Though the oxidation of C-H to C-OH is a thermodynamically favorable process with 
high enthalpy of reaction, the lack of proper reagents and inertness of hydrocarbons 
toward chemical transformations make it difficult to perform in a selective and efficient 
manner. Oxidants like KMnO4 or K2Cr2O7 are costly, not green and unselective, while 
environmentally friendly and cheap oxidants like O2 or H2O2 are highly inefficient with 
extremely poor yields. Also, most cases require harsh reaction conditions like high 
temperature and pressure.  
Given these challenges, it is interesting that nature performs C-H to C-OH 
reactions catalytically and efficiently with the help of metal-containing enzymes, termed 
metalloenzymes.3-5 A few examples of metalloenzymes involved in oxidative 
transformations are cytochrome P450, methane monooxygenases (MMO), catechol 
monooxygenases and Rieske dioxygenases. Most of these enzymes contain metal ions 
in their active sites and use bioavailable oxidants such as O2 or H2O2 to oxidize 
molecules. Inspired by nature, scientists started using Fe complexes as catalysts to 
oxidize organic substrates in combination with O2 or H2O2.6-8 Even though, these 
reactions caused C-H oxidation of organic molecules to alcohols, the product obtained 
  
2 
were further prone to oxidative transformations like C-OH → C=O. Moreover, these 
transformations were not selective. Thorough mechanistic investigation in these 
reactions led to the postulation that hydroxyl radical (OH•) is the key active species 
responsible for oxidation. The oxidation reaction with Fe(II) and H2O2 is termed Fenton 
chemistry (Scheme 1.1).9 Though this chemistry has been well studied over decades 
and looks simple, there is still debate on the nature of active oxidant responsible for 
oxidation in such transformation.6,10-12  
 
Scheme 1.1. Fenton chemistry 
To overcome the issue of selectivity and better understand the properties and 
reactivities of iron centers at enzymes active sites, researchers started making synthetic 
model complexes of heme-containing enzymes, specifically cytochrome P450, the well-
established and well studied heme-enzyme involved in various oxidative 
transformations.13,14 
1.2. Heme ligands 
1.2.1. Heme-enzymes in oxidation 
Heme-containing enzymes catalyze a diverse array of chemical reactions in 
biology.15  The most important among them is the oxidation reaction. A few examples of 
heme-enzymes involved in oxidative transformations are cytochrome P450 (CP450), 
secondary amine monooxygenase (SAMO), indoleamine 2,3-dioxygenase (IDO) and 
tryptophan 2,3-dioxygenase (TDO). CP450 catalyzes the hydroxylation of organic 
Fe(II) + H2O2 Fe(III) + OH- + OH
Fe(II) + OH Fe(III) + OH-
OH- + H+ H2O
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substrates,14 SAMO catalyzes the oxidative dealkylation of secondary amines to 
aldehydes and primary amines,16,17 and IDO and TDO both catalyze the conversion of 
L-tryptophan to N-formylkynurenine.18,19 They all contain heme prosthetic groups with 
iron bound to four nitrogen atoms from porphyrin ring (Figure 1.1), with the fifth 
coordination site occupied by either cysteine (CP450) or histidine residues (SAMO, IDO, 
TDO). The sixth position is available for oxidative transformations.  
 
Figure 1.1. Structure of protoheme IX (adapted from ref.15) 
1.2.2. Mechanism of heme-catalysis 
In order to understand the catalytic reactions performed by heme-enzymes, with 
emphasis on exploring the nature of active oxidant, the hydroxylation of organic 
substrates by CP450 has been extensively studied in the past.14,20 The proposed 
mechanism of CP450 catalysis has been depicted in Figure 1.2.21 A high-valent Fe(IV)-
oxo porphyrin π-cation radical ([FeIV(O)(Por)]•+ ↔ [FeV(O)(Por)]) has been postulated 
as an active oxidizing species which transfers the oxygen atom to the organic substrate. 
 
N N
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Figure 1.2. Proposed mechanism of the hydroxylation of organic substrates by CP450 
(adapted from ref.21) 
 
1.2.3. Synthetic heme-ligands and their applications 
Synthetic iron-porphyrin complexes have been developed to mimic the functions 
of heme-enzymes. Because, it is synthetically challenging and time consuming to 
assemble the natural porphyrin, modified porphyrins based on meso- 
tetraphenylporphyrin (TPP) were synthesized.22 The structures of various porphyrin 
ligands are shown in Figure 1.3.7 Catalytic alkane hydroxylation and olefin epoxidation 
using synthetic Fe(III) porphyrin complexes were first illustrated by Groves and 
coworkers where Fe(TPP)Cl was used as catalyst along with iodosylbenzene (PhIO) as 
an oxidant.23 Mechanistic investigations let them to identify the high-valent Fe(IV)-oxo 
porphyrin π-cation radical as the active oxidizing species.24 Thereafter, a series of 
synthetic Fe(IV)-oxo porphyrin π-cation radical species were prepared and their 
reactivities were studied in various oxidative reactions.25 These iron-porphyrins 
complexes were used as catalysts in alkane hydroxylation,23,24,26 alkene 
epoxidation,23,24,27 N- or O-dealkylation of aromatic amines or ethers,28-31 oxygenation of 
FeIII FeII
FeIII
FeIIIFeIIIFeIV
FeIII
S S
S
SSS
Cys Cys
Cys
CysCysCys
S
Cys
O2-
O22-OO
OH2
O H
e-R-H R-H
O2
e-
R-H
R-HR-H
H2O
H+
H2O
R-OH
R-H
H2O
R-H
H++
  
5 
dialkyl sulfides32,33 or electron removal from phenol derivatives,34 drugs,35 or lignin.36 
They also find applications in DNA cleavage.37 
 
Figure 1.3. Structures of synthetic porphyrin ligands. H2TPP: R1 - R5 = H, R6 = H. 
H2TMP: R1= R2 = R5 = Me, R3 = R4 = H, R6 = H. H2TPFPP: R1 - R5 = F. R6 = H. 
H2TDCPP: R1 = R2 = Cl, R3 - R5 = H, R6 = H. H2Br8TDCPP: R1 = R2 = Cl, R3 - R5 = H, R6 
= Br. H2Cl8TDCPP: R1 = R2 = Cl, R3 - R5 = H, R6 = Br. H2Br8TMP: R1 = R2 = R5 = Me, R3 
= R4 = H, R6 = Br. H2Cl12TDCPP: R1 = R2 = R5 = Me, R3 = R6 = Cl, R4 = H. H2F8TPFPP: 
R1 - R5 = F, R6 = F (adapted from ref.7) 
1.2.4. Drawback 
Though iron-porphyrin model complexes find their application as catalyst in 
selective oxidation of organic substrate and DNA damage, they suffer from several 
drawbacks. One of the biggest detriments to using heme ligands in oxidative 
transformations is the susceptibility of these ligands to oxidation.38,39 Moreover, though 
biologically available oxidants like O2 or H2O2 had been used as oxidants, the more 
expensive iodosylbenzene was the choice of oxidant because it rendered higher yields 
and turnover numbers in these reactions.39 This led scientists to explore non-heme 
metalloenzymes that also take part in catalyzing various oxidation reactions. 
1.3. Non-heme ligands 
1.3.1. Non-heme enzymes in oxidation 
Like heme-enzymes, non-heme iron enzymes also catalyze a wide range of 
reactions in biology.3,5 A few examples of non-heme iron enzymes are MMO, Rieske 
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dioxygenases, catechol dioxygenases, lipoxygenases and isopenicillin N synthase 
(IPNS). MMO catalyzes the oxidation of methane into methanol,4,40,41 Rieske 
dioxygenases and catechol dioxygenases catalyze the degradation of aromatic 
rings,42,43 lipoxygenases catalyze the oxidation of unsaturated fatty acids into lipoxins 
and leukotrienes,44 and IPNS take part in the biosynthesis of β-lactam antibiotics like 
penicillin.45 The structures of the coordination sphere around the active sites of four 
crystallographically characterized mononuclear non-heme iron enzymes have been 
illustrated in Figure 1.4.   
 
Figure 1.4. Coordination around metal center in non-heme iron enzymes a) 
protocatechuate 3,4-dioxygenase (3,4-PCD) b) 2,3-dihydroxybiphenyl 1,2-dioxygenase 
(BphC) c) lipoxygenases (SLO-1) and d) isopenicillin N synthase (IPNS, Mn-substituted) 
(adapted from ref.5) 
 
1.3.2. Mechanism of non-heme enzyme catalysis 
Unlike heme-enzymes, it is difficult to study the mechanism of non-heme enzyme 
catalysis as 1) they don’t show the strong π → π* transition, the signature transition of 
the porphyrin ligands, as they lack highly conjugated porphyrin system 2) they possess 
high spin Fe(II) centers with S = 2 (integer spin, non-Kramers ions) that generally are 
difficult to study using traditional EPR-related methods and 3) the ligand to metal charge 
transfer (LMCT) transitions fall in high energy region (< 30000 cm-1) making it difficult to 
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study using UV-vis spectroscopy.46 Lack of suitable characterization techniques 
restricted our knowledge about the active intermediates being formed in non-heme iron 
enzymes responsible for the oxidation of organic substrates. Though people were 
speculating similar mechanisms in analogy with heme-enzymes, the existence of high 
valent Fe(IV)=O (or formally Fe(V)=O) without the porphyrin ligand was skeptical, 
because ligands around iron center in non-heme enzymes might not stabilize the high 
oxidation state of iron. However, recently scientists have managed to identify the key 
oxidizing species in several non-heme iron enzymes such as taurine:α-ketoglutarate 
dioxygenase (TauD), prolyl-4-hydroxylase, and halogenase CytC3 using various 
spectroscopic techniques like Mössbauer, Raman resonance and X-ray absorption 
spectroscopy.47-49 Like in heme-enzymes, non-heme Fe(IV)-oxo species have been 
found responsible for oxidizing organic substrates. The mechanism of TauD catalysis is 
shown in Figure 1.5. 
 
Figure 1.5. Proposed mechanism of TauD catalysis (adapted from ref.21) 
  1.3.3. Synthetic non-heme ligands 
Synthetic model complexes of non-heme iron enzymes were explored to 
understand the chemical and physical properties of iron centers at the active site, with 
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emphasis on developing biomimetic catalysts for selective oxidation of the organic 
substrates. Structures of some non-heme ligands are shown in Figure 1.6. 
 
Figure 1.6. Non-heme ligands 
1.3.3.1. Applications 
Metal complexes of non-heme ligands find applications in a number of areas 
including small molecule oxidation, DNA cleavage, protein inhibition/inactivation and as 
models for biomolecules providing insight into their possible role in various biological 
pathways. 
1.3.3.1.1 Oxidation of organic substrates 
1.3.3.1.1.1. Generation and characterization of ferryls 
Since the commencement of the mechanistic studies on the oxidation of organic 
substrates by heme enzyme CP450,14,20,21 the high-valent Fe(IV)-oxo porphyrin π-cation 
radical ([FeIV(O)(Por)]•+ ↔ [FeV(O)(Por)]) has been postulated as an active oxidizing 
species. High-valent Fe(IV)-oxo porphyrin π-cation radicals were successfully 
synthesized and characterized  later using iron-porphyrin model complexes.24 However, 
the existence of high-valent Fe(IV)-oxo species in non-heme enzymes has recently 
been identified in taurine:α-ketogultarate dioxygenase (TauD), prolyl-4-hydroxylase, and 
halogenase CytC3. In 1981, Wieghardt and coworkers, working with non-heme model 
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complexes, provided the first indirect evidence of high-valent Fe(IV)-oxo species when 
they treated [FeIII(cyclam-acetato)(CF3SO3)]+ with O3 in acetone and water at -80 °C to 
yield a green intermediate, characterized using Mössbauer as low spin Fe(IV)-oxo with 
S = 1.50 The concrete proof of Fe(IV)-oxo species however, came from Que et al., when 
they isolated and reported the first crystal structure of the Fe(IV)-oxo complex of TMC 
ligand, [FeIV(O)(TMC)]2+.51 [FeIV(O)(TMC)]2+ was fully characterized using various 
spectroscopic techniques and X-ray crystallography. It is a low spin complex with S = 1 
and there exists a double bond-like character between Fe and O with Fe-O bond length 
of 1.646 Å. Later, a number of Fe(IV)-oxo complexes were generated and characterized 
spectroscopically, along with X-ray crystal structure of [FeIV(O)(N4Py)]2+ species.52-55 In 
general, high-valent Fe(IV)-oxo can be generated by treating iron complex of non-heme 
ligands with a series of oxygen donor atoms/oxidants such as PhIO,51 peracids,52 
KHSO5,56 O3,50 and NaOX (X = Cl, Br)57, hydroperoxides51,56 and molecular oxygen.58 In 
the case of molecular oxygen, a reductant such as ascorbate, BPh4-59 or NADH60 is 
often required. Very recently, the perferryl species, Fe(V)-oxo has been identified for the 
first time by Costas, Cronin and co-workers using cryospray-assisted variable-
temperature mass spectrometry (VT-MS) in the reaction between Fe(II) complex of 
tetradentate ligand Pytacn (Pytacn = 1-(2′-pyridylmethyl)-4,7-dimethyl-1,4,7-
triazacyclononane) and H2O2 at –40 °C in acetonitrile. The active oxidant was 
characterized as HO–Fe(V)=O species and was capable of cis-dihydroxylating 
alkenes.61 
1.3.3.1.1.2. Oxidation by ferryls 
Iron complexes of non-heme ligands in conjugation with oxidants have been 
used to oxidize a number of organic molecules (alkanes, olefins, alcohol, aromatic 
  
10 
compounds, alkylaromatic compounds, thioanisoles, PPh3, N,N-dialkylanilines) (Figure 
1.7). The first highly stereospecific alkane hydroxylation using synthetic non-heme 
complex was shown in 1996 by Que and coworkers where [FeII(TPA)(CH3CN)]2+ was 
used as catalyst in combination with H2O2. The active intermediate proposed in this 
transformation was [Fe(TPA)(η2-OOH)]2+.62 Later, a number of high-valent Fe(IV)-oxo 
species, termed ferryls, were generated and characterized, and were found to be highly 
efficient in selectively oxidizing small organic substrates. For example, [FeIV(O)(N4Py)]2+ 
oxidizes the organic substrates Ph3CH, cumene, Ph-Et, Ph-Me, 2,3-dimethylbutane and 
cyclohexane albeit at different rates.53 [FeIV(O)(BQEN)]2+, generated from 
[FeII(BQEN)](CF3SO3)2] using CH3CO3H, was involved in oxidation of  
triphenylmethane, indan, tetralin, cumene, ethylbenzene, and benzyl alcohol.63 A series 
of substituted hydroquinone substrates (H2Q–X; X = H, tBu, Me, Cl, Br) were oxidized by 
[FeIV(O)(TMC)]2+. Alkynes had been oxidized by [FeII(TPA)(CH3CN)2]2+ or 
[FeII(BPMEN)(CH3CN)2]2+ and H2O2 systems. Oxidative N-alkylation was seen with 
[FeIV(O)(N4Py)]2+ and [FeIV(O)(TMC)]2+.64 Aromatic compounds were oxidized by 
[FeIV(O)(N4Py)]2+ and [FeIV(O)(Bn-TPEN)]2+.65 PPh3 was oxidized using 
[FeIV(O)(TMC)]2+.51 Thioanisoles and benzyl alcohol were oxidized by 
[FeII(TMC)(OTf)2)]2+ in presence of air in a mixture of 1:1 CH3CN and tert-butylether.58 
Aliphatic and aromatic alcohols were selectively oxidized to aldehydes by 
[FeIV(O)(TPA)]2+ and [FeIV(O)(N4Py)]2+.66 
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Figure 1.7. Oxidation of organic substrates by non-heme iron ferryls (adapted from 
ref.21) 
1.3.3.1.2. DNA oxidation 
To date, a number of metal complexes (iron, copper, nickel, zinc, rhodium and 
lanthanides) have been developed as DNA cleaving agents.67-75 The most promising of 
these are iron complexes of non-heme natural product, bleomycins (BLMs) that are 
being used in the treatment of various cancers (cervix, head, neck and testicular 
cancers).67,76 Iron-bleomycins (Fe-BLMs) can cleave both single- and double-stranded 
DNA efficiently and specifically under aerobic conditions.77-79 The efficacy of Fe-BLMs in 
DNA cleavage has been attributed to the presence of both a DNA-binding motif and a 
metal-binding unit in the same molecule (Figure 1.8). The active oxidant responsible for 
DNA damage, commonly termed as “activated BLM” has been identified a Fe(III)-OOH 
species.80 The proposed mechanism of DNA cleavage with Fe-BLMs has been depicted 
in Figure 1.9. Inspired by the Fe-BLMs, a number of synthetic non-heme iron complexes 
mimicking the N5 binding motif of BLMs have been developed which cause oxidative 
DNA cleavage in presence of O2 (Figure 1.10).81-84 
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Figure 1.8. Structure of bleomycin (BLM) 
 
 
Figure 1.9. DNA cleavage by “activated bleomycin” in aerobic condition (adapted from 
ref.85,86) 
 
 
Figure 1.10. Structures of molecules mimicking the metal-binding unit of bleomycin 
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The inclusion of a DNA binding motifs like 9-aminoacridine, the ammonium group 
or 1,8-naphthalimide has led to increase in DNA cleavage efficiency. In some cases, the 
presence of an added reductant like DTT has been found to accelerate the rate of 
reaction as DTT accelerates the reduction of intermittent formed Fe(III) species to Fe(II), 
which is required for oxygen activation.87  
1.3.3.1.3. Protein oxidation 
Metal complexes are ideal catalysts for targeting proteins because of their 
reactivity. Proteins can be inactivated either by hydrolyzing the amide bonds of the 
peptide backbone, or oxidatively cleaving the peptide backbone or oxidizing the amino 
acid side chains. Based on the modes of their inactivation, these complexes are 
classified into either hydrolytic complexes or oxidative complexes.  
Examples of hydrolytic complexes include the copper(II) complex, 
Cu([9]aneN3)Cl2, ([9]aneN3 = 1,4,7-triazacyclononane) that hydrolyzes the unactivated 
dipeptide Gly-Gly as well as the protein BSA at near physiological pH,88  the Co(III) 
complexes ([CoIII(cyclen)] where cyclen = 1,4,7,10-tetraazacyclododecane and their 
derivatives, Figure 1.11) that cleave the soluble oligomer of amyloid β peptide (αβ), 
especially αβ42 (composed of 42 amino acids) responsible for synaptic dysfunction of 
the brain nerves (Alzheimer disease)89 and the palladium(II) complexes, 
[Pd(H2O)3(OH)]+, cis-[Pd(en)(H2O)2]2+, cis-[Pd(dtco)-(H2O)2]2+, and cis-[Pd(dtco-
OH)(H2O)2]2+, where dtco is 1,5-dithiacyclooctane and dtco-OH is its 3-hydroxy 
derivative, that specifically cleave the amide bond at His18-Thr19 position  in the 
enzyme Cytochrome c (Figure 1.12).90  
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Figure 1.11. Co(III)-cyclen, and their derivatives a and b 
 
Figure 1.12. Palladium complexes involved in the peptide cleavage in Cytochrome c 
Oxidative complexes can further be classified into two classes: ones that 
generate reactive oxygen species (ROS) like singlet oxygen, superoxide or hydroxyl 
radicals, and others that generate metal-based oxidants where the oxygen atom is 
attached to the metal center. The key difference between ROS and metal-based 
oxidants is that ROS are diffusible and can lead to scattered long distance damage (60-
93 Å for OH•)91  whereas the metal-based oxidants are non-diffusible and oxidation is 
localized and is limited only to close proximity around the metal center. Examples of 
ROS generating metal complexes include Fe(III)-EDTA based reagents that cleave the 
proteins calmodulin92 and streptavidin,93 the Cu(I) complex of 1,10-phenanthroline that 
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oxidizes carbonic anhydrase94 and the Ru(II) complexes of 2,2’-bipyridine ([RuII(bpy)]2+) 
that inactivate a variety of intra and extracellular proteins.95,96 The latter example uses 
chromophore-assisted light inactivation (CALI), generating singlet oxygen as an active 
oxidant leading to protein oxidation. Relative to ROS, the inactivation of proteins by 
metal-based oxidants has not been explored thoroughly, perhaps due to either the lack 
of ligands that can support the high-valent metal-based oxidant or the lack of 
spectroscopic techniques required to detect these reactive intermediates. For example, 
the Ni(II) and Cu(II) complexes derived from Gly-Gly-His tripeptide have been shown to 
oxidize calmodulin,97 and angiotensin-converting enzyme, endothelin-converting 
enzyme 198 and carbonic anhydrase-I99 respectively where the metal-based oxidants 
have been suggested to be involved in inactivation event. However, the exact nature of 
active oxidants has not been verified. Interestingly, with Cu(II) complexes above, the 
proteins were inactivated mainly due to the oxidation of the amino side chains of the 
proteins rather than cleavage of peptide backbone. 
Even though metal-based oxidants such as high-valent Fe(IV)-oxo complexes of 
non-heme ligands have been well characterized, they find applications mainly in 
oxidizing small molecules and DNA cleavage. Proteins have not yet been targeted with 
these metal-based oxidants. Metal complexes based on iron are attractive reagents for 
protein targeting because iron is the one of most abundant transition metal in the human 
body and “chelatable iron,” also known as the labile iron pool,100 is present at 
micromolar concentrations in the cytosol of mammalian cells,101-106 so iron ions could be 
available to act as a cofactor in protein-targeting complexes. Another important factor 
that makes these iron-based reagents potent toward targeting proteins is that they can 
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react with bioavailable oxidants like O2 or H2O2 in the cell to generate active species, 
which can oxidatively damage proteins. Extensive studies on oxidation of amino acids, 
the building blocks of proteins, in our laboratory, strengthen the possibilities of these 
iron complexes to oxidize full proteins.107,108 Since oxidation leads to irreversible 
(permanent) changes, tuning the properties of iron complexes (by tethering a protein-
affinity ligand or varying ligands around the iron center) has great potential to render 
efficient (low concentrations) and catalytic inactivation of proteins. These factors 
motivated us to investigate protein inactivation using a series of non-heme iron 
complexes in the presence of oxidants. The proteins being targeted were human 
carbonic anhydrase-I, trypsin, chymotrypsin and the 20S proteasome. 
1.3.3.1.3.1. Human carbonic anhydrase-I (CA-I) 
Carbonic anhydrases (CAs) are a family of metalloenzymes that catalyze the 
reversible reaction between carbon dioxide (CO2) and water to yield bicarbonate (HCO3-
) (Equation 1.1) and are known to be among the most active enzymes with a kcat/Km of 
1.5 x 108 M-1 s-1, almost approaching the diffusion-controlled limit.109  
 
This CO2 to HCO3- interconversion helps regulate pH and CO2 homeostasis in 
cells and tissues. The active sites of CAs consist of Zn2+ ion tetrahedrally bound by 
three histidine moieties (His 94, His 96, and His 119) and one water molecule/hydroxide 
ion. The mechanism of CO2 hydration by CA has been depicted in Figure 1.13. These 
enzymes are mainly inhibited by the metal complexing anions and sulfonamides.110,111 
Both of them inhibit CAs by binding to the Zn2+ ion, either by substituting the H2O/OH- 
CO2 + H2O HCO3- + H+                         (1.1)
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molecule or by directly attaching to Zn2+ (Figure 1.14).111-113 Sulfonamides inhibit CAs 
using the former mode with the nitrogen atom of the sulfonamide moiety coordinated to 
Zn2+ in a tetrahedral geometry, whereas anions like SCN- add to the Zn2+ coordination 
sphere giving the trigonal-bipyramidal geometry.114 Several sulfonamide-based 
inhibitors of CAs are potential therapeutic agents and are used as antiglaucoma 
agents,110,115,116 antitumor agents,117 antithyroid agents,115 diuretic agents and 
antiepileptic agents118 (Figure 1.15).  
 
Figure 1.13. Mechanism of CO2 hydration catalyzed by CA (adapted from ref.109) 
 
 
 
Figure 1.14. Mode of inhibition of sulfonamides and SCN- (adapted from ref.109) 
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Figure 1.15. Sulfonamide based CAs inhibitors 
1.3.3.1.3.2. Serine proteases (Trypsin and Chymotrypsin) 
Trypsin and chymotrypsin belong to the family of serine proteases and catalyze 
the hydrolysis of the peptide backbones in proteins.119 Trypsin predominantly cleaves 
peptide chains at the carboxyl side of the amino acid, lysine or arginine, whereas 
chymotrypsin cleaves at the carboxyl side of amino acids tyrosine, phenylalanine or 
tryptophan. Both are biosynthesized in the pancrease as inactive precursor zymogens, 
trypsinogen (trypsin) and chymotrypsinogen (chymotrypsin). They possess a catalytic 
triad consisting of histidine, aspartate and serine residues.120 These are connected 
through a series of hydrogen bonds making the serine residue highly nucleophilic 
(Figure 1.16). Most inhibitors of trypsin are based on amidine and guanidine moeities, 
as being positively charged, they interact and form salt bridges with negatively charge 
aspartate moeity residing in the S1 specificity pocket of trypsin (Figure 1.17).121-126 On 
the other hand, most inhibitors of chymotrypsin contain hydrophophic moeities that are 
stablized by hydrophobic interactions inside the S1 specificity pocket of chymotrypsin 
(Figure 1.18).127-129 Though trypsin and chymotrypsin themselves are not medicinal 
targets, several trypsin-like and chymotrypsin-like serine proteases are involved in 
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important biological processes like digestion, blood clotting and coagulation, and in 
diseases such as hypertension, arthritis, emphysema, Alzheimer's disease, and brain 
tumor growth. 
 
Figure 1.16. The catalytic triad in serine proteases 
 
Figure 1.17. Trypsin inhibitors 
 
Figure 1.18. Chymotrypsin inhibitors 
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1.3.3.1.3.3. Proteasome 
Proteasomes (26S proteasome) are large protein complexes of molecular weight 
approximately 12000 kD that catalyze the degradation of unwanted or damaged 
proteins inside the cell.130 The proteins to be degraded are first tagged with a small 
protein called ubiquitin.131,132 This ubiquitination process is catalyzed by enzymes called 
ubiquitin ligases. The ubiquitinated proteins are then recognized by proteasomes which 
degrade the proteins into smaller peptides. The 26S proteasomes are cylindrically 
shaped and consist of catalytic subunits (core) and regulatory subunits (caps) (Figure 
1.19 ).133,134  
 
Figure 1.19. Proteasome 26S showing catalytic (core) and regulatory unit with 
ubiquinitated protein inside it (adapted from ref.135) 
 
The 20S protesome, the catalytic core of 26S protesome, performs three different 
type of peptidase activities (chymotrypsin like, trypsin-like and peptidylglutamyl peptide 
hydrolizing-like (PGPH))136 whereas the 19S proteasome, the regulatory subunit of 26S 
protesome, recognizes and allows the passage of the polyubiquinitated proteins to 
catalytic core for degradation. The ubiquitin-proteasome system is important for many 
biological processes such as cell cycle regulation, angiogenesis and response to 
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oxidative stress.137 This system has also been an important target in cancer 
chemotherapy for decades. A number of small molecules and metal complexes have 
been developed as proteasome inhibitors which show potential anticancer activities 
(Figure 1.20).138-146 
 
Figure 1.20. Structures of various proteasome inhibitors 
1.3.3.1.4. Enzyme inhibition 
1.3.3.1.4.1. Stoichiometric vs. catalytic inhibitors 
 
Figure 1.21. Mode of action of stoichiometric and catalytic inhibitors 
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that binds to its target molecule one at a time. However, this inhibition mode has certain 
limitations. It is often difficult to identify highly potent and selective inhibitors for the 
target proteins. The mode of inhibition is the reversible and renders only temporary 
inactivation of the target molecule. Also, high concentrations of inhibitor may be 
required which may lead to off-target activity. To make enzyme inhibition more effective 
at lower concentrations, catalytic groups (warheads) need to be attached to these 
inhibitors, which would permanently and catalytically inactivate multiple target molecules 
(Figure 1.22). 
1.3.3.1.4.2. Metal complexes as catalytic inhibitors 
As discussed in the previous section, metal catalysts are ideal for targeting 
proteins because of their reactivities. Site-selective catalytic inactivation can be 
achieved by tethering either metal-binding units or metal complexes to the protein 
affinity ligands. Once these molecules bind to the specific position on proteins, metal 
complexes can selectively inactivate the proteins. Cowan and coworkers have used this 
strategy to catalytically inactivate CA-I.99 They tethered Cu(II) complex to the benzene-
sulfonamide group, a potent inhibitor of CA-I, which inactivated CA-I catalytically and 
selectively in presence of reductant like ascorbate. In another study, Kodadek and 
coworkers selectively inactivated proteasome by appending [Ru(bpy)]2+ complex to the 
site-specific peptoid ligand by irradiating light.96 
1.3.3.1.5. Glutathionylation of Cobalamin (Cbl) model 
complexes 
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In addition to iron, we also studied biomimetic reactions of cobalt complexes 
derived from non-heme ligands, including mimics of cobalamines (Cbls). Cobalamines 
are important class of biomolecules that are involved in various biological processes in 
humans, and deficiency of which may lead to diseases such as pernicious anemia, 
Alzheimer’s disease, prostate cancer, myocardial infarction and cerebral stokes.147-153 
As coenzymes, they participate in two major enzymatic reactions in mammals: 
methylcobalamin (MeCbl) mediated transfer of a methyl group from 
methyltetrahydrofolate to homocysteine by methionine synthase to generate 
methionine, and adenosylcobalamin (AdoCbl) mediated isomerization of methylmalonyl-
CoA to succinyl-CoA, which is catalyzed by methylmalonyl-CoA mutase.154-157 
Cbls are obtained through external diet in mammals, as they cannot synthesize 
them. Even when externally taken, these Cbls cannot pass through the cell plasma 
membrane, because they are highly polar. Therefore, mammals have developed a 
complex pathway for gastrointestinal absorption, blood transport and cellular uptake of 
dietary Cbl.158 These pathways use cell surface receptors and Cbl-transport proteins.159-
161 However, Cbl is biosynthesized in microorganisms via both aerobic and anaerobic 
pathways. Cbls are comprised of N5 donor atom sets bound to the cobalt center (four 
equatorial corrin ring nitrogen atoms and one axial benzimidazole moiety) and vary 
according to the sixth donor group (X, Figure 1.21). Known derivatives of Cbls include 
MeCbl (X = Me), AdoCbl (X = 5'-deoxyadenosyl), aquacobalamin (X = H2O) and 
cyanocobalamin (X = CN–), also known as vitamin B12. Another important form of Cbl is 
thiolate-ligated glutathionylcobalamin (GSCbl), which has recently been isolated from 
cultured endothelial cells. GSCbl forms rapidly upon reaction of glutathione GSH, 
present in cells up to concentrations of 10 mM,162,163 with aquacobalamin (H2OCbl+) and 
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has also been proposed as an intermediate in the biosynthesis of active cobalamin 
coenzymes, AdoCbl and MeCbl.164  It was also suggested that GSCbl is a more direct 
precursor of the coenzyme promoting methyl synthase activity. Hence, GSCbl might be 
more effective than other cobalamines in treatment of conditions associated with 
hyperhomocysteinemia and oxidative stress, including dementia, arthritis, and 
cancer.149,165  
 
Figure 1.22.Structures of natural cobalamines 
GSCbl has been synthesized,164,166-169 and well characterized through various 
spectroscopic techniques and X-ray crystallography.169-173 These studies confirm the 
thiolate ligation of the cysteine residue present in GSH to the Co(III) center in GSCbl. 
Detailed kinetic and thermodynamic studies of GSCbl formation from H2OCbl+ and GSH 
have been reported earlier and conclude that GSCbl formation from H2OCbl+ is both 
rapid and highly favorable.174 
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B12 coenzyme. Brown et al. reported the kinetic and equilibrium studies for axial thiolate 
ligation of methylaquocobaloxime but the thiols used in ligation were 2-
mercaptoethanol, S-methyl-2-mercaptoethanol, mercaptoacetate and 
methylmercaptoacetate.187 Though, the interaction of glutathione with vitamin B12 model 
complex [Me(CoIII)(tn)H2O] where tn = 2,3,9,10-tetramethyl-1,4,8,11-tetra-azaundeca-
1,3,8,10-tetraen-11-ol-1-olato anion, had earlier been reported by Pellizer et al.,188 a 
detailed kinetic and thermodynamic studies on glutathionylation has never been 
reported with synthetic vitamin B12 model complexes. This motivated us to synthesize 
cobalt complexes of non-heme polypyridyl ligands mimicking the N5 coordination 
environments like that of Cbl, and perform their detailed kinetic and thermodynamic 
studies with glutathione.  
1.4. Thesis statement 
Selective C-H functionalization has always been a challenge, and the quest for 
developing suitable reagents that can perform such transformations under milder 
conditions still drive the research interest in this area. However, nature uses 
metalloenzymes (especially heme- and non-heme iron enzymes) to perform these 
reactions catalytically and selectively. Inspired by nature, many synthetic iron complex 
models based on heme-and non-heme ligands were developed to understand the 
chemical and physical properties, and reactivities of the iron center at the active sites of 
these enzymes. Various spectroscopic techniques were used to determine the nature of 
active oxidizing species responsible for oxidizing the organic substrates. High-valent 
Fe(IV)-oxo species had been identified as the key intermediate in both heme- and non-
heme iron model complexes. Since iron-porphyrin complexes were susceptible to self-
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oxidation, non-heme iron complexes got an edge toward exploration for non-heme iron 
based catalysts for oxidative transformations. High-valent Fe(IV)-oxo of non-heme iron 
complexes find applications in oxidation of a wide range of organic molecules such as 
alkane, olefins, aromatic compound, thioanisoles, N-deamination and sulfides. Fe-BLM 
and its synthetic model complexes can oxidatively cleave DNA. However, oxidation of 
proteins by non-heme iron complexes represents an underexplored area of research. 
This motivated us to investigate protein inhibition/inactivation by non-heme iron 
systems.  
Apart from using non-heme iron complexes for oxidative chemistry, cobalt 
complexes of non-heme ligands provide excellent model systems for studying 
biomimetic reactions of biologically active cofactor, cobalamin or B12, which consists of 
cobalt(III) ion bound by N5 donor set (from corrin and benzimidazole moiety) and vary 
according to sixth donor group (C, S, O), and catalyzes various significant biological 
processes. Glutathionylcobalamin (GSCbl), formed from aquacobalamin and GSH, is an 
important form of cobalamin present in the cell and has been proposed as an important 
intermediate in the biosynthesis of two of the active cobalamin coenzymes MeCbl and 
AdoCbl. GSCbl has also been suggested to be more effective than other cobalamines in 
treatment of conditions associated with hyperhomocysteinemia and oxidative stress, 
including dementia, arthritis, and cancer. Though a large number of cobalamin models 
complexes have been synthesized in the past, a detailed kinetic and thermodynamic 
study on glutathionylation has never been performed with these complexes. This 
inspired us to study the biomimetic reaction of glutathione with cobalamin model 
complexes formed from pentadentate non-heme ligands. 
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The overall goals of my research thesis are:  1) to explore the role of non-heme 
iron complexes towards protein inactivation and 2) to extend this chemistry towards 
cancer target 20S proteasome, and finally 3) to study mechanistic (kinetic and 
thermodynamic) details of glutathionylation of cobalamin model complexes, synthesized 
from non-heme ligands to give glutathionylated products. 
Chapter 1 of my thesis deals with the overall introduction. First, heme-enzymes 
involved in oxidation were introduced and their modes of action were discussed. 
Mechanistic insights into heme-enzyme catalysis were provided using synthetic model 
complexes. Potential applications of these heme model complexes as catalysts were 
shown in various oxidative reactions. Susceptibility of heme complexes to self-degrade 
during oxidation led researchers to move toward non-heme iron enzymes. Mode of 
action and mechanistic details of non-heme iron enzyme catalysis using model 
complexes were provided. Applications of non-heme iron complexes in oxidation of 
various organic substrates, and DNA cleavage were summarized. The importance of 
non-heme iron complexes toward protein oxidation, which represents an underexplored 
area of research, has been outlined. Besides oxidation, the importance of non-heme 
ligands as a scaffold around cobalt centers, providing the N5 coordination sphere 
similar to found in biologically active cofactor cobalamin, and mimicking its behavior 
toward reaction with GSH (glutathionylation) has been mentioned.  
In Chapter 2, the first section deals with the inactivation studies of carbonic 
anhydrase-I with iron complex of N4Py-sulfonamide inhibitor in presence of a reductant, 
dithiothreitol (DTT), where IC50 values were determined, time-dependent inactivation 
studies were performed and characterization of the oxidized products were illustrated by 
SDS-PAGE, ESI-MS and LC/MS/MS. The later section deals with the inactivation of 
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serine proteases, trypsin and chymotrypsin first with pre-generated ferryls and then with 
iron complexes in presence of H2O2 as an oxidant. The products of reactions in both the 
cases were characterized by SDS-PAGE, LC/MS and amino acid analysis. Further 
mechanistic studies were performed to investigate the mechanism of oxidation and to 
determine the nature of active oxidant responsible for the oxidation.   
In Chapter 3, non-heme ligands N4Py and Bn-TPEN along with their iron 
complexes [FeII(N4Py)]2+ and [FeII(Bn-TPEN)]2+ were evaluated for their ability to inhibit 
20S proteasome. IC50 values for inhibition of chymotrypsin-like, trypsin-like and PGPH-
like activity of 20S proteasome were determined, followed by time-dependent 
inactivation studied with these ferrous complexes in absence and presence of DTT. 
Finally, to gain insight into the nature of oxidant, reactions were performed in the 
presence of radical scavengers. In addition, brief results of in vivo studies performed 
with prostate cancer PC-3 cells have been discussed. 
In Chapter 4, a synthetic Co(III) model complex [CoIII(N4PyCO2Me)Cl]Cl2, 
mimicking the N5 coordination sphere around Co(III) center in biologically active 
cobalamin was synthesized. The compound was fully characterized using various 
spectroscopic techniques (UV-vis, 1H- and 13C-NMR, HRMS) and X-ray crystallography. 
The molar conductivities of aqueous solutions of [CoIII(N4PyCO2Me)Cl]Cl2 were also 
determined. The detailed kinetic and thermodynamic studies on the biomimetic reaction 
of the synthesized cobalamin model complex [CoIII(N4PyCO2Me)Cl]Cl2 and one of its 
congener [CoIII(Bn-CDPy3)Cl]Cl2, with glutathione were performed in aqueous buffer. 
The second order rate constant k and observed equilibrium constant Kobs were 
calculated from the above data. Both glutathionylated products were further 
characterized in situ using 1H-NMR and UV-vis spectroscopies, and HRMS.  
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CHAPTER 2 
Inactivation of Carbonic Anhydrase-I and Serine Proteases by Non-Heme Iron 
Complexes 
Copyright Permission: Portions of the text in this chapter were reprinted or adapted 
with permission from: Prakash, J.; Kodanko, J. J. Inorg. Chem. 2011, 50, 3934-
3945.  All rights to the work are retained by the authors and any reuse requires 
permission of the authors 
2.1 Introduction 
Enzyme inhibitors play a pivotal role in life sciences today, as reagents for 
chemical biology and as therapeutics for the treatment of human diseases. Inhibition is 
achieved by delivering molecules that bind selectively to targets and diminish enzyme 
activity. This inhibition can be reversible or irreversible. In the case of reversible 
inhibition, the inhibitor molecule binds tightly to the target using non-covalent 
interactions. Although this strategy is most common, it is reversible and can require high 
concentrations of inhibitor to achieve the desired effect, which can lead to off-target 
activities. Irreversible inactivation of the target enzyme, or suicide inhibition, involves 
formation of a covalent bond between the inhibitor molecule and target enzyme. 
Because of issues with toxicity and immunogenicity, suicide inhibition is less common in 
pharmaceuticals. Importantly, both of these strategies require a stoichiometric amount 
of the inhibitor. 
An attractive method towards enzyme inhibition is to use metal-based reagents 
that generate either ROS or metal-based oxidants, diminishing enzyme activity through 
catalytic oxidation. Enzyme oxidation has great potential because of its irreversible 
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nature, and its ability to minimize the dose of inhibitors needed to have the desired 
effect. Damage to proteins by ROS has been well studied because of its significance in 
aging, neurodegenerative diseases, and radiation therapy.189-193 Early examples of 
catalysts that relied on the formation of ROS included FeIII(EDTA)-based reagents for 
targeting calmodulin92 and streptavidin93 which used O2 and a reductant, as well as a 
Cu(I) complex of 1,10-phenanthroline tethered to a sulfonamide for targeting carbonic 
anhydrase94 where oxidative cleavage of the peptide backbone was observed in the 
presence of O2 and a reductant. Later work with chromophore-assisted light inactivation 
showed that proteins can also be inactivated selectively using singlet oxygen 1O2, 
generated by the metal-based chromophore [RuII(bpy)3]2+,96,194 which showed an 
advantage over more traditional organic photosensitizers,195-197 which are susceptible to 
photobleaching. For example, [RuII(bpy)3]2+ attached to HaloTag Protein upon irradiation 
to UV light can inactivate the protein Luciferase by producing singlet oxygen.95 Similarly 
[Ru(bpy)2]2+-peptoid conjugates have shown potent and selective inactivation of  
vascular endothelial growth factor (VEGF)-induced autophosphorylation of VEGF 
receptor 2 (VGRF2),  and 26S proteasome upon photo-irradiation by means of 
generating singlet oxygen 1O2 as reactive oxidizing species.96 Such peptoid derivatives 
provided a straightforward way to increase potency without resorting to extensive 
optimization of the inhibitor structure.96 Importantly, selective targeting of intra- and 
extracellular proteins was demonstrated with this approach.  
When compared with ROS, inactivation of proteins by metal-based oxidants 
represents an underexplored area of chemistry. Considering there were only a few 
examples of targeting proteins with metal-based oxidants,97,198,199 we found interest in 
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applying a set of iron complexes developed for small molecule oxidation for this 
purpose. Metal complexes based on iron are attractive reagents for protein targeting 
because iron is the most abundant transition metal in the human body and “chelatable 
iron,” also known as the labile iron pool,100 is present at micromolar concentrations in 
the cytosol of mammalian cells,101-106 so iron ions could be available to act as a cofactor 
in protein-targeting catalysts. Since studies with iron catalysts and proteins first began, 
EDTA has been the ligand of choice, especially for footprinting applications.200-205 
However, others established that moving from carboxylate-rich ligands such as EDTA to 
more nitrogen-rich ligands resulted in better control and higher levels of selectivity in the 
oxidation of small molecules206 due to the action of metal-based oxidants, rather than 
ROS, specifically HO• through the Fenton reaction.207 Work in this area proved that iron-
based oxidants, such as the well characterized high-valent Fe(IV)-oxo species 
[FeIV(O)(N4Py)]2+,55,56,208 have spectacular applications in the selective oxidation of 
organic molecules53,56,64,65,209-213 and in mimicking non-heme protein active sites found 
in nature,21,214,215 including enzymes that are used to oxidize amino acids.48,216 We were 
further motivated to investigate these complexes as protein-targeting reagents because 
extensive investigations of bleomycin, an example of an iron-based catalytic drug that 
has been used for decades in cancer chemotherapy, as well as its model complexes, 
demonstrated that iron complexes can selectively oxidize and cleave DNA catalytically 
using bioavailable oxidants such as O2 or H2O2.67,81,82,217-222 Yet the targeting of proteins 
with these reagents remained unexplored.  
As a starting point to investigate protein-targeting with iron-based oxidants, our 
group demonstrated that the well characterized ferryl [FeIV(O)(N4Py)]2+ oxidizes side 
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chains and cleaves the backbone of protected amino acids.107,108 However, questions 
remained regarding the reactivity of iron-based oxidants towards proteins, where the 
reactivities of amino acid residues could be dependent on the local protein structure and 
could differ from the model systems. Would a ferryl, which is typically more selective 
than HO•, be reactive enough to inactivate a protein, and if so, could this be done 
selectively? Could the parent Fe(II) complexes oxidize and inactivate enzymes in a 
catalytic and selective fashion using bioavailable oxidants, and if so would protein 
cleavage or side chain oxidation be observed? In order to address these questions, 
studies were performed commencing with inactivation of carbonic anhydrase-I with 
ferrous complex of N4Py-based sulfonamide inhibitor (Figure 2.1) in presence of a 
reductant dithiothreitol (DTT). Later, the reactivity of two ferryl complexes, the known 
ferryl [FeIV(O)(N4Py)]2+ and a derivative containing a acylpropylguanidinium group for 
protein-binding named [FeIV(O)(3CG-N4Py)]3+ for 3-carbon guanidinium (Figure 2.1), 
were evaluated for their ability to inactivate serine proteases trypsin and chymotrypsin 
under single turnover conditions. The starting ferrous complexes [FeII(N4Py)]2+ and 
[FeII(3CG-N4Py)]3+ were further combined with enzyme and treated with oxidants to 
determine if catalysis was possible. Results disclosed herein confirm for the first time 
that the new class of iron complexes that have extensive applications in the oxidation of 
small molecules can be applied to the selective targeting of proteins. 
 
Figure 2.1. Structures of ligands used in the inactivation studies 
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2.2. Inactivation of carbonic anhydrase-I 
2.2.1. Results 
2.2.1.1. Inhibitor design 
Designing the iron-based inhibitor for CA-I involved tethering a protein-affinity 
group, in this case an arylsulfonamide, to the iron-binding ligand N4Py. Simple 
arylsulfonamides are known to inhibit carbonic anhydrases effectively by displacing a 
zinc-bound hydroxide moiety found in the active site with a deprotonated sulfonamide or 
NH– group. In order to keep the inhibitor most similar to the copper-based inhibitors of 
CA-I used in the past, a benzenesulfonamide group was chosen to anchor the inhibitor 
to the enzyme. 
X-ray crystallographic data of CA-I bound to 4-aminobenzenesulfonamide (PDB 
ID 1CZM)223 were used to design the structure of the iron-based inhibitor. After 
inspecting the three-dimensional structure of the enzyme and attempting to dock 
several variants, linking a (4-methylamino)benzenesulfonamide to the N4Py ligand 
through an amide bond tether was deemed optimal (see structure 4, Figure 2.1). An 
extra methylene unit was incorporated between the aryl ring of the sulfonamide and the 
amino group of the inhibitor, different from previous studies, which incorporated 4-
aminobenzenesulfonamide,94,99 in order to prevent the bulky iron-bound N4Py unit from 
bumping into residues around the rim of the active site. Shown in Figure 2.2a are results 
from a molecular modelling study where the benzenesulfonamide portion of the inhibitor 
[FeIV(O)(4)]2+ was overlapped with the benzenesulfonamide of the original crystal 
structure. The space-filling representation shown in Figure 2.2b illustrates that the 
inhibitor can fit in the active site without creating unfavorable non-bonding interactions 
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with the surface of CA-I. Attempts were made to calculate binding energies with the 
inhibitor and CA-I using Monte Carlo methods. Results were judged to be unreliable, 
due to complications in assigning the appropriate partial charges on the iron-bound 
inhibitor and the lack of flexibility and solvation in the active site model. 
 
Figure 2.2. (a) Molecular modelling representation of [FeIV(O)(4)]2+ docked in the active 
site of CA-I. The structure of the original inhibitor, shown in green, was overlapped with 
the benzenesulfonamide group of [FeIV(O)(4)]2+. (b) Space filling representation of 
[FeIV(O)(4)]2+ docked in the active site of CA-I. 
2.2.1.2. Inhibitor synthesis 
The inhibitor designed in the previous section was synthesized in three steps 
starting from a known N4Py derivative, the ester N4PyCO2Me 1 (Scheme 2.1).222 
Saponification of ester 1 using NaOH in MeOH furnished an acid 2 that was condensed 
with N,N-disuccinimidyl carbonate in a mixture of refluxing pyridine and MeCN, giving 
the unstable ester N4PyCO2Su 3 in 84% yield and > 90% purity over the two steps. 
Reaction of the crude activated ester 3 with 4-(aminomethyl)benzenesulfonamide in 
DMF at room temperature furnished the inhibitor 4 in 54% yield. Development of a 
synthetic route to the succinimide ester N4PyCO2Su was significant, because this 
versatile starting material can be used to link the N4Py ligand to various protein-binding 
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motifs under mild conditions. 
 
Scheme 2.1. Synthesis of N4Py-sulfonamide inhibitor 4 
2.2.1.3. Inhibition studies 
In order to evaluate the ability of the ligand 4 to inhibit CA-I, enzyme activities 
were determined in the presence of varied concentrations of free ligands 1 and 4, as 
well as several metal complexes that were generated in situ (Figure 2.3 and Table 2.1). 
A concentration-dependent inhibition of CA-I was observed in all cases in assays that 
contained the ligand 4 (entries 1–3). Precomplexation of 4 with the metal ions FeII or ZnII 
prior to conducting the assay did not change the inhibition dramatically, and IC50 values 
were nearly identical in all three cases. The ligand N4PyCO2Me 1 (Scheme 2.1), as well 
as its FeII or ZnII complex, did not inhibit CA-I in the range of concentrations surveyed, 
giving a lower limit for the IC50 values of >1000 mM, consistent with strong binding of 
the ligand 4 to CA-I due to the sulfonamide functional group of the inhibitor (entries 4–
6), rather than the metal ion or N4Py moiety. Neither FeII nor ZnII alone inhibited CA-I at 
the concentrations used in these assays (entries 7–8). 
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Table 2.1. IC50 values for inhibition of CA-I for compounds 1 and 4 their metal 
complexes and free metal ionsa 
Entry Compound IC50 (µM) 
1 4 1.7 ± 0.1 
2 FeII·4 1.1 ± 0.1 
3 ZnII·4 1.4 ± 0.4 
4 1 > 1000 
5 FeII·1 > 1000 
6 ZnII·1 > 1000 
7 FeII > 1000 
8 ZnII > 1000 
 
a Metal complexes were generated in situ with using ligands 1 or 4 and 
FeII(NH4)2(SO4)2 or ZnCl2. Enzyme (CA-I) concentration was 1.0 µM; substrate 
(4-nitrophenyl acetate) concentration was 1.0 mM. The reactions were 
conducted at pH = 8.0, in 12.5 mM Tris buffer containing 75 mM NaCl and 5% 
DMSO. 
 
 
Figure 2.3. Inhibition of CA-I by FeII·4. Enzyme (CA-I) concentration was 1.0 µM; 
substrate (4-nitrophenylacetate) concentration was 1.0 mM. The reactions were 
conducted at pH = 8.0, in 12.5 mM Tris buffer containing 75 mM NaCl and 5% DMSO. 
 
   2.2.1.4. Inactivation studies 
 
  After gathering inhibition data, the inactivation of CA-I by FeII·4 was examined. 
Following the method from the literature with copper-based metallopeptide,198 CA-I (1 
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observed with FeII·4 in the presence of 0.5 mM dithiothreitol (DTT) at 37 °C (Figure 2.4). 
By measure of the assay, the activity changed from over 90% at t = 0 to under 40 % 
after 140 min under these conditions. Control experiments concluded that the rate of 
inactivation by 1 µM FeII·4 was significantly faster than the background rate of 
inactivation by either FeII alone or the control experiment with no metal ion added. In the 
absence of DTT, enzyme activities did not change significantly over time in the 
presence of FeII·4, FeII or the blank, confirming that loss of catalytic activity required a 
reductant to proceed. It was also noted that ascorbate as a reductant was not as 
effective as DTT. Therefore, a thiol-based reductant was ideal. Taken together, these 
observations are most consistent with reductive activation of dioxygen by the FeII·4 
complex and subsequent oxidation and inactivation of CA-I, as witnessed in oxidative 
studies with DNA.219,222,224  
 
Figure 2.4. Plot of CA-I activities vs. time of preincubation at 37 °C in the presence of 
the reductant DTT. Enzyme (CA-I) concentration was 1.0 µM; DTT concentration was 
0.5 mM; H2O was added as blank (▲); concentration of FeII (●) or FeII·4 (■) was 1.0 
µM. Reactions were conducted at pH = 8.0, in 12.5 mM Tris buffer containing 75 mM 
NaCl and 5% DMSO using a total volume of 1.5 mL. Activities, measured as initial 
velocities, were determined at each time interval by removing aliquots (100 µL) and 
adding the substrate 4-nitrophenylacetate (1 mM). Activities were converted to % CA-I 
activity, with 100% activity equal to the activity of the blank reaction in the absence of 
inhibitor 4 or FeII at t =0. 
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   2.2.1.5. Characerization of products 
  To gain insight into the mode of inactivation, CA-I products were analyzed by 
SDS-PAGE and ESI-MS. Incubation of CA-I with FeII·4 did not lead to cleavage of the 
protein backbone, as evidenced by SDS-PAGE analysis (Figure 2.5). No major 
fragments of the enzyme were observed in this case. Characterization of the CA-I 
inactivation products by ESI-MS revealed that several new products had formed, in the 
presence of FeII·4, all with higher molecular weights (Figure 2.6). These data are in 
good agreeement with data from the copper metallopeptide used in the past,198 and are 
consistent with oxidation of the protein by the addition of oxygen atoms to one or more 
amino acid side chains, rather than fragmentation of the protein backbone.94  
  Nano LC/MS/MS analysis of trypsin and chymotrypsin digests of CA-I confirmed 
that the the majority of oxidized residues were located in direct proximity of the active 
site, where FeII·4 is expected to bind. In total, ten oxidized residues were located 
through this analysis, including five histidines (H40, H64, H67, H200 and H243), which 
were oxidized to 2-oxo-histidine, four tryptophan residues (W16, W123 and W192), 
which were oxidized to formylkynurenine, and two methionine residues (M148 and 
M241), which were oxidized to methionine sulfoxide. Using the molecular model of 
[FeIV(O)(4)]2+, docked in the active site of CA-I (Figures 2.2), it was confimed that eight 
of these residues were located near the active site, between 6-18 Å from the benzylic 
methylene carbon of the sulfanilamide inhibitor, which lies near the opening of the active 
site (Figure 2.7). In addition, two oxidized residues, H40 (~ 32 Å) and W192 (~ 25 Å), 
were located on the peripheral surface, similar to observations with the copper 
metallopeptide, which could indicate a secondary binding site for the inhibitor, or 
alternatively a non-specific surface oxidation. 
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Figure 2.5. SDS-PAGE analysis (12%), stained with Coomassie blue, of CA-I (20 µM) 
incubated at 37 °C for 3 h at pH = 8.0, in 12.5 mM Tris buffer containing 75 mM NaCl 
and 10 mM DTT. Cleavage products of CA-I were not observed. Lane 1: MW marker. 
Lane 2: enzyme only. Lane 3: FeII (20 µM). Lane 4: FeII·4 (20 µM). 
 
 
 
 
 
Figure 2.6. Deconvoluted ESI-MS spectra of CA-I after treatment with FeII (spectrum a) 
or FeII·4 (spectrum b) in the presence of DTT. Peaks observed at 28800 and 28939 in 
spectrum b are consistent with oxidation of CA-I. Reactions were conducted at 37 °C by 
incubating CA-I (20 µM), FeII (40 µM) or FeII·4 (40 µM), DTT (20 mM) for 3 h before 
desalting and subjecting the samples to ESI-MS analysis. 
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Figure 2.7. (a) Figure showing location of oxidized histidine (H67, H64, H200 and 
H243), tryptophan (W16 and W243) and methionine (M241) residues of CA-I (shown in 
red) with respect to the active site and the docked inhibitor [FeIV(O)(4)]2+. The zinc  ion 
of the active site is represented as a blue sphere.(b) Surface model of CA-I docked with 
[FeIV(O)(4)]2+ showing oxidized residues near the active sites (in red) 
 
  The localized pattern of oxidized residues around the active site indicates that 
the inhibitor has some flexibility in its ability to oxidize residues. The ability of FeII·4 to 
transfer oxygen atoms to the protein could signify that the ferryl complex [FeIV(O)(4)]2+ 
might be the active oxidant, due to the fact that similar reactivity was demonstrated with 
[FeIV(O)(N4Py)]2+ and protected amino acid derivatives.107 
  2.2.2. Discussion 
  Results reported herein are significant as they confirm for the first time that the 
iron complex FeIIN4Py can oxidize proteins when tethered to a protein-affinity group. 
Though, the binding of iron to the N4Py-sulfonamide inhibitor 4 did not increase its 
efficiency to inhibit CA-I (infact they show similar IC50 values), the ferrous complex led to 
time-dependent inactivation of CA-I in presence of O2 and a reductant DTT. The loss of 
CA-I activity over time was not seen with either FeII or FeII⋅4 in the absence of DTT 
confirming that FeII·4 and a reductant were needed to achieve efficient inactivation, 
consistent with a pathway involving the reductive activation of O2. Although the rate of 
  
41 
CA-I inactivation was slower compared with copper-peptide reagent used in the past,198 
the mode of their action seems to be similar i.e., oxidative inactivation. Oxidative mode 
of inactivation was further corroborated by SDS-PAGE and ESI-MS analysis. Absence 
of bands leading to cleavage products in SDS-PAGE, and  presence of higher 
molecular weight peaks in ESI-MS concluded that CA-I was inactivated by the oxidation 
of their side chain amino acid residues rather than cleavage of the protein backbone. 
Additional evidence of oxidative damage came from LC/MS/MS analysis which 
illustrated that  histidine and trypotphan residues near the active site were selectively 
oxidized. This localized pattern of oxidized amino acid residues also supports the role of 
metal-based oxidant responsible for the enzyme inactivation rather than diffusable ROS. 
Taken together, these make iron-based inhibitors as the potential candidates for in vivo 
applications that could emerge by taking advantage of the labile iron pool in the cell.  
  Unfortunately, the results from this study suffer the drawback of reproducibility. 
Though the data from time-dependent inactivation and SDS-PAGE were consistently 
reproduced, the oxidation results obtained from ESI-MS and LC/MS/MS were highly 
inconsistent.This may be due to the fact that we were largely relied on O2 as source of 
oxidant in our studies which is not efficiently being activated by reductant. Another 
plausible reason that may lead to observed inconsistent results is that CA-I might be 
inactivated by non-oxidative pathways i.e., either blocking the activity of zinc at the 
active site by direct binding of inhibitor molecule or stripping off Zn2+ ion by the metal-
binding N4Py moeity of the inhibitor.  
  This led us to move toward targeting other protein systems devoiding of metal 
center at the active site, mainly trypsin as it has been broadly studied in terms of its 
function and has well established crystal structure (PDB ID# 3ITI), and the use of 
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pregenerated ferryls and other suitable biological oxidant like H2O2 that has been used 
extensively in the past for oxidation chemistry.   
2.3. Inactivation of serine proteases (trypsin and chymotrypsin) 
 2.3.1. Results 
2.3.1.1. Synthesis of ligand 7  
The N4Py derivative 7, which contains a pendant acylpropylguanidinium group, 
was synthesized in three steps starting from the known ester 1 (Scheme 2.2).222 
Following a literature procedure, refluxing the methanolic solution of 3 and 1,3-
diaminopropane in the presence of a catalytic amount of NaCN under a N2 atmosphere 
gave the aminated product 5 in 77% yield.222 The resultant primary amine 5 was treated 
with 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea in THF/H2O at 50 °C for 1 
h, furnishing 6 in 88% yield. Compound 6 was deprotected by treatment with 4 M HCl in 
1,4-dioxane for 3 h at room temperature, giving the ligand 3CG-N4Py (7) as a 
hydrochloride salt in quantitative yield. 
 
Scheme 2.2. Synthesis of ligand 3CG-N4Py 
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2.3.1.2. Generation and characterization of ferryl species 
The ferrous complexes 9 and 10 were generated in situ by adding 1 equiv of 
FeII(ClO4)2 to aqueous solutions of ligands and N4Py (8) and 7 respectively. The orange 
complexes 9 and 10 were characterized by UV-vis and 1H-NMR spectroscopies and 
MS. UV-vis spectroscopy indicated similar data for 9 and 10 (ε380 = 1700 M-1 cm-1 with a 
shoulder at 460 nm and ε375 = 1700 M-1 cm-1 with a shoulder at 470 nm for 9 and 10, 
respectively). 1H-NMR spectra for 9 and 10 in D2O were consistent with the complexes 
bearing high-spin S = 2 FeII centers. Broad resonances ranging from 150 to 20 ppm, 
well outside of the diamagnetic region, were observed for 9. Complex 10 showed 
resonances within the same region, except that downfield resonances were split in two, 
which is consistent with the lower symmetry of 10 (C1 symmetry) with respect to 9 (Cs 
symmetry) because of the acylpropylguanidinium group on the ligand 3CG-N4Py. 
Magnetic moments for 9 and 10 in D2O were 4.4 and 4.5 µB, respectively, as 
determined by Evan’s method, which are close to the expected spin-only values for a 
high-spin Fe(II) complex.225 Interestingly, treatment of 9 or 10 in D2O with excess 
CH3CN (50 equiv) caused a spin transition from high to low spin, as judged by 1H-NMR 
spectroscopy, in which resonances between 200 and 20 ppm were no longer observed. 
In addition, a sharp drop in the magnetic moment, < 0.2 µB for both samples, was 
observed by Evan’s method. MS data for 9 in H2O matched the formula 
[FeII(OH2)(N4Py)]2+ as described previously,226 and data for 10 in H2O showed a 
prominent molecular ion at m/z 300.5860, along with an isotope pattern that agreed with 
the molecular formula [FeII(Cl)(3CG-N4Py)]2+, where chloride presumably binds to the 
iron center in place of H2O because it is present as the counterion to the guanidinium 
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salt. Treatment of 9 with peracetic acid at 25 °C gave a pale-green species, 
[FeIV(O)(N4Py)]2+ (11), in ∼ 20 min with a maximum absorption wavelength at λmax = 
680 nm (ε = 170 M-1 cm-1), which agrees with the published data.227 A similar procedure 
was used to prepare the ferryl [FeIV(O)(3CG-N4Py)]3+ (12; λmax = 675 nm, ε = 170 M-1 
cm-1; Figure 2.8) from 7, where it took ∼ 10 min for complete generation. Ferryl 12 was 
characterized by high-resolution electrospray ionization MS (ESI-MS), which displayed 
a prominent molecular ion at m/z 194.0682, along with a suitable isotopic pattern, 
consistent with a trication derived from the molecular formula [FeIV(O)(3CG-N4Py)]3+.   
 
Figure 2.8. UV-vis spectra of ferrous and ferryl complexes in H2O: (a) 9 (red) and 10 
(blue); (b) 11 (red) and 12 (blue) 
2.3.1.3. Enzyme inactivation with ferryl compounds 
In order to evaluate the ability of the ferrous and ferryl complexes 7-12 to 
inactivate trypsin, the enzyme activities were determined in the presence of varied 
concentrations of these reagents along with controls, and IC50 values were calculated 
(Table 2.2). In these studies, trypsin (1 µM) was treated with each reagent (0-1000 µM) 
in acetate buffer (pH = 6.0, 150 mM NaCl) at room temperature. After incubation for 1 h, 
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the enzyme activities were determined by addition of the chromogenic substrate 
BAPNA. These experiments indicated that ligands 8 and 7 inhibit trypsin in the mid-
micromolar range (entries 1 and 2). Ligand 7 containing the propylguanidinium group 
was the more potent inhibitor. Despite the fact that FeII(ClO4)2 had no effect on the 
trypsin activity, the ferrous complexes 9 and 10 showed more potent inhibition than 
ligands alone (entries 3 and 4). Although peracetic acid inhibited trypsin, ferryls 11 and 
12 were more potent oxidants (entries 5-7). Between the ferryls (Figure 2.9a), 12  (IC50 
= 54 µM) was found to be a better oxidant than 11  (IC50 = 71 µM). 
 
Figure 2.9. IC50 plots with ferryl species 11 (red ▲) and 12 (blue ♦) for trypsin (a) and 
chymotrypsin (b). The % enzyme activities at different concentrations were averaged 
out from three different independent runs, with 100% activity equal to the activity of the 
blank reaction in the absence of inhibitor and the error equal to the standard deviation of 
the data set. Enzyme (trypsin/chymotrypsin) concentration was 1.0 µM; trypsin 
substrate N-α-Benzoyl-DL-arginine-4-nitroanilide hydrochloride and chymotrypsin 
substrate N-Succinyl-Ala-Ala-Pro-Phe-pNA concentrations were 1.0 mM. The reactions 
were conducted at pH = 6.0, in 10 mM acetate buffer containing 150 mM NaCl. 
When inactivation studies were performed on chymotrypsin, different results 
were obtained (Table 2.2). Neither the ligands 8 and 7 nor the ferrous complexes 9 and 
10 (entries 1-4) inhibited chymotrypsin in the range from 0 to 1000 µM, with the 
exception of 10, which inhibited chymotrypsin only at very high concentrations (IC50 = 
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790 µM). This observation is consistent with the loss of binding at the active site 
because the S1 pocket of chymotrypsin prefers hydrophobic groups as opposed to the 
charged propylguanidinium group of 7. Despite the fact that ligands 8 and 7 and their 
iron complexes show only weak inhibition of chymotrypsin, both ferryls 11 and 12  
(entries 6 and 7) inactivate chymotrypsin in a concentration-dependent fashion (Figure 
2.9b). Between the two ferryls, again 12 was found to be a better oxidant, and a higher 
level of selectivity was observed between the ferryls with chymotrypsin versus trypsin. 
Binding of ferryl 12 near the active site is not likely because the S1 pocket prefers 
hydrophobic groups. Instead, the lower IC50 value of 12 compared to 11 may be 
attributed to favorable electrostatic interactions between the charged ferryl 12 and 
carboxylates on the surface of chymotrypsin, which are present in higher abundance 
than with trypsin.228 
Table 2.2. IC50 values (µM) for the inhibition of trypsin and chymotrypsin by ligands 8 
and 7 and their respective ferrous (9 and 10) and ferryl (11 and 12) complexes 
Entry Compound Trypsina Chymotrypsina 
1 N4Py (8) 493 >1000 
2 3CG-N4Py (7) 354 1024 
3 [FeII(OH2)(N4Py)]2+ (9) 301 >1000 
4 [FeII(OH2)(3CG-N4Py)]3+ (10) 217 787 
5 Peracetic acid 236 128 
6 [FeIV(O)(N4Py)]2+ (11) 71 119 
7 [FeIV(O)(3CG-N4Py)]3+ (12) 54 26 
8 FeII(ClO4)2 >1000 >1000 
 
a Reaction conditions are mentioned in detail in Figure 2.9 footnote. 
  
47 
2.3.1.4. Characterization of products 
 
Figure 2.10.  (a) SDS-PAGE analysis (16%), stained with Coomassie blue, of trypsin 
(20 µM) incubated at room temperature for 1 h at pH = 6.0, in a 10 mM acetate buffer 
containing 150 mM NaCl. A smeared band near 23 kD in lanes 3-5 showed oxidized 
enzyme. Lane 1: MW marker. Lane 2: enzyme only. Lane 3: peracetic acid (1000 µM). 
Lane 4: 11 (1000 µM). Lane 5: 12 (1000 µM). (b) SDS-PAGE analysis (16%), stained 
with Coomassie blue, of chymotrypsin (20 µM) incubated at room temperature for 1 h at 
pH = 6.0, in a 10 mM acetate buffer containing 150 mM NaCl. A smeared band near 25 
kD in lanes 3 and 4 showed oxidized enzyme. Lane 1: MW marker. Lane 2: enzyme 
only. Lane 3: 11 (500 µM). Lane 4: 12 (500 µM). Lane 5: enzyme with DTT (100 mM). 
Lane 6: 11 (500 µM) with DTT (100 mM). Lane 7: 12 (500 µM) with DTT (100 mM). 
Equal amounts of protein were loaded in each lane. 
To gain insight into the mode of inactivation, enzyme products were analyzed by 
SDS-PAGE (Figure 2.10), which confirmed that trypsin was oxidized but not cleaved 
extensively after treatment with ferryls 11 and 12. Incubation of the protein alone for 1 h 
resulted in a major loss of intensity for the parent band at 23 kD and the formation of 
new bands with lower molecular weight, consistent with cleavage of the protein by 
autoproteolysis (Figure 2.10a). In contrast, enzyme samples treated with peracetic acid 
or ferryls 11 and 12 showed little or no cleavage of the protein, consistent with an 
inactivation event being faster than autoproteolysis of the enzyme. In the case of trypsin 
treated with peracetic acid (lane 3), a sharp, well defined band was observed at 23 kD, 
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whereas samples treated with the ferryl complexes showed a broad, smeared band 
(lanes 4 and 5) near the trypsin region (∼  23 kD), indicating a distribution of molecular 
weights near the parent mass of the enzyme.229 
Similar results were obtained with chymotrypsin. In the control sample with 
enzyme alone, fragments with lower molecular weights were observed, which is 
consistent with autoproteolysis (Figure 2.10b, lane 2). Autoproteolysis was inhibited by 
peracetic acid, but the enzyme appeared as a sharp band. In contrast, broad smeared 
bands near the 25 kD region were observed for chymotrypsin treated with ferryls 11 and 
12  (lanes 3 and 4). Fragments of lower molecular weight were not observed in lanes 3 
and 4, indicating that inactivation of the enzyme was rapid and complete before 
autoproteolysis began. Because chymotrypsin is composed of three subunits, α  (1254 
kD), β (13924 kD), and γ (10067 kD), which are linked by disulfides, the same three 
samples were treated with dithiothreitol (DTT) to determine if internal cross-links had 
formed between the subunits. Lane 5 with enzyme plus DTT showed three major 
fragments, plus new bands that were expected because of autoproteolysis. Only three 
bands were observed in samples treated with ferryls 11 and 12 followed by DTT (lanes 
6 and 7), which are consistent with the expected molecular weights for the subunits (β 
and γ) plus an additional band resulting from incomplete cleavage of the disulfide bond 
between the α and β subunits. Although the band at 14 kD could represent a covalent 
cross-link that was not cleaved by DTT, the sample of enzyme only treated under the 
same conditions shows the same pattern, suggesting that incomplete reduction of the 
disulfide bond between the α and β subunits occurred. However, bands at 14 and 11 kD 
in samples treated with ferryls 11 and 12 appear broad with respect to the same bands 
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observed in lane 5, as would be expected if the individual subunits were oxidized at the 
side chains and present as a distribution of masses near the parent region. 
 
Figure 2.11. LC chromatograms (top) and deconvoluted MS spectra (bottom) of trypsin 
(spectrum a) and after treatment with 12 (spectrum b) or 11 (spectrum c). Reactions 
were conducted at room temperature by incubating trypsin (20 µM) with 11 or 12 (1000 
µM) for 1 h before desalting and subjecting the samples to ESMS analysis.  
 
 
  
50 
 
Figure 2.12. LCMS chromatograms (top) and deconvoluted MS spectra (bottom) of 
chymotrypsin (spectrum a) and after treatment with 12 (spectrum b) or 11 (spectrum c). 
Reactions were conducted at room temperature by incubating chymotrypsin (20 µM) 
with 11 or 12 (1000 µM) for 1 h before desalting and subjecting the samples to ESMS 
analysis. 
LCMS chromatograms of trypsin (20 µM, not incubated), and trypsin incubated 
with the ferryls 11 and 12 (1000 µM) for 1 h at room temperature, show different 
retention times and product distributions for enzyme (control) versus enzymes treated 
with ferryls 11 and 12 (Figure 2.11). Integration of the peaks and deconvolution of the 
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MS spectra gave a single peak for the control sample with enzyme only, which 
corresponds to the MW of bovine trypsin (MW = 23293) and complex spectra for both 
samples treated with ferryls. For the treated samples, a distribution of molecular weights 
larger than that of trypsin was observed consistent with oxidation of the enzyme by the 
addition of multiple oxygen atoms to the protein, as evidenced by the difference 
between masses corresponding to 16 units. In the case of the sample treated with ferryl 
12  (Figure 2.11, spectrum b), a second group of peaks was observed below the parent 
mass of trypsin, which is consistent with oxidation of trypsin and cleavage of a small 
fragment, approximately 2 kD in weight, most likely from the N terminus (vide infra). 
Similar results were observed for chymotrypsin. LCMS chromatograms of chymotrypsin 
(20 µM) incubated with the ferryls 11 and 12 (1000 µM) for 1 h at room temperature are 
shown in Figure 5 (Figure 2.12). The sample with enzyme only showed a sharp peak 
that was integrated and deconvoluted to a mass of 25449, whereas broad peaks were 
observed for samples treated with ferryls 11 and 12. Again integration of these peaks 
gave complex spectra with peaks higher in masses than the chymotrypsin itself 
consistent with oxidation of protein. 
2.3.1.5. Enzyme Inactivation with Ferrous Complexes and H2O2 
After it was established that trypsin and chymotrypsin could be inactivated 
selectively with ferryls 11 and 12, experiments were performed in which the enzymes 
were treated with ferrous complexes 9 and 10 prior to the addition of oxidant. These 
conditions were examined to determine if catalytic inactivation of the proteases was 
possible. When enzymes were incubated in the presence of 9 or 10 under an aerobic 
atmosphere, the enzyme activity did not change within reasonable time periods (< 6 h). 
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Similar results were obtained in the presence of the reductant ascorbate or DTT, which 
did not accelerate enzyme inactivation. Thus, these results confirm that enzyme 
inactivation of trypsin and chymotrypsin using O2 as the oxidant, either in the presence 
or absence of reductant, is a relatively slow process with these iron complexes.230 
 
Figure 2.13. Trypsin (graph a) and chymotrypsin (graph b) activities as a function of 
added H2O2. Samples containing enzyme only (brown ●, 1 µM) and enzyme treated 
with FeII(ClO4)2 (green n), 9 (red ▲), or 10 (blue u) (20 µM) were pulsed with H2O2 
every 10 min (40 µM per pulse). The reaction was performed in an acetate buffer of pH 
= 6.0 containing 150 mM NaCl. The activities were converted to % enzyme activity, with 
100% activity equal to the activity of the blank reaction in the absence of inhibitor at t = 
0. Data points are averages from three independent experiments, where errors are 
reported as standard deviations. 
More promising results were obtained when H2O2 was used as the oxidant. For 
these experiments, solutions of trypsin (1 µM) and several iron species [FeII(ClO4)2, 9 or 
10, 20 µM] were pulsed with H2O2 (40 µM per pulse). Enzyme activities were 
determined by removing aliquots after each pulse (10 min between pulses) and plotted 
against the total amount of peroxide added (Figure 2.13a). Negligible changes in the 
activities were observed with trypsin alone and trypsin treated with FeII(ClO4)2. In the 
case of the sample treated with FeII(ClO4)2, the trypsin activity dropped immediately by 
∼15% after the first addition of H2O2 but did not drop further after the addition of more 
  
53 
H2O2, which is consistent with a Fenton reaction carried out by an iron species that was 
no longer viable after the first addition of the oxidizing reagent. In contrast, enzyme 
activities were lost in a concentration-dependent fashion with respect to H2O2 when 
pulsing was performed in the presence of 9 or 10. In both cases, the activities were 
diminished by roughly 80% after the addition of 200 µM H2O2, 10 equiv with respect to 
the iron complexes. These data confirm that 10, which contain the propylguanidinium 
group, inactivate trypsin more effectively than 9. For example, after three additions of 
H2O2 (120 µM total), the trypsin activity dropped by 80% with 10 compared to 60% with 
9. The more efficient inactivation of trypsin with 10 compared to 9 confirms that 
selectivity can be gained between two iron complexes and is consistent with the protein-
affinity group (propylguanidinium) of 10 directing the complex toward the protein, 
presumably the S1 pocket where Asp 189 may form a salt bridge with the guanidinium 
group. 
When chymotrypsin was treated with H2O2 under the same conditions, controls 
with enzyme alone or enzyme plus FeII(ClO4)2 showed no significant changes after the 
addition of 200 µM H2O2 (Figure 2.13b). Again, the enzyme activity was lost in a 
concentration-dependent fashion when chymotrypsin was pulsed with H2O2 in the 
presence of 9 and 10. However, the enzyme activities dropped only by ∼  35% in both 
cases after the addition of 200 µM H2O2, as opposed to 80% with trypsin. Selectivity 
was not observed between 9 and 10. These data confirm that selective inactivation of 
trypsin over chymotrypsin can be observed with the iron complexes 9 and 10 in the 
presence of H2O2. Differences in reactivity for 9 and 10 with trypsin versus chymotrypsin 
parallel data from inhibition studies (Table 2.2, entries 3 and 4), where the complexes 9 
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and 10 show more a potent inhibition of trypsin than chymotrypsin. The trend observed 
is consistent with the active reagents derived from 9 or 10 and H2O2 possessing a 
higher effective molarity for trypsin over chymotrypsin and causing more efficient 
oxidative damage. 
 
Figure 2.14. SDS-PAGE analysis (16%), stained with silver, of (a) trypsin and (b) 
chymotrypsin (1 µM), pulsed with H2O2 (40 µM) every 10 min in the presence of 10 (20 
µM) at room temperature at pH = 6.0, in a 10 mM acetate buffer containing 150 mM 
NaCl. Smeared bands near 23 kD in part a and 25 kD in part b in lanes 3-7 showed 
oxidized enzymes. Lane 1: MW marker. Lane 2: enzyme only. Lane 3: H2O2 (40 µM). 
Lane 4: H2O2 (80 µM). Lane 5: H2O2 (120 µM). Lane 6: H2O2 (160 µM). Lane 7: H2O2 
(200 µM). 
Analysis by LCMS and SDS-PAGE was used in order to characterize the enzyme 
products from trypsin and chymotrypsin. SDS-PAGE analysis of the enzymes (1 µM), 
pulsed with H2O2  (40 µM per pulse) every 10 min, in the presence of 10 showed an 
increase in the smearing of the band near the parent trypsin band (23 kD, Figure 2.14a) 
and the chymotrypsin band region (25 kD, Figure 2.14b) with added H2O2, although 
smearing was less extensive than in the samples treated with ferryls 11 and 12. This 
observation is consistent with a distribution of molecular weights after oxidation with 10 
and H2O2. Because other bands were not observed in either case, the oxidation with 10 
and H2O2 does not lead to cleavage of the enzymes. The chromatograms of trypsin (1 
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µM) and chymotrypsin pulsed with H2O2 (40 µM per pulse) in the presence of 9 or 10 
(20 µM) at room temperature show different retention times and product distributions for 
enzyme (control) versus treated samples. Integration of the peaks and deconvolution of 
the MS spectra gave single peaks for the control samples with enzyme only, while 
complex spectra were obtained for samples where enzymes were pulsed with H2O2 in 
the presence of 9 or 10, confirming that oxidation of the proteins occurred. 
2.4.1.6. Mechanistic studies 
Additional experiments were carried out to gain further insight into the nature of 
protein inactivation under single-turnover (ferryls 11 and 12) and catalytic conditions (9 
or 10 plus H2O2). In particular, the identity of the active oxidant under catalytic 
conditions was in question. Both HO• (Fenton chemistry) and iron-based oxidants have 
been implicated in oxidation reactions when ferrous complexes such as 9 are treated 
with H2O2, and the outcome varies according to the ligand set and the conditions of the 
experiment (vide infra).231-233 To distinguish between Fenton chemistry (HO•) and iron-
based oxidants, control experiments were performed in the presence of reagents that 
scavenge ROS. When the inactivation of trypsin with 10 was performed in the presence 
of D-mannitol, a potent hydroxyl radical scavenger, inactivation was not inhibited with 
0.1 mM D-mannitol and was only slightly inhibited with 20 mM D-mannitol, confirming 
that HO• can act as only a minor component of the inactivation pathway if at all (Figure 
2.15 for trypsin). Thus, another oxidant was likely at play. Similar results were obtained 
in the presence of imidazole, a scavenger of the hydroxyl radical and 1O2. Interestingly, 
inactivation was inhibited somewhat in the presence of NaN3 (0.1-1 mM), again in a 
concentration-dependent fashion. Although azide is a scavenger of 1O2, it is known to 
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inhibit tyrosine nitration catalyzed by the heme enzyme myeloperoxidase.234 In this 
case, rather than quenching 1O2, competitive binding of azide to the peroxidase iron 
center may poison the heme by blocking access to H2O2.235 In support of this mode of 
inhibition, the binding of azide to 10 was confirmed by UV-vis titration of 10 with NaN3, 
which suggests that the action of peroxide with the iron catalyst can be inhibited by 
ligands that bind competively to the sixth site of the iron center. Together, these results 
indicate that an oxidant other than HO• or 1O2 is responsible for the inactivation of 
trypsin and chymotrypsin in the presence of 9 or 10 and H2O2. 
 
Figure 2.15. Inactivation of trypsin in the presence of ROS scavangers (azide, D- 
mannitol, and imidazole). The reactions were conducted at pH = 6.0, in a 10 mM 
acetate buffer containing 150 mM NaCl. Trypsin (1 µM) with 10 (20 µM) was pulsed with 
H2O2 (40 µM) in the presence of a buffer as a blank (blue n) and ROS scavengers D-
mannitol (0.1 mM, green ▲; 20 mM, black ¢), imidazole (0.1 mM, purple ☐), and NaN3 
(0.1 mM, maroon u; 1.0 mM, red ●). Enzyme activities, where 100% activity is equal to 
the activity of the blank reaction in the absence of inhibitor at t = 0, were determined by 
removing aliquots before each pulse (10 min between pulses) and plotted against the 
total amount of peroxide added. Data points are averages from three independent 
experiments; errors were ± 5%. 
The presence of ketones and aldehydes in proteins, known as the carbonyl 
content, is a key indicator of oxidative damage observed in vitro and in vivo during aging 
and under conditions of oxidative stress.236 Because normal proteins do not contain 
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ketone or aldehyde carbonyls that react electrophilically with hydrazine nucleophiles, 
the reagent 2,4-dinitrophenylhydrazine can be used to determine the overall protein 
carbonyl content resulting from protein oxidation. Following a literature method,236 the 
amount of carbonyl groups formed with trypsin and chymotrypsin (20 µM) was 
determined as a function of the pulsed H2O2 concentration in the presence of 10  (50 
µM; Figure 2.16). Similar results were obtained with 9. In the case of both enzymes, an 
increase in the carbonyl content was observed that plateaued at 500 µM H2O2 to 
approximately 20 nmol/mg of protein. Because nearly identical results were obtained 
with trypsin and chymotrypsin, these data indicate that the formation of protein 
carbonyls is not coupled to the inactivation event imparted by 10 and H2O2 (Figure 
2.13a,b). In fact, using the molecular weight of the proteins and the observed content of 
protein carbonyls, one can estimate that only four or five carbonyls are formed per 
protein out of 223 (trypsin) and 241 (chymotrypsin) residues when the proteins (20 µM) 
are treated with 10 (50 µM) and 500 µM H2O2. Assuming that a single carbonyl is 
formed per oxidized residue, this modification accounts for less than 3% of all residues. 
 
Figure 2.16. Carbonyl content (nmol/mg of protein) as a function of pulsed H2O2 (0-500 
µM) for enzymes (20 µM) trypsin (blue ●) and chymotrypsin (red ▲) in the presence of 
10 (50 µM). Data points are averages from three independent experiments, where the 
errors are reported as standard deviations. 
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The aforementioned results confirm that a unique oxidant must give preferential 
inactivation of trypsin over chymotrypsin under catalytic conditions. Attempts to analyze 
the oxidized proteins by LCMS/MS analysis were inconclusive due to low sequence 
coverage because the oxidized proteins did not respond well to digestion. Although 
LCMS/MS analysis can reveal information about the location of oxidized residues in 
proteins, it is difficult to obtain quantitative measurements of protein oxidation using this 
method. Therefore, amino acid analysis was performed on the oxidized samples, in 
order to determine which types of residues were affected by treatment of trypsin and 
chymotrypsin under the single-turnover (ferryls 11 and 12) and catalytic conditions 
(ferrous complexes 9 and 10 plus H2O2) (Figure 2.17).  
Strikingly, catalytic conditions produced a major modification in the levels of the 
amino acid tyrosine with respect to the control, while leaving other amino acid levels 
unchanged within the margin of error. Different results were obtained with the ferryls, 
where the levels of tyrosine, cysteine, and tryptophan were diminished significantly with 
respect to controls. These data are consistent with published model studies that 
indicated that cysteine, tyrosine, and tryptophan were the most reactive amino acids 
with 11.108 Results obtained in the single-turnover and catalytic conditions were not 
highly dependent on the ligand structure, suggesting that only a modest level of 
directablility was achieved by attaching the propylguanidinium group to the N4Py ligand. 
These results confirm that catalytic conditions result in a milder form of oxidation than 
oxidation by the ferryls and support the hypothesis that an oxidant other than ferryl is 
acting in the presence of H2O2. 
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Figure 2.17. Bar graphs showing the compositions of five natural amino acids present 
in the oxidized proteins samples isolated from single-turnover (ferryls 11 and 12 in 
green and gold, respectively) and catalytic conditions (9 or 10 plus H2O2 in red and blue, 
respectively) for trypsin (a) and chymotrypsin (b). Compositions are reported as 
percentages normalized with respect to the control experiments with no iron or oxidant 
added. Enzymes trypsin and chymotrypsin (20 µM) were treated with ferryl 11 or 12 
(1000 µM) or with 9 or 10 (50 µM) and pulsed with H2O2 (500 µM total, 100 µM per 
pulse). Standard errors are 10%. The results indicate that tyrosine was modified 
selectively in the case of catalytic conditions with 9 or 10 plus H2O2, whereas cysteine, 
tyrosine, and tryptophan were modified by ferryls 11 and 12. 
In order to gain insight into the reaction of the iron catalyst with tyrosine in the 
presence of H2O2, the oxidation of 13 was examined. Under the same conditions as 
those used in the enzyme experiments, the catechol product Ac-DOPA-OH (14) was 
observed as a major product by HPLC analysis (Scheme 2.3). Dityrosine, a common 
product of tyrosine oxidation resulting from oxidative coupling of the two phenol rings, 
was detected by fluorescence analysis of the crude reaction mixture but not by ESMS, 
suggesting that this product was present in only trace amounts. Importantly, 
chlorotyrosine was not detected by ESMS or HPLC analysis of the crude reaction 
mixture, which confirmed that oxidation of 13 was not due to the action of HOCl 
generated from H2O2 and chloride ion.237,238 Taken together, these observations are 
diagnostic and significant because catechol products are not formed when tyrosine 
derivatives are treated with the ferryl 11, confirming that a different mechanism of action 
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takes place when H2O2 is used as the oxidant. In other words, ferryl 11 was not the 
active oxidant. To probe this further, the reaction was monitored by UV-vis 
spectroscopy. When the ferrous complex 9 was treated with 0.5 equiv of H2O2 under 
these conditions, bleaching occurred, which consumed the signature absorbance for 
FeII at 380 and 464 nm. However, ferryl 11 was not observed, suggesting that a ferric 
complex was formed instead (vide infra). When this mixture was treated with 13, the 
yellow color of the starting ferrous complex returned and reached completion after 
approximately 10 min, as judged by UV-vis spectroscopy. If this reaction solution was 
treated again with peroxide, bleaching occurred again, and after ca. 10 min, the UV 
spectrum returned to its original intensity, suggesting that turnover was possible without 
significant loss of the starting ferrous complex. In conclusion, these results are 
consistent with the phenol ring of tyrosine being oxidized by an oxidant other than ferryl 
11, which is discussed in the following section. 
 
Scheme 2.3. Conversion of Ac-Tyr-OH into Ac-DOPA-OH in presence of ferrous 
complex and H2O2 
2.3.2. Discussion 
Our results confirm that ferryls are potent and selective oxidants that inactivate 
serine proteases. The ferryls 11 and 12 were more powerful oxidants than peracetic 
acid. Selectivity was observed for a single ferryl between two enzymes (trypsin and 
chymotrypsin; Table 2.2, entry 7 vs. entry 8) but also for a single enzyme between two 
ferryls (Table 2.2, entries 7 and 8, trypsin vs. chymotrypsin). Ferryl 12 was most 
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effective in the inactivation of chymotrypsin with an IC50 value of 24 µM. With both 
serine proteases, the oxidation of protein side chains occurred. Major cleavage products 
were not observed by SDS-PAGE or LCMS, confirming that cleavage of the protein 
backbone is a slow process relative to side-chain oxidation. In the oxidation of trypsin by 
12, LCMS analysis indicated a minor cleavage product consistent with a loss of 
approximately 2 kD, presumably at a glycine residue located near the active site, 20 
residues from the N terminus of the enzyme. Therefore, these results are in good 
agreement with model studies that focused on protected amino acids,108 which 
confirmed that activation of the α-CH bond of amino acids and resultant oxidative 
cleavage of the backbone are slow relative to side-chain oxidation with ferryl 
complexes. Furthermore, the results from the amino acid analysis of enzyme samples 
oxidized by the ferryls prove a direct correlation between the most reactive amino acids 
(cysteine, tyrosine, and tryptophan) in the model studies with Ac-AA-NHtBu substrates 
and the residues modified in the proteins trypsin and chymotrypsin. These results have 
relevance to biology because, under conditions of oxidative stress, ferryls such as 
ferrylmyoglobin can oxidize proteins.193,239-245 Observations reported herein reveal 
useful information about how proteins are modified and inactivated by ferryls. For 
example, when tyrosine and tryptophan residues are oxidized, as our results confirm, 
this type of oxidation is often irreversible.189 In contrast, oxidative modification of 
cysteine residues can be reversed if disulfides are formed.246 However, when higher 
oxidation states of sulfur are obtained, such as sulfenic and sulfonic acid derivatives, 
oxidative damage becomes irreversible. The levels of cystic acid did not change in 
these studies between control and treated samples of enzyme, consistent with the 
oxidants presented herein forming products other than cystic acid.  
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Reasonable levels of selectivity were observed in the oxidation of trypsin and 
chymotrypsin catalyzed by 9 and 10 in the presence of H2O2. However, as opposed to 
the single-turnover conditions where ferryl 12 was the most effective at inactivating 
chymotrypsin, catalytic conditions provided the most efficient inactivation of trypsin with 
both 9 and 10. The advantage of incorporating iron and oxidant with the inhibitors 8 and 
7 was clear. Upon addition of these two reagents, a ligand concentration of 20 µM 
becomes more effective than 500 µM inhibitor alone, which amplifies the effects of the 
ligand by almost 2 orders of magnitude. The results obtained from amino acid analysis 
prove that tyrosine residues of both proteins were selectively targeted under these 
conditions, with residues of trypsin being diminished to a greater extent (60% of control) 
than chymotrypsin (80%). These results suggest that iron complexes derived from N4Py 
mimic the action of myeloperoxidase, a heme enzyme produced by neutrophil 
granulocytes (white blood cells) that is known to oxidize tyrosine residues of proteins 
using H2O2 as the oxidant.247  
 
Figure 2.18. Surface models of trypsin and chymotrypsin with tyrosine residues near 
the active site highlighted in red. Trypsin contains four residues near the active site, 
whereas chymotrypsin contains three. 
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The selective inactivation of trypsin observed under catalytic conditions may be 
due to the active iron reagent obtained with H2O2, giving a higher effective molarity with 
trypsin than with chymotrypsin. Alternatively, this selectivity could be due to an inherent 
sensitivity of trypsin over chymotrypsin to oxidation of its Tyr residues. Both enzymes 
have numerous tyrosine residues on the surface near the active site (Figure 2.18). The 
fact that ligands 8 and 7 were more effective at inhibiting trypsin than chymotrypsin, in 
the absence and presence of FeII(ClO4)2, supports the hypothesis that the active 
reagents derived from 9 and 10 bind tighter to trypsin than chymotrypsin. Furthermore, 
previous studies performed with 1O2 confirmed that trypsin and chymotrypsin have 
similar sensitivity to oxidation, although the types of residues targeted in this case were 
likely different and were not confirmed.248 More studies in this area are needed, 
specifically over a larger group of enzymes such as the family of serine proteases, to 
discern between these two possibilities. Importantly, these studies suggest that 
incorporating protein affinity groups that bind tighter to enzyme targets and place iron 
catalysts in the vicinity of tyrosine residues has the potential to achieve protein 
inactivation at low concentrations.  
The results with iron complexes and H2O2 indicate that a unique oxidant was 
responsible for the selective protease inactivation. Control experiments ruled out ROS 
such as HO• (Fenton chemistry) or 1O2. The action of ferryls under these conditions is 
also unlikely because ferryls were not observed when the ferrous complexes 9 or 10 
were treated with peroxide. Furthermore, studies in Table 2.1 prove that chymotrypsin is 
inactivated at lower ferryl concentrations than trypsin, so the opposite trend in selectivity 
would be expected under catalytic conditions if ferryls were operating. The action of a 
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different oxidant is also supported by the fact that catechol is observed in the oxidation 
of Ac-Tyr-OH (13) with H2O2. Catechols are not observed when tyrosine derivatives are 
treated with ferryl 11; instead, hydrogen-atom transfer occurs to generate phenoxyl 
radicals that decompose, presumably by polymerization.108 Taking into account our 
results and data in the literature,249 we can conclude that another oxidant is likely to be 
generated under catalytic conditions. However, further mechanistic studies in this area 
are needed to differentiate between the potential pathways and to determine if there is 
an analogy between the chemistry reported herein and the action of the non-heme iron 
enzyme tyrosine hydroxylase216,250,251 or the heme enzyme myeloperoxidase.247 In any 
case, the effect of the ligand N4Py is clear in the inactivation experiments because 
FeII(ClO4)2 did not give the same level of dose-dependent inactivation with H2O2. 
2.4. Conclusions and future directions 
Non-heme iron complexes inactivate serine proteases selectively. Ferryls are 
potent oxidants that inactivate trypsin and chymotrypsin by oxidation of amino acid side 
chains rather than backbone cleavage, where the residues cysteine, tyrosine, and 
tryptophan are the most susceptible to oxidation. Oxidation of the proteases by ferrous 
complexes in the presence of hydrogen peroxide leads to the preferential inactivation of 
trypsin over chymotrypsin. In this case tyrosine residues are targeted, and data support 
action of a pathway unique from that of an FeII/FeIV cycle involving ferryl compounds. 
Importantly, these results suggest a promising future direction for the method presented 
herein where complexes that cycle between accessible oxidation states are used to 
target proteins. Although the scope of such a method may be limited with respect to 
ROS for attack on tyrosine residues, there are many proteins, including important 
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medicinal targets that contain crucial tyrosine residues near their active sites. 
2.5. Experimental section 
  2.5.1. General considerations 
  All reagents were purchased from commercial suppliers and used as received. 
NMR spectra were recorded on a Varian FT-NMR Mercury-400 MHz Spectrometer. 
Mass spectra were recorded on a Micromass Quattro LC Triple-Quad mass 
spectrometer using an electrospray ionization source. IR spectra were recorded on a 
Nicolet FT-IR spectrophotometer. Enzymatic assays were performed on a TECAN 
Infinite M200 microplate reader. UV-vis spectra were recorded on a Varian Cary 50 
spectrophotmeter. Human carbonic anhydrase-I (product # C4396) and its substrate, 4-
nitrophenyl acetate (product # N8130), were obtained from Sigma. Trypsin from bovine 
pancreas (product # T8003) and its substrate, N-α-benzoyl-DL-arginine-4-nitroanilide 
hydrochloride (catalog # 227740050), were obtained from Sigma and Acros Organics, 
respectively, and were used as received. Chymotrypsin (product # C4129) and its 
substrate N-succinyl-Ala-Ala-Pro-Phe-pNA (product # S7388) were obtained from 
Sigma. Absorbance data were collected on a GENios Pro, microplate reader, TECAN, 
using 96-well microplates. The compounds 1,1-dipyridin-2-yl-N,N-bis(pyridin-2-
ylmethyl)methanamine (N4Py, 8),218 methyl 6-[[(dipyridin-2-ylmethyl)(pyridin-2-
ylmethyl)-amino]methyl]nicotinate (1),222 and N-acetyltyrosine (13)252 were synthesized 
using literature procedures. 
  2.5.2. Molecular modelling 
  Docking studies were performed with the program MacPyMOL using 
crystallographic data from 4-aminobenzenesulfonamide bound to CA-I (PDB ID 1CZM). 
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For these studies, a model of the ferryl inhibitor [FeIV(O)(4)]2+ was constructed using the 
program Spartan 04. Bond length and angle constraints were made on the 
[FeIV(O)(N4Py)]2+ unit of the inhibitor using crystallographic data for the ferryl species 
before MM2 minimization of the overall structure [FeIV(O)(4)]2+ was carried out. After 
minimization, a pdb file of the inhibitor was exported from Spartan 04 and imported into 
MacPyMOL for docking in the active site of CA-I. Dihedral angles of the inhibitor were 
adjusted to place the inhibitor in the active site after overlapping benzenesulfonamide 
portions of the orignal inhibitor and [FeIV(O)(4)]2+. The dihedral angle of the amide bond 
of the inhibitor was maintained at 180 °. 
  2.5.3. Inhibitor synthesis 
  Preparation of 6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino)methyl)-
N-(4-sulfamoylbenzyl)nicotinamide (4). Sodium hydroxide (2 N, 1 mL) was added 
dropwise to a solution of ester 1 (0.225 g, 0.481 mmol) in methanol (3 mL). This 
reaction mixture was stirred vigorously at rt. After 4 h, the reaction mixture was acidified  
to pH = 2 with 2 N HCl and then concentrated. Methanol (5 mL) was added to the 
remaining residue. The white solid formed was removed by filtration and the filtrate was 
concentrated to give slightly wet brown solid. The brown solid was dried under vacuum 
desiccator over P2O5 and KOH to give the acid 2 (0.24 g, quant.). LRMS (ESI) Calcd for 
C28H30N5O2 [(M+H)+]:  m/z 468. Found: m/z 468. 
  DSC (250 mg, 0.98 mmol) and pyridine (195 µL, 2.43 mmol) were added to a 
solution of the crude acid 2 (100 mg, 0.243 mmol) in acetonitrile (25 mL) and stirred at 
80 °C under nitrogen.  After 2 h, the reaction mixture was cooled to room temperature 
and concentrated to remove pyridine and acetonitrile.  The remaining residue was 
dissolved in 5% NaHCO3 (50 mL) and extracted with chloroform (50 mL x 3).  The 
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organic layers were then combined, dried with anhydrous sodium sulfate, and 
concentrated to yield the corresponding N-hydroxysuccinimde ester 3 (104 mg, 84%) as 
a brown oil that was unstable to chromatography and used without further  purification. 
1H-NMR (CDCl3) δ 9.11 (d, J = 2.4 Hz, 1H), 8.53 (d, J = 4.9 Hz, 2H), 8.45 (d, J = 4.1 Hz, 
1H), 8.21–8.31 (dd, J = 2.4, 1.6 Hz, 1H), 7.79 (d, J = 8.1, 1H), 7.42–7.69 (m, 6H), 7.06–
7.15 (m, 3H), 5.34 (s, 1H), 4.09 (s, 2H),  3.95 (s, 2H),  2.87 (s, 4H); 13C-NMR (CDCl3) δ 
168.9, 167.5, 160.9, 159.7, 159.1, 150.7, 149.2, 149.0, 137.8, 136.4, 126.4, 125.2, 
124.0, 123.2, 122.8, 122.3, 122.0, 72.6, 57.9, 57.4, 25.6; LRMS (ESMS) calcd for 
C28H25N6O4 [(M+H)+]: m/z 509. Found: m/z 509. 
  4-(aminomethyl)benzenesulfonamide (20 mg, 0.11 mmol) was added to a 
solution of N-hydroxysuccinimde ester 3 (54 mg, 0.11 mmol) and DMF (5 mL) and 
stirred for 5 h at room temperature.  After 5 hours, the reaction mixture as concentrated 
in vacuo to remove DMF. Alumina gel chromatography (EtOAc, then MeOH) was used 
to purify the crude mixture.  A brown oil was obtained after MeOH elution that was 
stirred with EtOAc and filtered. The inhibitor 4 precipitated upon addition of hexanes to 
the filtrate and was isolated as a tan amorphous solid (33 mg, 54%). 1H-NMR (CD3OD) 
δ 8.83 (d, J = 1.8 Hz, 1H), 8.46 (d, J = 4.9 Hz, 2H), 8.35 (d, J = 4.3, 1H), 8.12 (dd, J = 
2.2, 6.1 Hz, 1H), 7.80-7.65 (m, 7H), 7.58-7.40 (m, 5H), 7.30-7.18 (m, 3H), 5.36 (s, 1H), 
4.63 (s, 2H), 4.03 (s, 2H), 3.97 (s, 2H); 13C-NMR (d6-DMSO) δ 172.9, 165.0, 162.7, 
159.9, 159.2, 149.0, 148.9, 147.9, 143.5, 142.7, 136.6, 136.5, 135.6, 128.0, 127.6, 
125.8, 123.7, 122.5, 122.2, 122.0, 71.4, 57.0, 56.6, 42.3; IR (film) 3583, 3219, 2922, 
2851, 2360, 1705, 1651, 1592, 1569, 1537, 1469, 1433, 1260, 1158, 1036, 752 cm-1; 
LRMS (ESMS) calcd for C31H30N7O3S [(M + H)+]: m/z 580. Found: m/z 580. 
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Preparation of tert-Butyl-1-(6-[[(Dipyridin-2-ylmethyl)(pyridin-2-
ylmethyl)amino]methyl]pyridin-3-yl)-11,11-dimethyl-1,9-dioxo-10-oxa-2,6,8-
triazadodecan-7-ylidenecarbamate (6). A solution of N-(3-aminopropyl)-6-[[(dipyridin-
2-ylmethyl)(pyridin-2-ylmethyl)-amino]methyl]nicotinamide 5 (100 mg, 0.213 mmol) in a 
mixture of tetrahydrofuran (THF; 0.3 mL) and H2O (20 µL) was treated with a solution of 
1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (61.8 mg, 0.213 mmol) in THF 
(0.2 mL) dropwise at room temperature. The reaction mixture was heated to 50 °C for 1 
h and then concentrated in vacuo. The resulting crude reaction mixture was partitioned 
between CHCl3 (5 mL) and a saturated aqueous solution of NaHCO3 (5 mL). The 
organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated 
to obtain 6 as a pale-yellow solid (131 mg, 88%). 1H-NMR (CDCl3): δ 11.50 (s, 1H), 9.07 
(d, J = 1.6 Hz, 1H), 8.55-8.52 (m, 3H), 8.48 (d, J = 4.0 Hz, 1H), 8.29-8.26 (m, 1H), 8.16 
(dd, J = 8.1 and 2.4 Hz, 1H), 7.71-7.56 (m, 7H), 7.24-7.07 (m, 3H), 5.29 (s, 1H), 3.99 (s, 
2H), 3.93 (s, 2H), 3.47-3.41 (m, 4H), 1.74-1.72 (m, 2H), 1.48 (s, 9H), 1.28 (s, 9H). 13C-
NMR (CDCl3): δ 165.5, 163.2, 162.9, 159.8, 157.5, 153.2, 149.3, 149.1, 148.4, 136.4, 
136.2, 135.5, 128.4, 123.9, 122.7, 122.2, 122.1, 121.9, 83.5, 79.7, 71.3, 57.2, 56.9, 
36.9, 35.5, 30.3, 28.2, 28.0. IR (cm-1): 3324, 3055, 2978, 2931, 2359, 2239, 1723, 1642, 
1589, 1569, 1474, 1433, 1368, 1325, 1223, 1135, 1049, 1026, 995, 912, 855, 732, 645, 
616. HRMS (ESI) Calcd for C38H47N9O5 [(M + Na)+]: m/z 732.3598. Found: m/z 
732.3589. 
  Preparation of 6-[[(Dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino]-methyl]-
N-(3-guanidinopropyl)nicotinamide hydrochloride (7). Compound 6 (100 mg, 0.141 
mmol) was maintained with 4 M HCl in 1,4-dioxane (2 mL) for 3 h at room temperature. 
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The reaction mixture was concentrated to furnish 7 (100 mg) as a hydroscopic pale-
yellow solid in quantitative yield as its hydrochloride salt. Stock solutions of 10 in H2O (4 
mM) were prepared from this solid for the following studies based on the quantitative 
yield in the conversion of 6 to 7. 1H-NMR (DMSO-d6): δ 9.18 (s, 2H), 8.82 (d, J = 4.1 Hz, 
1H), 8.62 (d, J = 4.1 Hz, 2H), 8.41 (d, J = 7.3Hz, 1H), 8.27 (t, J = 7.3 Hz, 1H), 8.18-8.14 
(m, 2H), 8.01 (br s, 1H), 7.92 (d, J = 8.1 Hz, 2H), 7.82 (d, J = 7.3 Hz, 2H), 7.69-7.62 (m, 
4H), 6.06 (s, 1H), 4.44 (s, 2H), 4.26 (s, 2H), 3.37-3.33 (m, 2H), 3.23-3.21 (m, 2H), 1.76-
1.73 (m, 2H). 13C-NMR (CD3OD): δ 167.3, 161.4, 161.2, 161.1, 156.1, 156.0, 148.7, 
147.5, 146.6, 143.3, 143.0, 138.5, 131.0, 127.8, 127.3, 126.7, 126.4, 124.8, 118.7, 
115.8, 58.1, 55.9, 40.0, 38.2, 29.8. IR (cm-1): 3105, 2359, 1674, 1539, 1469, 1435, 
1320, 1200, 835, 798, 721. HRMS (ESI) Calcd for C28H32N9O [(M + H)+]: m/z 510.2730. 
Found: m/z 510.2733. 
  2.5.4. Metal complexation (FeII·4) 
  The iron-inhibitor complex was prepared by adding a 10 mM solution of 
FeII(NH4)2(SO4)2 (3 mL) into a mixture of 4 (18 mg, 0.030 mmol) and H2O (7 mL). The 
reaction mixture was stirred vigorously for 3 h until the inhibitor dissolved. The complex 
FeII·4 was characterized in solution by UV-vis spectroscopy (λmax 380 nm, ε = 1400 M–1 
cm–1) which agrees well with data for the ferrous complex of N4Py (λmax 390 nm, ε = 
1500 M–1 cm–1) in aqueous solution. A 3 mM stock solution of FeII·4 in H2O was divided 
and frozen. Upon thawing, the quality of the solution was confirmed by UV-vis before 
each enzymatic assay. 
  2.5.5. Metal complexation (9 and 10) and ferryl generation 
  The iron-ligand complexes [FeII(OH2)(N4Py)]2+ (9) and [FeII(Cl)(3CG-N4Py)]2+ 
(10) were prepared by adding 1 equiv of FeII(ClO4)2⋅xH2O (100 mM stock solution in 
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H2O) to H2O solutions of 8 and 7, respectively. Ferryls [FeIV(O)(N4Py)]2+ (11) and 
[FeIV(O)(3CG-N4Py)]3+ (12) were generated by adding 8 µL of a 100 mM solution of 
peracetic acid in H2O (2 equiv) to solutions of 9 and 10 (200 µL, 2 mM). 
  2.5.6. CA-I activity assay 
  Human CA-I activity was measured by collecting absorbance measurements at 
400 nm, using 4-nitrophenyl acetate as the substrate. The final volume used for the 
assay was 100 µL (1 µM CA-I and 1 mM substrate in Tris buffer (12.5 mM) containing 
75 mM NaCl, pH = 8.0). Changes in absorbance were measured for 3 min at an interval 
of  6 sec. The stock solution of substrate was made in DMSO and added to initiate the 
assay. The final concentration of DMSO in the assay was kept at 5%. 
  2.5.7. CA-I inhibition assay 
  Inhibitors, used for inhibition of CA-I activity, were 4, FeII·4, ZnII·4, FeII and ZnII. 
Enzyme was incubated with various concentrations of inhibitor for 5 min prior to 
initiating the assay by addition of substrate. The initial velocities, obtained from A400 vs. 
time plot, were converted to % CA-I activity with respect to the control reaction 
containing no inhibitor. For each assay, % CA-I activity was plotted as a function of 
inhibitor concentration to obtain the dose-dependent curve, which was fit using a 
sigmoid equation to obtain the IC50 value. Each IC50 was computed using the average of 
three runs, with the error equal to the standard deviation. 
  2.5.8. Time-dependent inactivation of human CA-I activity 
  Enzyme (1 µM) was incubated with inhibitor (1 µM) and DTT (500 µM) at 37 °C 
and a series of assays were performed at specified time intervals, with zero time equal 
to the start of incubation. For each activity measurement, the assay was initiated by 
adding substrate to an aliquot, taken out from the reaction mixture. Control reactions 
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with and without inhibitor and no DTT were performed simultaneously. The initial 
velocities were converted to % CA-I activities, with 100% equal to the enzyme activity 
from the control reaction with enzyme only at t = 0, and were plotted as a function of 
preincubation time. 
  2.5.9.  Trypsin and chymotrypsin inactivation assay 
  The enzymatic assays were initiated by adding the substrate (N-α-benzoyl-DL-
arginine-4-nitroanilide hydrochloride for trypsin and N-succinyl-Ala-Ala-Pro-Phe-pNA for 
chymotrypsin) to the solutions of enzyme containing varied concentrations of inhibitor 
(0-1000 µM). The initial velocities, obtained from the A405 versus time plot, were 
converted to the percentage of enzyme activity (% enzyme activity) with respect to the 
control reaction containing no inhibitor. For each assay, % enzyme activity was 
computed using the average of three runs, with the error equal to the standard 
deviation, and plotted as a function of the inhibitor concentration. Data were fit using a 
sigmoidal equation to obtain the IC50 value.  
  2.5.10. Pulse experiments with H2O2 
  The enzyme (1 µM) was incubated with FeII(ClO4)2, or 9 or 10 (20 µM) (total 
volume 600 µL), and H2O2 (5 × 40 µM) was added every 10 min. Enzyme activities were 
determined on aliquots removed from the solution as described above, 10 min after 
each addition of H2O2. Activities were adjusted for dilution prior to their conversion to % 
enzyme activity, with 100% activity equal to the activity of the blank reaction in the 
absence of inhibitor at t = 0. In control experiments, ROS scavengers D-mannitol, 
imidazole, and NaN3 (see Figure 2.14) were added as aqueous solutions before the 
addition of H2O2. 
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  2.5.11. Magnetic susceptibility measurements and NMR studies 
  The solution-phase magnetic moments of iron complexes 9 and 10 were 
determined by 1H-NMR in a D2O solvent following Evan’s method using tert-butyl 
alcohol as the reference. A small capillary tube (closed at one end) was filled with a 
solution of D2Oand tert-butyl alcohol [50-75 µL, 7:1 (v/v)] and sealed. Solutions of 9 (4 
mM, 0.016 mmol, 4 mL) and 10 (5 mM, 0.015 mmol, 3 mL) were made by mixing 
ligands 8 and 7 with 1 equiv of Fe(ClO4)2, respectively, in D2O containing tert-butyl 
alcohol. The sealed capillary tubes were placed inside the NMR tubes, iron complex  
solutions (800 µL) were added, and 1H-NMR spectra were recorded. For solution NMR 
studies, 10 mM solutions of ligands 8 and 7 were prepared in a D2O solvent. Their iron 
complexes 9 and 10 were generated in situ by mixing 800 µL of ligand solutions 8 and 
7, with 10 µL of a 0.8 M Fe(ClO4)2 solution (203.8 mg, 0.8 mmol, 1 mL, 1 equiv) in D2O, 
respectively. The samples were analyzed by 1H-NMR spectroscopy after the addition of 
ligand, iron, and CH3CN (21 µL, 50 equiv). 
  2.5.12. Liquid chromatography/Mass spectrometry (LCMS) 
  Analysis of protein samples. LCMS was performed on a Micromass QuattroLC 
triple quadrupole mass spectrometer with an electrospray/APCI source and Waters 
Alliance 2695 liquid chromatograph. Approximately 100 pmol of the sample was injected 
onto a Jupiter 5 µm C18 300 Å 50 × 2.0 mm column (Phenomenex) using an 
autosampler. Separation was achieved using a linear gradient of 20-30% (trypsin) and 
20-40% (chymotrypsin) CH3CN in water and a 0.1 % HCO2H solution in water. A total of 
80 µL of H2O (blank) was injected after each sample to minimize any carryover from the 
previous sample. High-performance liquid chromatography (HPLC) was carried out at a 
flow rate of 0.6 mL min-1 with the column heated to 45 °C. 
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  2.5.13. Carbonyl assay 
  The carbonyl contents of the oxidized enzyme samples were determined using 
the following literature method. Enzymes (20 µM) were treated with 9 or 10 (50 µM) and 
pulsed with varying amounts of H2O2 (100-500 µM, 100 µM per pulse). After pulsing, 
protein samples were precipitated with 20% (w/v) trichloroacetic acid, centrifuged (5 
min, 25 °C, 6600 rpm), the supernatant was removed, and the precipitate was treated 
with 2,4-dinitrophenylhydrazine in 2 M HCl (10 mM, 500 µL). The samples were allowed 
to stand at room temperature for 1 h with vortexing every 10-15 min. Enzymes were 
precipitated with 20% trichloroacetic acid (500 µL) and centrifuged (5 min, 25 °C, 6600 
rpm), the supernatant was discarded, and the pellet was washed three times with 1 mL 
of ethanol/ethyl acetate (1:1) to remove any free reagent. The sample was allowed to 
stand 10 min before centrifugation (5 min, 25 °C, 6600 rpm), and the supernatant was 
discarded each time. The precipitated enzyme was dissolved in 0.6 mL of a 6 M 
guanidine solution (pH = 2.3, 20 mM potassium phosphate), and the carbonyl contents 
were deteremined by UV-vis spectroscopy using the known molar extinction coefficient, 
ε360 = 22 000 M-1 cm-1. 
  2.5.14. Synthesis of 14 
  A solution of Ac-Tyr-OH (13; 56 mg, 0.25 mmol) and [FeII(N4Py)(CH3CN)](ClO4)2 
(17 mg, 25 µmol) in a 10 mM acetate buffer (25 mL, pH = 6.0, 150 mM NaCl) was 
pulsed with H2O2 (50 µL × 5, 10 mM total, 2 mM per pulse) every 10 min over the 
course of 1 h. The solution was frozen and lyophilized. The lyophilized powder was 
dissolved in water and filtered through Dowex 50WX4-100 ion-exchange resin to 
remove ligand and iron. The filtrate was frozen and lyophilized. The product 14 was 
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purified by HPLC (HPLC column Zorbax XDB-C18, 21.2 × 150 mm, 5 µm equipped with 
a guard column Zorbax XDB-C18, 21.2 mm, 5 µm, 0.1% TFA/MeOH 87:13, flow rate = 
20 mL min-1; TR = 6.24 min); 1H-NMR and MS data of isolated 14 matched the literature 
data for the known compound.253 
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CHAPTER 3 
Inhibition of 20S Proteasome by Non-Heme Iron Complexes 
Copyright Permission: Portions of the text in this chapter were reprinted or adapted 
with permission from: (a) Prakash, J.; Schmitt, S. M.; Dou Q. P. and Kodanko J. J. 
Metallomics, 2012, 4, 174-178. (b) Zou, J.; Schmitt, S. M.; Zhang Z.; Prakash, J.; Fan, 
Y.; Bi, C.; Kodanko, J. J.; Dou, Q. P. J. Cell. Biochem. 2012, DOI: 10.1002/jcb.24132. 
All rights to the work are retained by the authors and any reuse requires permission of 
the authors. 
3.1. Introduction 
The ubiquitin-proteasome system plays a central role in the regulatory 
degradation of unfolded or unwanted proteins inside the cell, which would otherwise 
result in tumor growth and cancer.130,137 This makes the ubiquitin-proteasome system 
an important target in cancer chemotherapy. Though in the beginning, targeting 
ubiquitin-proteasome system for therapeutic was seen with great apprehension because 
of its essential role in normal cellular homeostasis, later work illustrated that proteasome 
inhibitors could induce apoptosis in cancer cells while at the same time show attenuated 
toxicity towards normal cells.254-256 Another feature that makes proteasome inhibitors 
even more promising as cancer chemotherapy agents is that cancer cells are more 
sensitive, as compared to normal cells, to apoptosis-inducing stimuli including 
proteasome inhibitors.257-259 For example, a boron-based peptidomimetic proteasome 
inhibitor bortezomib has recently been approved for the treatment of multiple myeloma 
and mantle cell lymphoma.138,139 A series of transition metal complexes based on nickel, 
copper, zinc, gold and gallium are in preclinical development and show promising 
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anticancer activities in live cells and animals.140-144 Most of these medicinal agents 
inhibit the proteasome by binding directly to the enzyme’s catalytic subunits (20S core). 
However, another exciting strategy that has recently been utilized effectively towards 
enzyme inhibition is the use of metal-based reagents, either generating ROS or metal-
based oxidants that diminish enzyme activity through catalytic oxidation.96,198,199,260 For 
example, [Ru(bpy)2]2+-peptoid conjugates have shown potent and selective inactivation 
of  vascular endothelial growth factor (VEGF)-induced autophosphorylation of VEGF 
receptor 2 (VGRF2), and 26S proteasome upon photo-irradiation by means of 
generating singlet oxygen 1O2 as reactive oxidizing species.96 This strategy renders 
several advantages over traditional enzyme inhibition as mentioned in the previous 
section. It uses biologically relevant oxidants like H2O2 and O2, can be performed 
selectively in live cells, and is often irreversible in nature, and can reduce the 
concentration of inhibitor needed to provide the desired effect. 
In this chapter, we describe a new iron-based approach towards the catalytic 
targeting of the proteasome that occurs spontaneously in the presence of a non-heme 
iron complex and air. The non-heme ligands used in our studies are pentadentate 
nitrogen-containing ligands N4Py and Bn-TPEN (Figure 3.1).208,218,222,261 These ligands 
were selected because they find applications in biology as they bind strongly to iron with 
dissociation constants in the pM-fM range. They can mobilize FeII from ferritin, the major 
intracellular storage site for iron suggesting that these ligands can access iron from the 
“labile iron pool” in cells.262 The high valent iron (IV)-oxo complexes of these ligands 
have been shown to selectively oxidize small organic molecules.261,263-265 Recent 
studies from our laboratory have already established that iron complexes based on 
pentadentate ligands have applications in the area of amino acid, peptide and protein 
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oxidation.107,108,226,260 Because previous work with the proteasome demonstrated that 
the enzyme could be inactivated by oxidants,146,266,267 and by knowing the importance of 
proteasome in cancer therapy, we decided to examine the ability of these iron 
complexes to inactivate the proteasome. This chemistry was established against the 
purified 20S proteasome instead of 26S proteasome in vitro. 20S proteasome was 
selected against 26S proteasome because of the following reasons: (a) 20S 
proteasomal activity is similar to that of 26S proteasome since 19S cap increases the 
specificity but not potency; (b) purified 20S proteasome is cheaper and more stable than 
purified 26S proteasome.  
 
Figure 3.1. Polydentate nitrogen-containing ligands 
3.2. Results 
3.2.1. IC50 determination 
Studies commenced with evaluating the ability of ligands 1 and 2 and their 
ferrous complexes [FeII(OH2)(N4Py)]2+ (3) and [FeII(OH2)(Bn-TPEN)]2+ (4), to inhibit the 
chymotrypsin-like activity of the purified 20S proteasome. The ferrous complexes 3 and 
4 were generated in situ by mixing equal equivalents of ligand 1 and 2 with iron(II) 
perchlorate salt, respectively. The purified 20S proteasome (0.5 nM, final concentration) 
was treated with varied concentrations (0−1000 mM) of 1−4, along with 
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FeII(ClO4)2⋅xH2O as a control, in 100 mM MOPS buffer (pH = 7.4). Proteasome activities 
were measured using fluorescence spectroscopy and corresponding IC50 values were 
calculated (Table 3.1). 
The results indicated that ligand 1 was ineffective in inhibiting the chymotrypsin-
like activity of the proteasome (IC50 > 1000 µM) but its ferrous complex 3 was a more 
potent inhibitor with an IC50 value of 9.2 µM (Table 3.1, entry 2). Similar results were 
observed for ligand 2 where its ferrous complex 4 was more potent than ligand 2. 
Table 3.1. IC50 values (µM) for inhibition of chymotrypsin-like (CT), trypsin-
like (T) and peptidylglutamyl peptide hydrolyzing-like (PGPH) activity of 20S 
proteasome by ligands 1 and 2 and their respective ferrous complexes (3 
and 4) along with iron metal ion control 
Entry Compound CTa Ta PGPHa 
1 N4Py (1) >1000 >1000 >1000 
2 [FeII(OH2)(N4Py)]2+ (3) 9.2 >1000 >1000 
3 Bn-TPEN (2) 96 >1000 >1000 
4 [FeII(OH2)(Bn-TPEN)]2+ (4) 4.0 >1000 >1000 
5 FeII(ClO4)2 >1000 ndb >1000 
 
a The % proteasome activity at different concentrations was determined as 
the average from three independent experiments, with 100% activity equal to 
the fluorescence of the proteasome in the absence of inhibitor. Proteasome 
concentration was 0.5 nM; fluorogenic peptide substrates, Suc-LLVY-AMC 
(for proteasomal chymotrypsin-like activity), Bz-VGR-AMC (for proteasomal 
trypsin-like activity) and Z-LLE-AMC (for proteasomal peptidylglutamyl 
peptide hydrolyzing-like activity), concentrations were 20 µM. The reactions 
were conducted at pH = 7.4 in 100 mM MOPS buffer for 30 min at 37 °C. b 
nd = not determined. 
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Ligand 2, unlike ligand 1, also inhibited the proteasome, albeit at a 25-fold higher 
concentration than its ferrous complex 4 (Table 3.1, entries 3 and 4). Despite the fact 
that FeII(ClO4)2 had no effect on proteasome activity (Table 3.1, entry 5), the ferrous 
complexes 3 and 4 showed more potent inhibition than the ligands alone. These results 
confirm that iron and the ligand together play a key role in proteasome inhibition. 
Similarly, IC50 values for inhibition of the trypsin- and PGPH-like activities of the 
proteasome were determined for compound 1−4. To our surprise, the trypsin- and 
PGPH-like activities of the proteasome were not affected by these ferrous complexes, 
indicating a high level of selectivity by these ferrous complexes toward inhibition of 
chymotrypsin-like activity of the proteasome, which is consistent with oxidative 
inactivation.268 
    3.2.2. Mechanistic Studies 
        3.2.2.1. Time-dependent inactivation 
 
Figure 3.2. Binding and oxidation mode of action of iron complexes for 20S proteasome 
inactivation 
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Figure 2. Oxidation and binding mode of action of iron complexes
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Based on literature data, two possible pathways were considered for proteasome 
inhibition, either direct binding of the iron complexes to the β5 subunits (responsible for 
the chymotrypsin activity) of the 20S proteasome,140,142 or alternatively oxidation of the 
enzyme (Figure 3.2).96,146,266,269 In order to gain insight into the mode of action, the 20S 
proteasome was incubated with ferrous complexes 3 and 4 (10 µM) at room 
temperature under an aerobic atmosphere and the activities were determined as a 
function of incubation time. Proteasome activity did not change over time with 3, 
suggesting that direct binding of the iron complex to the enzyme contributed to the 
observed inhibition (Figure 3.3a). In contrast, time-dependent inactivation was observed 
in the presence of 4, where 20S proteasome activity was diminished from ∼ 70% to ∼ 
10% over the course of 165 min at room temperature (Figure 3.3b). Time-dependent 
loss of proteasome activity was not observed with ligand 2 or with FeII(ClO4)2 alone, 
both in the presence and absence of the reductant dithiothreitol (DTT). However, 
proteasome activity was lowered, albeit slightly, with 4 in the presence of DTT, 
consistent with the reductive activation of O2 playing a role in enzyme inactivation 
(Figure 3.3d).198 This mode of action was further corroborated by the fact that time-
dependent inhibition was not observed with [FeII(TPEN)]2+ (Figure 3.3c), in which all six 
coordination sites around the iron center are occupied (Figure 3.4). Blocking all six sites 
would inhibit access of O2 to the iron center with respect to 4 which contains a labile 
H2O, presumably allowing 4 to reach a coordinatively unsaturated state easier than 
[FeII(TPEN)]2+. It is important to note that the timescale for the decay of proteasome 
activity observed with 4 is too long to result from simple binding of the iron complex to 
the enzyme. Rates for association of small molecules with proteins are extremely fast (k 
= 106–108 M-1 s-1),270 much faster than the time scale of the experiments (165 min). 
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Taken together, these results are consistent with 4 oxidizing the 20S proteasome over 
time, leading to its inactivation. 
 
Figure 3.3. Time-dependent inactivation of the purified 20S proteasome. The reaction 
was performed by incubating the proteasome (0.5 nM) with 10 µM of ferrous complexes 
3 (a), 4 (b and d (blue) without DTT, d (red) with DTT, 250 µM) and [FeII(TPEN)]2+ (c) in 
100 mM MOPS buffer at pH = 7.4. The fluorescence intensity was converted to % CT-
like activity, with 100% activity equal to fluorescence of the blank reaction containing 
proteasome, in the absence of the inhibitor at t = 0. 
 
Figure 3.4. Model illustrating the coordination sphere around iron centers of the ferrous 
complexes derived from (a) Bn-TPEN and (b) TPEN. The sixth coordination site in 
model ‘a’ is vacant for redox chemistry. 
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3.2.2.2. ROS scavengers 
In order to gain further insight into the nature of the oxidant, control experiments 
were performed in the presence of reactive oxygen species (ROS) scavengers. When 
the inactivation of the 20S proteasome with 4 was performed in the presence of NaN3 
(10 mM), a potent singlet oxygen (1O2) scavenger, 20S proteasome inhibition was still 
observed, precluding a major role for 1O2 (Figure 3.5).194,260 Similar results were 
obtained in the presence of D-mannitol (20 mM), a potent scavenger of the hydroxyl 
radical and superoxide,194,260 confirming that another oxidant apart from ROS is 
responsible for the time-dependent proteasome inhibition observed with 4.  
 
Figure 3.5. Inactivation of the purified 20S proteasome by ferrous complex 4 in the 
presence of ROS scavengers (azide and D-mannitol). The reactions were performed by 
incubating proteasome with 4 (10 µM) in the presence/absence of DTT (250 µM) for 80 
min at rt in 100 mM MOPS buffer at pH = 7.4. The fluorescence intensity was converted 
to % CT-like proteasome activity, with 100% activity equal to fluorescence of blank 
reaction containing proteasome in the absence of inhibitor and additive. Data points are 
averages from three independent experiments, errors equal to the standard deviation of 
the data set. 
These results suggest that a metal-based oxidant derived from 4 may be 
responsible for the loss of proteasome activity over time. Although the exact nature of 
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this oxidant has not been confirmed, activation of O2 by non-heme iron complexes is 
known to generate FeIII-superoxo, -hydroperoxo and FeIV-oxo species.59,60,271,272 Our 
own work proved that iron-based oxidants of this class inactivate the serine proteases 
trypsin and chymotrypsin efficiently.260 Furthermore, we have observed that 3 
decomposes much slower than 4 under aerobic conditions, which agrees well with 4 
activating O2 at a faster rate than 3, and with differences in time-dependent inhibition 
between 3 and 4 (Figure 3.3a and 3.3b). Therefore, faster oxidation of 4 may lead to a 
more rapid loss of the purified 20S proteasome activity over time under aerobic 
conditions. 
3.2.2.3. In cellulo studies 
 
Figure 3.6. Effect of compounds 1-4 on apoptosis induction in PC-3 cells. Circular and 
elongated cells represent dead and live cells respectively. 
Studies were conducted to gain insight into modes of action for compounds 1–4 
in cells. PC-3 cells were incubated with these compounds and cell proliferation data 
were collected. These data, reported in another manuscript,273 indicate that compounds 
1–4 elicit apoptotic effects and give rise to potent cell death (Figure 3.6). Proteasome 
inhibition, however, was not observed, presumably because cell death occurs at lower 
concentrations than proteasome inhibition. However, even though proteasome inhibition 
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was not observed in these live cell assays, it is important to note that the ligands and 
complexes 1–4 used in this study do not contain a proteasome-binding motif. Directing 
these compounds to the proteasome by attachment of a binding motif could lead to 
more potent proteasome inhibition, giving the possibility of inhibiting the proteasome 
before cell death occurs. 
3.3. Discussion 
Proteasome inhibitors can cause apoptosis in cancer cells and are promising 
candidates for the development of novel anti-cancer drugs. Though many potent 
proteasome inhibitors are either in preclinical or clinical trials for the treatment of one or 
other forms of cancer, most of them inhibit proteasome by binding to the central 
catalytic 20S subunit. For example, Bortezomib is a FDA approved drug. Studies 
reported herein are significant because these are indicative of oxidative inactivation of 
proteasomes that can be achieved spontaneously in the presence of non-heme iron 
complex and air. Though the in vitro studies with purified 20S proteasome led to its 
oxidative inactivation, in cellulo data pointed toward apoptotic induction leading to cell 
death prior to proteasome inhibition.  
The ferrous complexes of ligand 1 and 2 show more potent inhibition (IC50 < 10 
µM) towards chymotrypsin-like activity of proteasome than the ligands or the iron salt 
alone. These results are indicative of key role played by iron and the ligand together 
towards proteasome inhibition. Moreover, a high level of selectivity toward inhibition of 
chymotrypsin-like activity of proteasome was seen with these ferrous complexes as 
compared to trypsin- and PGPH-like activities of the proteasome. Mechanistic studies 
revealed two different modes of action of ferrous complexes towards proteasome 
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inhibition. Loss of 20S proteasome activity was not observed with 3 over time, 
suggesting inhibition through direct binding of the iron complex to the enzyme.  In 
contrast, a time-dependent decay of proteasome activity was seen with ferrous complex 
4 that was accelerated in presence of a reducing agent like DTT. This suggests 
reductive activation of O2 and oxidation of the 20S proteasome as a mode of action. 
This mode of action was further supported by the fact that proteasome activity was not 
affected by [FeII(TPEN)]2+ over the course of reaction. [FeII(TPEN)]2+ is a coordinately 
saturated system with central FeII atom bound strongly by six N-atoms from the TPEN 
ligand, inhibiting access of O2 to the iron center as compared to 4, which contains a 
labile H2O ligand at the sixth position.  
The role of ROS as an active oxidant was precluded by the fact that reactive 
oxygen species scavengers (NaN3 and D-mannitol) failed to block the inhibition of 20S 
proteasome by 4, and hence, alternatively supported a unique oxidant being 
responsible for the time-dependent inhibition observed. Non-heme iron complexes are 
known to react with O2 resulting in generation of high valent metal-based oxidants like 
Fe(IV)-oxo that selectively oxidize small organic molecules. Recent studies have 
provided strong evidence for the existence of perferryl species, commonly known as 
Fe(V)-oxo, and can be generated from similar ligand sets.61 However, the exact nature 
of the oxidizing species in this study is yet to be investigated. 
To gain insight into the mode of action of compound 1-4 in vivo, cell proliferation 
and cell morphological changes were studied against PC-3 cells. The results have been 
discussed in detail in another manuscript. In brief, the compounds 1-4 were found to 
induce apoptosis that led to potent cell death. The role of proteasome inhibition in cell 
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death was precluded mainly because of the fact that cell death was seen at lower 
concentrations than the proteasome inhibition. However, by attaching proteasome-
affinity groups to compound 1-4 may result into selective and potent proteasome 
inhibition prior to cell death. 
3.4. Conclusions and future directions 
In conclusion, non-heme ligands 1 and 2 and their iron complexes 3 and 4 were 
investigated for their ability to inhibit the purified 20S proteasome. Ferrous complexes 3 
and 4 showed more potency in inhibiting the proteasome than the ligands and iron salts 
alone. Control experiments confirmed a key role for iron and ligands in enzyme 
inhibition. The time-dependent inactivation studies suggested that the ferrous 
complexes of N4Py and Bn-TPEN have different modes of action, either binding to the 
target enzyme, or alternatively enzyme oxidation. Investigations precluded the role of 
ROS and suggested that an iron-based oxidant was responsible for loss of proteasome 
activity observed. Studies are now underway to understand the biological activities of 
these complexes further and to extend this method of enzyme targeting towards 
achieving anticancer activities. 
3.5. Experimental section 
3.5.1. Materials and methods 
3.5.1.1. Materials 
N4Py (1),218 Bn-TPEN (2)274 and TPEN275 were synthesized according to 
literature methods. Iron(II) perchlorate hydrate and dithiothreitol (DTT) were purchased 
from Sigma-Aldrich and Acros chemicals, respectively. Purified human 20S proteasome 
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and fluorogenic substrates, Suc-LLVY-AMC and Bz-VGR-AMC (for proteasomal 
chymotrypsin- and trypsin-like activities, respectively), were from Boston Biochem 
(Cambridge, MA) whereas the fluorogenic substrate Z-LLE-AMC (for proteasomal 
peptidylglutamyl peptide hydrolyzing-like activity) was from Calbiochem. Human 20S 
proteasome was aliquoted in buffer (1 M HEPES, 3 M NaCl, final concentration: 25 nM). 
The iron complexes [FeII(OH2)(N4Py)]2+ (3) and [FeII(OH2)(Bn-TPEN)]2+ (4) were 
generated in situ by treating ligands 1 and 2 in 100mM MOPS buffer (pH = 7.4) 
containing % DMSO with 1.0 equiv. of FeII(ClO4)2⋅xH2O. 
3.5.1.2. Purified 20S proteasomal inhibition assay 
Purified human 20S proteasome (0.5 nM, final concentration) was incubated with 
20 µM of a fluorogenic substrate, Suc-LLVY-AMC or Bz-VGR-AMC or Z-LLE-AMC (for 
proteasomal chymotrypsin-, trypsin- and peptidylglutamyl peptide hydrolyzing-like 
activities, respectively), in 100 µL assay buffer (100 mM MOPS buffer, pH = 7.4) for 30 
min at 37 °C in the presence of inhibitor molecules at different concentrations (0–1000 
µM). After incubation, proteasomal activities (production of hydrolyzed AMC) were 
measured with a Wallac Victor multilabel counter (PerkinElmer, Waltham, MA) with an 
excitation filter of 365 nm and emission filter of 460 nm. Background fluorescence was 
subtracted from the blank reaction. Activities were plotted against log [inhibitor] and fit to 
a sigmoidal curve to calculate IC50 values. 
3.5.1.3. Time-dependent 20S proteasomal inactivation assay  
Purified human 20S proteasome (0.5 nM, final concentration) was incubated at 
room temperature with 10 µM inhibitor in the presence or absence of DTT (250 µM) for 
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different time periods (0–165 min) in assay buffer (100 mM MOPS buffer, pH = 7.4). A 
fluorogenic substrate, Suc-LLVY-AMC (20 µM), was added and the mixture was further 
incubated for 15 min at 37 °C. Proteasomal activities (production of hydrolyzed AMC) 
were measured with a Wallac Victor multilabel counter with an excitation filter of 365 nm 
and emission filter of 460 nm. In control experiments, reactive oxygen species 
scavengers D-mannitol (20 mM) and NaN3 (10 mM) were added as aqueous solutions 
prior to treatment with the iron complexes. 
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CHAPTER 4 
Synthesis, Characterization and Glutathionylation of Cobalamin Model 
Complexes [CoIII(N4PyCO2Me)Cl]Cl2 and [CoIII(Bn-CDPy3)Cl]Cl2 
 
Copyright Permission: Portions of the text in this chapter were reprinted or adapted 
with permission from: Prakash, J.; Kodanko, J. J. Inorg. Chem. 2012, 51, 2689-
2698.  All rights to the work are retained by the authors and any reuse requires 
permission of the authors 
4.1. Introduction 
Glutathionylcobalamin (GSCbl) forms rapidly upon reaction of glutathione (GSH) 
with aquacobalamin (H2OCbl+). Because of the fact that GSH is present in cells up to a 
concentration of 10 mM,162,163 GSCbl is though to be an important form of cobalamin 
present in cells. GSCbl finds many applications in biology. For example, it has been 
shown that it can reverse the biological effects caused by NO,276 and can induce potent 
antioxidant properties in vitro.277 GSCbl has also been proposed as an important 
intermediate in the biosynthesis of two of the active cobalamin coenzymes MeCbl and 
AdoCbl which are involved in transfer of a methyl group from methyltetrahydrofolate to 
homocysteine by methionine synthase to generate methionine, and isomerization of 
methylmalonyl-CoA to succinyl-CoA, catalyzed by methylmalonyl-CoA mutase, 
respectively.155-157,278,279 The former reaction is significant because it helps regenerate 
folate, which is essential for DNA synthesis, and at the same time reduces the 
concentration of homocysteine that is associated with various diseased states. The later 
reaction helps in metabolic pathways associated with consumption of branched and odd 
chain fatty acids. Moreover, GSCbl has been suggested to be more effective than other 
cobalamines in treatment of conditions associated with hyperhomocysteinemia and 
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oxidative stress, including dementia, arthritis, and cancer.149,164,165 
This inspired various researchers to study the formation of GSCbl from GSH and 
aquacobalamin.164,167,169,280 A large formation constant (Kf = 5 x 109 M-1) and 
bimolecular rate constant as high as 163 ± 8 M-1 s-1 have been reported recently, 
concluding that GSCbl formation from H2OCbl+ is both rapid and highly favorable.174 The 
nature of this reaction suggests that any free intracellular H2OCbl+ (H2OCbl+ not 
attached to protein) is prone to conversion to GSCbl, as GSH is found up to 10 mM in 
concentration in most biological tissues.  However, the extent of this facile conversion 
may be limited in cells by the fact that free Cbl is estimated to be < 5 %.281 
Though a large number of cobalamin models complexes have been synthesized 
in the past, a detailed kinetic and thermodynamic study on glutathionylation has never 
been performed with these complexes. In this chapter, we report the interesting 
observation that glutathionylation is not unique to Cbl, but infact occurs readily with a 
series of other Co(III) complexes that mimic the structure of this important biological 
cofactor.  In this study, the synthesis and characterization of a new Co(III) complex is 
described, which is derived from the polypyridyl pentadentate N5 ligand N4PyCO2Me 
(1) (Figure 4.1). The complex [CoIII(N4PyCO2Me)Cl]Cl2 (3), and related congener 
[CoIII(Bn-CDPy3)Cl]Cl2 (4), which contain a N5 coordination environments like that of 
Cbl, undergo biomimetic reactions with GSH to generate the species 
[CoIII(N4PyCO2Me)(SG)]2+ (5) and [CoIII(Bn-CDPy3)(SG)]2+ (6), respectively. Species 5 
and 6 were generated in situ and characterized in solution. Data for 5 and 6 are 
consistent with the cysteine thiolate in GSH binding to the Co(III) centers of these 
complexes. The kinetics and thermodynamic studies for glutathionylation of 3 and 4 are 
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reported, and relevance of these data to the analogous reaction with H2OCbl+ is 
discussed. To the best of our knowledge, this is the first example of synthetic Co(III) 
coordination complexes based on polypyridine ligands mimicking the behavior of Cbl 
and undergoing glutathionylation with GSH. 
 
Figure 4.1. Structures of polypyridyl N5 pentadentate ligands 1 and 2, and glutathione 
4.2. Results 
4.2.1. Synthesis of [CoIII(N4PyCO2Me)Cl]Cl2 (3) 
 The Co(III) complex, [CoIII(N4PyCO2Me)Cl]Cl2 (3), where N4PyCO2Me (1) is 
methyl-6-(((di(pyridin-2-yl)methyl)(pyridin-2-ylmethyl)amino)methyl)nicotinate, was 
synthesized using the Co(III) starting material trans-[CoIII(Py)4Cl2]Cl·6H2O282,283 
(Scheme 1). Ligand 1 was stirred with 1 equiv of trans-[CoIII(Py)4Cl2]Cl·6H2O in CH2Cl2 
for 60 min at room temperature resulting in the formation of 3 as a pink precipitate. This 
pink solid was further recrystallized by vapor diffusion of Et2O into EtOH, followed by 
Et2O into MeOH, giving pink crystals of 3 suitable for X-ray crystallographic analysis. 
 
Scheme 4.1. Synthesis of [CoIII(N4PyCO2Me)Cl]Cl2 (3) 
 4.2.2. UV-vis spectroscopic data 
N N N
N N
N4PyCO2Me (1)
CO2Me
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 Typical of other low spin Co(III) complexes, the compound 3 shows two major 
absorption bands, λmax, at 370 nm and 520 nm with molar extinction coefficient, ε, 340 
M-1 cm-1 and 210 M-1 cm-1 in MeOH, respectively (Figure 4.2). These bands are 
assigned to transitions from the 1A1g ground state to the upper 1T1g and 1T2g states in 
the parent octahedral species, based on analogy with related Co(III) complexes.284,285 
 
Figure 4.2. UV-vis spectrum of 3 in MeOH (1 mM) at 298 ± 2 K 
 4.2.3. 1H-NMR and 13C-NMR spectroscopic data 
 The 1H-NMR spectrum of 3 in CD3OD revealed that resonances were sharp, well 
resolved, and lie between 3.9 and 9.9 ppm, consistent with a diamagnetic low spin 
Co(III) complex. Likewise, resonances observed in 13C-NMR spectrum of 3 lie between 
54–170 ppm. The most important features of these resonances, both in 1H-NMR and 
13C-NMR spectra (Figure 4.3), are that they are shifted downfield in 3 when compared 
with the parent ligand 1, consistent with the pyridine N-atoms remaining bound to the 
metal center in solution. Resonances assigned to the H-atoms located at the 2-position 
of the four pyridine rings shift by approximately 1 ppm when compared with the 
spectrum of 1, consistent with the hypothesis that all four pyridine rings remain bound to 
the Co(III) center. Particularly striking is the 1.71 ppm downfield shift of the methine C-H 
  
93 
resonance, from 5.36 ppm in the parent ligand 1 to 7.07 ppm in the complex 3. In 
addition, the four-methylene protons of the ligand become diastereotopic upon 
coordination to the metal center and each proton shows a unique resonance in the 
complex 3 (5.13–5.43 ppm). Typical coupling values of 16-19 Hz for geminal protons 
are observed, consistent with the chiral properties of 3, which unlike symmetric 
complexes of N4Py, does not possess a mirror plane due to the ester substituent. 
 
Figure 4.3.  1H-NMR (left) and 13C-NMR (right) spectrum of 3 in CD3OD 
4.2.4. High-resolution mass spectrometric data 
 
Figure 4.4. Calculated (top) and observed (bottom) high resolution mass spectra 
(ESMS) for the dication [CoIII(N4PyCO2Me)Cl]2+ of 3 
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The high-resolution electrospray ionization mass spectrum (ESI-MS) for 3 in H2O 
solution reveals a prominent ion cluster with a dominant peak at m/z 259.5437. This 
cluster displayed an isotopic pattern that fits with molecular formula 
[CoIII(N4PyCO2Me)Cl]2+ (Figure 4.4). It is noteworthy that the axially coordinated Cl- 
ligand remains attached in solution. 
 4.2.5. X-ray crystallographic data 
 Crystallographic data for 3 are given in Table 4.1. Table 4.2 and Table 4.3 list 
selected bond lengths and bond angles, respectively. Complex 3 crystallized in the 
space group P1, with Z = 2. Figure 4.5 shows an ORTEP diagram of the dication 
[CoIII(N4PyCO2Me)Cl]2+. The Co(III) center of the dication [CoIII(N4PyCO2Me)Cl]2+ has a 
N5Cl donor atom set. Bond lengths are consistent with a low-spin Co(III) ion. The 
octahedral geometry is slightly distorted, due to acute bite angles typical of 5-membered 
rings. The angles between Cl(1) and N(4-5) are approximately 3° smaller than angles 
involving N(2-3), resulting from the restriction of the common atom C(15). Even though 
the environments are dissimilar, bond lengths between Co(1) and all the five nitrogen 
donors of N4PyCO2Me are nearly identical, varying from 1.930(2) to 1.938(2) Å, 
indicating that the ester moiety on the pyridine ring of the ligand does not affect the 
bond length between Co(1) and N(2) to a great extent. These Co-N lengths are 
decidedly short.286 Furthermore, the Co-Cl bond length (2.222 Å) is at the very shortest 
end of the recorded ranges for similar complexes, which may indicate a strong Co-Cl 
bond.287-289 The Co ion lies 0.171(1) Å out of the N4 equatorial plane towards the Cl 
atom (cf. Ru displacement of 0.263 Å in RuN4PyCl).290 
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Table 4.1. Crystal data and structure refinement for 3·MeOH·EtOH 
Empirical Formula C28 H33Cl3CoN5O4 
Formula weight 668.87 
Crystal system Triclinic 
Space group P1 
a (Å) 9.6350(3) 
b (Å) 11.5595(4) 
c (Å) 15.6403(5) 
α (0) 97.695(2) 
β (0) 106.955(1) 
γ (0) 109.816(2) 
V (Å3) 1514.23(9) 
Z 2 
Dcalc (mg/m3) 1.467 
Absorption coefficient, µ (mm-1) 0.874 
F (000) 692 
Crystal size (mm3) 0.29 x 0.26 x 0.18 
θ-range for data collection (°) 1.94 to 28.48 
Limiting indices -12≤ h ≤12, -15≤ k ≤15 
0≤ l ≤ 20 
Unique Reflections 36734 / 7571 [R (int) = 0.0342] 
Goodness-of-fit on F02 1.033 
Final R indices [I>2σ(I)] R1 = 0.0450, wR2 = 0.1227 
R indices (all data) R1 = 0.0530, wR2 = 0.1269 
Highest peak and deepest hole (e·Å-3) 1.642 and -0.388 
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Table 4.2. Selected bond lengths (Å) of 3. 
 
 
 
 
 
 
Table 4.3. Selected bond angles (°) of 3. 
N(3)-Co(1)-N(1) 86.40(8) N(3)-Co(1)-N(5) 89.50(8) 
N(1)-Co(1)-N(5) 83.55(9) N(3)-Co(1)-N(4) 169.66(9) 
N(3)-Co(1)-N(2) 91.52(8) N(1)-Co(1)-N(2) 86.35(8) 
N(5)-Co(1)-N(2) 169.76(9) N(4)-Co(1)-N(2) 89.35(8) 
N(3)-Co(1)-Cl(1) 96.33(6) N(1)-Co(1)-Cl(1) 175.84(6) 
N(5)-Co(1)-Cl(1) 93.32(6) N(4)-Co(1)-Cl(1) 93.81(6) 
N(2)-Co(1)-Cl(1) 96.70(6) C(1)-N(1)-Co(1) 110.1(1) 
C(9)-N(1)-Co(1) 110.0(1) C(15)-N(1)-Co(1) 98.9(1) 
C(2)-N(2)-Co(1) 112.9(2) C(6)-N(2)-Co(1) 127.7(2) 
C(14)-N(3)-Co(1) 127.1(2) C(10)-N(3)-Co(1) 113.6(2) 
C(20)-N(4)-Co(1) 128.6(2) C(16)-N(4)-Co(1) 111.3(2) 
C(25)-N(5)-Co(1) 128.9(2) C(21)-N(5)-Co(1) 111.0(2) 
  
  
 
 
 
Co(1)-N(3) 1.930(2) 
Co(1)-N(1) 1.933(2) 
Co(1)-N(5) 1.933(2) 
Co(1)-N(4) 1.933(2) 
Co(1)-N(2) 1.938(2) 
Co(1)-Cl(1) 2.222(6) 
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Figure 4.5. ORTEP diagram of the dication [CoIII(N4PyCO2Me)Cl]2+, thermal ellipsoids 
are drawn at the 50 % probability. Hydrogen atoms and chloride counter ions have been 
omitted for clarity. 
 4.2.6. Molar conductivity data 
 Molar conductivity (ΛM) values for 3 in H2O range from 133–180 S cm2 mol-1 for 
concentrations ranging from 2.0–0.5 mM (Table 4.4). These data agree well with the 
data for other 2:1 electrolytes in H2O.291 Importantly, these data are consistent with the 
dication of 3 maintaining its structure in solution, and not undergoing rapid hydrolysis to 
form [CoIII(N4PyCO2Me)(H2O)]3+, which would act as a 3:1 electrolyte.  
Table 4.4.  Molar conductivities for 3 in H2O at 298 ± 2 K 
3 (mM) ΛM (S·cm2·mol-1) 
2.0 133 
1.5 152 
1.0 160 
0.5 180 
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 4.2.7. Glutathionylation of the cobalt complex 3 
 
 
 
Figure 4.6. UV-vis spectral change for 3 (0.5 mM) on reaction with GSH (10 mM) in 100 
mM acetate buffer at 298 ± 2 K (Inset: Abs vs time plot for growth of peak at 323 nm) 
 
 Treatment of the Co(III) complex 3 with GSH in 100 mM acetate buffer (pH 5.00, 
I =100 mM (KNO3)) resulted in a color change from pink to brown within minutes at 
room temperature. Upon following the reaction of 3 (0.5 mM) with GSH (10 mM) by UV-
vis spectroscopy, the disappearance of a peak at 520 nm and appearance of two new 
peaks at 323 nm and 440 nm with a shoulder at 490 nm were observed, with two 
isosbestic points at 490 nm and 560 nm (Figure 4.6). These results are consistent with 
conversion of 3 into a new product without the formation of any long-lived intermediate. 
When the initial rates of the reaction (dA323/dt) of 3 (0.5 mM) with GSH (0.5–25 mM) 
were plotted against the total concentration of GSH, a line passing through the origin 
can be fit, indicating the reaction (eq 4.1) to be first order with respect to GSH. A second 
[CoIII(N4PyCO2Me)(Cl)]2+ [CoIII(N4PyCO2Me)(SG)]2+ +    HCl       (4.1)
k1
k-1
+ GSH
Kobs (5) = [5]/([3][GSH])                                                             (4.2)
3                                                                                    5
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order rate constant, k1, of 9.3 x 10-2 M-1 s-1 was obtained from these data (Figure 4.7a). 
Similarly, when the initial rates of reaction of GSH (4 mM) with 3 (0.5–5 mM) were 
plotted against concentration of 3, a line passing through origin can be fit, indicating the 
reaction to be first-order also with respect to 3 and, from these data, a second-order 
rate constant, k1, of 10.8 x 10-2 M-1 s-1 was obtained (Figure 4.7b).  The values of k1 
obtained from both the plots were in good agreement within the experimental error 
confirming the reaction follows the rate law, Rate = k1[3][GSH] under the condition used 
in this study. It is noteworthy that this reaction is approximately two orders of magnitude 
slower than the reaction of GSH with H2OCbl+.174  
 
Figure 4.7. (a) Plot of initial rate (dA323/dt) vs. [GSH] for substitution of Cl- with GSH 
(0.5–25 mM) in 3 (0.5 mM) in 100 mM acetate buffer to form 
[Co(N4PyCO2Me)(SG)]2+.(b) Plot of initial rate (dA323/dt) vs. [3] for substitution of Cl- with 
GSH (4.0 mM) in 3 (0.5–4 mM) in 100 mM acetate buffer.  
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 Next, the observed equilibrium constant was determined for the reaction of 3 with 
GSH (eq 4.2) in 100 mM acetate buffer (Figure 4.8). The value calculated for Kobs was 
870 ± 50 M-1, which is approximately three orders of magnitude smaller than that of 
GSCbl (9.5 x 105 M-1).174 
 
 
Figure 4.8. Abs323 vs [GSH] plot, obtained from the equilibrated solutions of 3 (0.5 mM) 
and GSH (0.0–15 mM) kept at 298 ± 2 K for 2 h (The data was fit according to the 
literature method, fixing [3] = 5.0 x 10-4 M, A323 (3) = 0.237 and A323 (5) = 1.263).174  
  Further examination revealed that rates for glutathionylation of 3 showed a 
significant dependence on pH. Studies carried out between pH 4.0-8.0 confirmed that 
the rates for the substitution reaction increased with increase in pH (Table 4.5). This 
was expected, because the concentration of the more nucleophilic thiolate GS- (pKa of 
thiol of GSH = 8.72)292 increases with respect to the neutral thiol GSH at higher pH. It is 
important to note that conditions of these experiments are relevant to biology, because 
GSH is estimated to be present at concentrations much higher (up to 106) than H2OCbl+ 
in cells. 
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Table 4.5. Initial rates of reaction of 3 (0.5 mM) with GSH (15 mM) as a function of pH 
Entry Initial Rate of Reaction (M s-1) 
pH 4.0a pH 5.0a pH 6.0a pH 7.0b pH 8.0b 
3 + GSH 1.78 x 10-7 1.46 x 10-6 5.31 x 10-6 3.44 x 10-5 nd 
a100 mM acetate buffer  
b100 mM phoshphate buffer (I = 100 mM (KNO3)) 
nd = not determined (Initial rate of the reaction was too fast to measure under the 
reaction condition) 
 
 The species [CoIII(N4PyCO2Me)(SG)]2+ (5), obtained from reaction of 3 and GSH, 
was generated in situ and characterized further by UV-vis and 1H-NMR spectroscopies 
and mass spectrometry. The in situ generated 5, obtained from the reaction of 3 with 
GSH, shows two major absorption bands, one intense at 323 nm and other relatively 
weaker at 440 nm with shoulder at 490 nm (Figure 4.6). The intense peak at 323 nm is 
consistent with thiolate ligation to Co(III) in 5 and is assigned to S → Co(III) ligand-to-
metal charge transfer (LMCT) transition based on analogy with other Co(III) 
complexes.187,293,294 The thiolate ligation in 5 was further corroborated by the fact that 
other thiols i.e., N-acetylcysteine and 2-merceptoethanol upon reaction with 3, gave 
similar absorption bands. The weaker band at 440 nm with shoulder at 490 nm can be 
due to a splitting of the 1A1g → 1T1g transition arising by a lowering of the symmetry from 
Oh, based on literature assignments.294,295 Using the maximum absorbance observed 
for reaction of 3 (0.5 mM) with GSH (10 mM), a molar extinction coefficient of ε323 = 
4300 M-1 cm-1, ε440 = 280 M-1 cm-1 and ε490 = 120 M-1 cm-1 was calculated for 5, 
respectively. 
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Figure 4.9. 1H-NMR spectra (6-10 ppm) of reaction mixture containing 3 (10 mM) and 
GSH (40 mM), after a time interval of 0 h (top), 16 h (middle) and 96 h (bottom) in D2O 
 1H-NMR spectra were recorded at regular time intervals to follow the reaction of 3 
(10 mM) with GSH (40 mM) in D2O (Figure 4.9). At the beginning of the reaction, no 
immediate change was observed. As the time progressed over the course of 96 h,296 
original resonances diminished and new resonances appeared. Major changes were 
noted with resonances at 6.6, 9.4 and 9.9 ppm (Figure 4.10, labeled a-c, respectively). 
The resonance at 6.6 ppm (a), assigned to the methine proton of the ligand 
N4PyCO2Me, shifted to 7.0 ppm (a’) over time. A resonance assigned to the pyridyl 
protons of the ligand at 9.4 ppm (b) disappeared with concomitant growth of a new 
resonance at 9.2 ppm (b’). The resonance at 9.8 ppm (c) split to form two peaks (c’) 
with similar intensities. Based on the distance between the peaks (9.7 Hz), which are 
too large for 1H-1H coupling in a pyridine ring, and the lack of cross peaks in 2D-COSY 
correlation spectrum (Figure 4.10), the two peaks are assigned as independent singlets 
rather than a doublet. This is consistent with the formation of a 1:1 mixture of 
diastereomers of 5, which occurs because both starting materials are chiral, where 3 is 
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racemic and GSH is enantioenriched. Also, shifts in the peaks corresponding to Cysα 
(4.5 → 4.3 ppm) and Cysβ (2.9 → 3.1 ppm) protons of GSH were observed, consistent 
with the direct thiolate ligation to the cobalt center.169,186 All resonances lie between 1-
10 ppm region, confirming that 5 is a low-spin Co(III) complex. Furthermore, even after 
96 h, resonances were still sharp and well defined, and no broadening occurred. This is 
consistent with a lack of paramagnetic impurities, as would be expected if diamagnetic 3 
or 5 was reduced by GSH to form a Co(II) complex during the reaction. Less than 5% of 
the total GSH was oxidized to form GSSG, as judged by 1H-NMR spectroscopy, which 
confirmed a negligible role for oxidation of GSH by atmospheric O2 in this process, 
either uncatalyzed or catalyzed by 3. Taken together, these data confirm that the 
reaction of 3 with GSH proceeds cleanly to generate 5 under these conditions. 
 
Figure 4.10. COSEY spectra (1 – 10 ppm) for the reaction of 3 (10 mM) with GSH (40 
mM) in D2O after 96 h 
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 The high-resolution ESMS spectrum of 5 generated in situ displayed a prominent 
ion cluster with a peak at m/z  = 395.5974. This cluster displayed an isotopic pattern 
that fits with molecular formula [Co(N4PyCO2Me)(SG)]2+ (Figure 4.11), albeit the 
intensities of calculated and experimental isotopic pattern do not correlate exactly. In 
this dication, the ligand derived from GSH is treated as a monoanion (i.e., GSH-H+), as 
would be expected if the thiolate of GSH were deprotonated and bound to the Co(III) 
center of 5. The difference in intensities from the calculated spectrum may indicate that 
5 is partially reduced to form [CoII(N4PyCO2Me)(GSH)]2+ under the harsh conditions of 
analysis (150 °C, 40V).  
 
Figure 4.11. Calculated (top) and observed (bottom) high resolution mass spectra 
(HRMS) for the dication [CoIII(N4PyCO2Me)(SG)]2+ of 5. 
 
 Like compound 3, the Co(III) complex [CoIII(Bn-CDPy3)Cl]Cl2 (4) reacts with GSH 
in 100 mM acetate buffer to generate the species [CoIII(Bn-CDPy3)(SG)]2+ (6). The 
reaction of 4 (0.5 mM) with GSH (10 mM) was followed by UV-vis spectroscopy over 
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time at 298 ± 2 K (Figure 4.12). As with 3, the disappearance of a peak at 555 nm and 
appearance of two new peaks at 320 and 580 nm were observed, with shoulders at 500 
and 450 nm. In addition two isosbestic points were present at 520 nm and 610 nm. The 
new peak at 320 nm is consistent with a S → Co(III) LMCT band, and with the thiolate 
of GSH binding to the Co(III) center of 6. 
 
Figure 4.12. UV-vis spectral change for 4 (0.5 mM) upon reaction with GSH (10 mM) in 
100 mM acetate buffer pH 5.00 at 298 ± 2 K (Inset: Abs vs time plot for growth of peak 
at 320 nm) 
 
 Kinetic and thermodynamic analysis indicated that the observed rates and 
equilibrium constant for formation of 6 were similar to 5. The reaction of 4 with GSH 
follows the rate law, Rate = k2[4][GSH] under the condition used in this study, the same 
as with 3. The order of the reaction is unity with respect to both 4 and GSH as 
evidenced from the straight lines obtained when the initial rates of the reaction (dA320/dt) 
of 4 (0.5 mM) with GSH (0.5−25 mM) were plotted against the total concentration of 
GSH (Figure 13a), and when the initial rates of the reaction (dA320/dt) of GSH (25 mM) 
with 4 (0.25–1.5 mM) were plotted against the concentration of 4 (Figure 4.13b). 
Second-order rate constants, k2 of 8.7 x 10-2 M-1 s-1 and 8.0 x 10-2 M-1 s-1 were obtained 
from the individual plots which are in good agreement within the experimental error. 
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Figure 4.13. (a) Plot of initial rate (dA320/dt) vs. [GSH] for substitution of Cl- with GSH 
(0.5–25.0 mM) in 4 (0.5 mM) in 100 mM acetate buffer. (c) Plot of initial rate (dA320/dt) 
vs. [4] for substitution of Cl- with GSH (25 mM) in 4 (0.25–1.5 mM) in 100 mM acetate 
buffer. 
 
 
 
Figure 4.14. Abs320 vs [GSH] plot, obtained from the equilibrated solutions of 4 (0.5 
mM) and GSH (0.0–25.0 mM) kept at 298 ± 2 K for 3 h (The data was fit according to 
the literature method, fixing [4] = 5.0 x 10-4 M, A320 (4) = 0.378 and A320 (6) = 1.170).174 
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 A value of 740 ± 47 M-1 was obtained for the observed equilibrium constant, Kobs 
for formation of 6 compared to 870 ± 50 M-1 for 5 in 100 mM acetate buffer (Figure 
4.14). 
 
Figure 4.15. Calculated (top) and observed (bottom) high resolution mass spectra 
(HRMS) for the dication [Co(Bn-CDPy3)(SG)]2+ of 6. 
 
 The species [CoIII(Bn-CDPy3)(SG)]2+ (6), obtained from reaction of 4 and GSH in 
situ, was characterized further by UV-vis, 1H-NMR spectroscopies and mass 
spectrometry. Like 3, new resonance peaks were observed when 4 (10 mM) was 
treated with GSH (40 mM) in D2O, though the complete conversion of 4 into 6 was not 
observed. However, evolution of a new ion cluster with a dominant peak at m/z = 
421.1452 was observed by ESMS, which agrees well with that expected for a dication 
with the chemical formula [CoIII(Bn-CDPy3)(SG)]2+ of 6 (Figure 4.15). The timescale for 
evolution of this new peak correlated well with the timescale of the new peak at 320 nm 
from the kinetic experiments, consistent with its assignment as 6. Using the maximum 
absorbance observed for reaction of 4 (0.5 mM) with GSH (10 mM), a molar extinction 
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coefficient of ε320 = 4300 M-1 cm-1 was calculated for 6, which agrees with the intensity 
and wavelength of S → Co(III) LMCT bands observed for 5 and other related 
complexes.187,293,294 Taken together, these data are consistent with 4, which contains a 
N5 donor set like that of H2OCbl+ and 3, undergoing glutathionylation. Thus, 
glutathionylation appears to be a general reaction of N5 donor Co(III) complexes that 
contain a labile coordination site, although reaction mechanisms and rates of 
glutathionylation differ between related complexes. 
4.3. Discussion 
 Glutathionylation of Cbl to form GSCbl is an important reaction in biology. 
Although this process is well understood at the fundamental chemistry level,166,174,297 the 
role of GSCbl in Cbl metabolism and its applications in medicine are still being actively 
investigated. Studies reported herein are significant, because they are the first example 
of synthetic Co(III) model compounds bearing a unique polypyridyl ligand set mimicking 
the chemistry of Cbl and undergoing glutathionylation in a similar fashion to H2OCbl+. 
Data for 5 and 6, which were generated in situ and characterized in solution by 1H-NMR 
(only 5) and UV-vis spectroscopies and mass spectrometry, are consistent with ligation 
of the cysteine thiolate of GSH to the Co(III) centers, as occurs in GSCbl. This result 
was noteworthy as GSH though possesses three donor atoms (N, O and S) that can 
ligate to cobalt center, it selectively ligates through S atom in 5 and 6. Despite the fact 
that 5, 6 and GSCbl have similar structures, containing N5S donor atom sets and low-
spin Co(III) centers, the formation of 5 and 6 occurs much slower (~100 times) than 
GSCbl at pH 5.0. The reaction of 3 or 4 with GSH was found to be bimolecular in 
nature, the order of reaction being unity with respect to each reactant. The pH 
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dependence studies (pH 4.0–8.0) further confirmed that the rates for the substitution 
reaction increase with increasing pH, as would be expected, because of the higher 
concentration of GS-. This is different from H2OCbl+, where the observed rate constants 
for the reaction of GSH with H2OCbl+ were found to decrease with increasing pH, 
presumably because of increase in concentration of hydroxycobalamine (HOCbl), which 
does not react with GSH and hence decreases the rate of reaction.174 This same issue 
does not apply to 3 and 4, which have chloride rather than H2O bound at the sixth 
position. Discrepancies regarding the mechanism of the axial ligand substitution 
reactions of vitamin B12, its derivatives, and model complexes have been seen in the 
literature. Since, octahedral Co(III) complexes are coordinately saturated systems with 
18 e- in their valence shells, the SN2 (associative) type of mechanism for ligand 
substitution appears impervious. However, some authors have favored the associative 
mechanism298 whereas a limiting dissociative (D) mechanism299-303 or a dissociative 
interchange (Id) mechanism304-313 has been favored by others. High-pressure kinetic 
techniques314-316 can differentiate between D or Id substitution mechanism.304,307-309,314-
317 Further studies will be required to elucidate the exact mechanism of substitution of 
Cl- in 3 and 4 by GSH. Nonetheless, kinetics of glutathionylation are clearly second-
order. 
 In contrast to 3 and 4, corrin and porphyrin-derived Co(III) complexes react much 
faster in ligand substitution reactions, where data suggests a dissociative interchange 
mechanism takes place.305,306,310 Difference in kinetics may be due to the nature of the 
ligand structure. In the delocalized structure of H2OCbl+, the Co(III) oxidation state may 
be a formalism, where the complex is more like Co(II) due to delocalization into the 
corrin ring.318-320 This idea was recently supported with Cbl derivatives. A significant 
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decrease in the rate of ligand substitution was observed with the stable yellow 
aquacyanocobyrinic acid heptamethyl ester, which contains less conjugation in corrin 
ligand than H2OCbl+.321 Even though the kinetics and reaction pathways for 
glutathionylation of H2OCbl+ differ from that of complexes 3 and 4, it is significant that 
these synthetic model compounds mimic the chemistry of H2OCbl+, which implies that 
Co(III) complexes related to Cbl used in biological studies may become glutathionylated 
in cell culture and in vivo, especially with complexes containing labile ligands such as 
chloride or H2O. For example, the soluble oligomer of amyloid β peptide (αβ), especially 
αβ42, responsible for synaptic dysfunction of the brain nerves (Alzheimer disease) are 
cleaved by [CoIII(cyclen)(OH2)2] derivatives,89 and since these complexes contain two 
labile H2O ligands, glutathionylation may render a competing reaction resulting in 
inefficacy of these complexes to hydrolyze these peptides. Similarly, potency of Co(III)-
Ebox complex, a  Co(III) Schiff base–DNA conjugate, to inhibits snail family zinc finger 
transcription factor may be diminished by glutathionylation at the cobalt center, affecting 
the binding of histidine (via ligand substitution of labile amine at Co(III) center), 
responsible for the inhibitory action.322-325 
 Glutathionylation of H2OCbl+ occurs readily and GSCbl is one of the most 
abundant forms of Cbl isolated from mammalian cells. Previous studies reported rate 
constants as high as 163 ± 8 M-1 s-1 (4.5 < pH < 11.0) for the formation of GSCbl.174 
Unlike H2OCbl+, compounds 3 and 4 react slower with GSH, with rate constants ranging 
between 8.3-9.3 M-1 s-1 respectively. The slower rates of formation for 5 and 6 may be 
attributed to differences in ligand structure. Unlike corrin rings or planner oxime/Schiff 
base ligands found in cobalamin or cobaloxime, which contain large planar conjugated 
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rings, the polypyridyl rings in 3 and 4 are perpendicular to the basal plane and can not 
adopt the same conformation, which may limit the amount of delocalization.  
 The observed equilibrium constants, Kobs for the formation of glutathionylated 
products 5 and 6 ranged between 740-870 M-1, which are considerably smaller than 
earlier reported values of Kobs, for GSCbl formation, of (9.5 ± 0.9) x 106 M-1 (pH 5.0, 25 
°C),174 (~ 5) x 105 M-1 (pH 4.7, temperature not specified)297 and (1.1 ± 0.3) x 105 M-1 
(pH 5.0, 25 °C)280 and also Kobs, for [Me(Co)(tn)(SG)] formation where tn = 2,3,9,10-
tetramethyl-1,4,8,11-tetra-azaundeca-1,3,8,10-tetraen-11-ol-1-olato anion, of ~106.6 M-1 
(pH 7.0, temperature not specified).293 The high formation constants of thiolate-bound 
vitamin B12 model complexes have been attributed to π-bonding from the ligand to the 
cobalt center. The lower values of Kobs for 5 and 6 may be attributed to weak 
interactions of thiolate ligands with Co(III) center, as a result of steric hindrance of GSH 
with N4PyCO2Me and Bn-CDPy3 ligands on the cobalt center. Alternatively, 
backbonding could be lower because of electronic considerations. The lower value of 
Kobs for 6 as compared to 5 can also be explained because of the fact that the Co center 
is crowded in 6 as compared to 5 (based on crystallographic data), resulting in a weaker 
bonding interaction between the thiolate and Co(III) center. By changing the electronic 
structure of the ligand around Co(III) center, the kinetic and equilibrium parameters for 
glutathionylation may be tuned. 
4.4. Conclusions and future directions 
 Glutathionlylation of synthetic Co(III) model compounds 3 and 4 was reported 
that mimics the biological chemistry of Cbl. These compounds show similar chemistry to 
H2OCbl+, although kinetic and thermodynamic parameters differ. Unlike H2OCbl+, where 
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the Co(III) center is bound by the highly delocalized corrin ring and GSCbl formation is 
rapid and highly favorable, compounds 3 and 4 react slower with GSH in substitution 
reactions, and formation constants are not as strong. These results entail the 
importance of ligand structure toward tuning the special reactivity of H2OCbl+. 
Nonetheless, the ease with which complexes such as 3 and 4 undergo gluathionlylation 
suggests this may be a general reaction for cobalt complexes of this type. 
Understanding how facile gluathionlylation is for synthetic cobalt complexes may lead to 
a better understanding of the behavior of these interesting metal complexes in biological 
systems, due to the natural abundance of GSH.  
4.5. Experimental section 
 4.5.1. General considerations  
 All reagents were purchased from commercial suppliers and used as received. 
Ligands N4PyCO2Me (1)222 and (R,R)-Bn-CDPy3 (2),287 and the complex [Co(Bn-
CDPy3)Cl]Cl2 (4)287,326 were prepared using literature procedures. NMR spectra were 
recorded on a Varian FT-NMR Mercury- 400 MHz Spectrometer. Mass spectra were 
recorded on a Waters ZQ2000 single quadrupole mass spectrometer using an 
electrospray ionization source. IR spectra were recorded on a Nicolet FT-IR 
spectrophotometer. All reactions were performed under ambient atmosphere unless 
otherwise noted. Conductivity measurements were performed with an Omega portable 
conductivity meter (Model CDH-280). X-ray diffraction data were collected on a Bruker 
APEX-II diffractometer at 100K. Kinetic and thermodynamic studies have been 
performed in 100 mM acetate buffer (pH 5.0, I = 100 mM (KNO3)) unless otherwise 
noted. 
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 4.5.2. Synthesis of [CoIII(N4PyCO2Me)Cl]Cl2 (3) 
 The compound, trans-[CoIII(Py)4Cl2]Cl·6H2O,282,283 (277 mg, 0.470 mmol) was 
added to a solution of 1 (200 mg, 0.470 mmol) in CH2Cl2 (5 mL). The mixture was stirred 
for 60 min, during which time a light purple solid formed. The resultant solid was 
isolated by filtration in analytically pure form (173 mg, 71%). Single crystals of 3 suitable 
for X-ray crystallographic analysis were obtained by recrystallization of the purple 
precipitate from EtOH with Et2O vapor diffusion, followed by isolation of the pink solid 
and recrystallization from MeOH with Et2O vapor diffusion. Mp = 144-146 °C. 1H-NMR 
(CD3OD) δ 9.94 (s, 1H), 9.47 (d, J = 5.67 Hz, 1H), 8.90 (t, J = 8.92 Hz, 2H), 8.49 (dd, J 
= 6.48, 1.62 Hz, 1H), 8.25-8.34 (m, 4H), 7.99 (dt, J = 1.62, 7.19 Hz, 1H), 7.69 (t, J = 
6.48, 1H), 7.6-7.66 (m, 3H), 7.46 (d, J = 8.1 Hz, 1H), 7.07 (s, 1H), 5.13-5.43 (m, 4H), 
4.01 (s, 3H); 13C-NMR (CD3OD) δ 169.9, 166.4, 160.8, 160.7, 156.5, 156.4, 153.38, 
152.8, 144.2, 142.5, 142.4, 130.9, 128.7, 128.5, 127.0, 125.1, 81.1, 67.6, 67.5, 53.7 
ppm; IR (KBr) 3588 (w), 3568 (w), 3407 (s), 2922 (m), 1735 (s), 1610 (s), 1300 (s) cm-1; 
HRMS (ESMS) calc’d for C25H23O2N5CoCl (M2+) 259.5436, found: 259.5437. Anal. Calc. 
for C25H28Cl3CoN5O4.5 (2·2.5H2O): C, 47.23; H, 4.44; N, 11.01. Found: C, 47.21; H, 
4.19; N, 10.95. 
4.5.3. Kinetic studies 
 Generation of the complexes [Co(N4PyCO2Me)(SG)]2+ (5) and [Co(Bn-
CDPy3)(SG)]2+ (6), formed in situ from reaction of GSH with 3 and 4 respectively, were 
followed spectrophotometrically. The solutions of 3 or 4 (1 mM, 50 µL, final 
concentrations = 0.5 mM,) in 100 mM acetate buffer were treated with solutions of GSH 
in the same buffer (50 µL, final concentration = 0-25 mM). Absorbance at 323 nm for 
formation of 5 and 320 nm for formation of 6, respectively was recorded over a period of 
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2 h at 298 ± 2 K with a GENios Pro, microplate reader (TECAN) using a 96 well 
microplate. All data were collected in triplicate. Initial rates (dA320/323/dt) were calculated 
from slopes obtained from linear portions of absorbance vs. time graphs for the first 5% 
of the reaction.  
 4.5.4. Determination of equilibrium constant (Kobs) 
 The observed equilibrium constants for the formation of glutathionylated products 
5 and 6 were determined by measuring the absorbances of equilibrated reaction 
mixtures containing cobalt complexes 3 or 4 (0.5 mM) and GSH (0-15 mM or 25 mM, 
respectively) in 100 mM acetate buffer. A323/320 values were plotted against [GSH] and 
the data was fit according to literature methods.174 
 4.5.5. 1H-NMR spectroscopic studies 
 A solution of GSH (12.3 mg, 40.0 µmol) and 3 (5.91 mg, 10.0 µmol) or 4 (6.43 
mg, 10.0 µmol) in D2O (1 mL) was prepared. The reaction was monitored by 1H-NMR 
spectroscopy at regular time intervals. The reaction was maintained at room 
temperature (298 ± 2 K) during the experiment. 
 4.5.6. X-ray crystallographic studies 
 Diffraction data were collected on a Bruker X8 APEX-II kappa geometry 
diffractometer equipped with Mo radiation and a graphite monochromator at 100 K. 
Frames were recorded for 10 s and 0.3 degree between frames. APEX-II and SHELX 
software327,328 were used in the collection and refinement of the model. Crystals of 3 
appeared as red rhomboids. 36734 reflections were measured, of which 7571 were 
independent. Hydrogen atoms were placed in calculated positions. The asymmetric unit 
contains one coordination complex, two Cl anions, and one equivalent each of methanol 
and ethanol. The ethanol was disordered over two sites and described with partial 
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occupancies and isotropic thermal parameters. There is a network of hydrogen bonds 
linking the anions and solvates in the lattice. 
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Chapter 5 
Conclusions and Future Directions 
This chapter comprises of two sections, where the first section deals with the 
accomplishments of my research goals described at the beginning of the dissertation 
with suggestions to improve the present outcome of the research, and the second 
section entails the conclusions and future prospects highlighting the significance and 
scope of the research reported in this dissertation. 
5.1. Research goal accomplishments and suggestions 
5.1.1. Application of non-heme iron complexes in protein oxidation 
Non-heme iron complexes were investigated for their ability to inactivate a series 
of proteins. The proteins being inactivated in these studies were human carbonic 
anhydrase-I (CA-I), serine proteases (trypsin and chymotrypsin) and 20S proteasome. 
Different non-heme ligands for iron complex formation were designed and synthesized 
to target different proteins. Proteins inactivation was achieved either by pre-generated 
ferryl (serine proteases) or by an iron complex in presence of O2 and a reductant (CA-I 
and 20S proteasome) or H2O2 (serine proteases). Mode of action of these iron 
complexes to inactivate proteins was determined by characterizing the protein 
inactivation products using SDS-PAGE, ESI-MS, LC/MS and LC/MS/MS. These 
characterization techniques enabled me to confirm that CA-I is inactivated by an 
oxidation event that does not result in cleavage of the protein backbone where specific 
oxidation of His, Trp and Met residues, mostly localized around the active site, was 
achieved. The time-dependent inactivation of CA-I and 20S proteasome in presence of 
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O2 and DTT was consistent with a pathway involving the reductive activation of O2 
playing a role in enzyme inactivation. The results obtained for CA-I inactivation were 
found irreproducible probably due to inefficacy of O2 activation by the reductant DTT 
under the reaction condition used in this dissertation. This led us to move toward 
inactivating proteins with pre-generated ferryl and using relatively stronger bioavailable 
oxidant H2O2 replacing O2. Ferryls were found potent oxidants inactivating trypsin and 
chymotrypsin by oxidation of amino acid side chains rather than protein backbone 
cleavage, similar to seen in CA-I oxidation. Amino acid analysis further confirmed that 
the residues Cys, Tyr and Trp were the most susceptible to oxidations. Oxidation of the 
proteases by ferrous complexes in the presence of hydrogen peroxide led to the 
preferential inactivation of trypsin over chymotrypsin where tyrosine residues were 
selectively oxidized. Further investigation into the details of active oxidant responsible 
for protein oxidation was achieved by performing the inactivation studies in presence of 
radical scavengers like NaN3, D-mannitol and imidazole. The data precluded the role of 
ROS and supported that a metal-based oxidant was responsible for inactivation of 
proteins (serine proteases and 20S proteasome), though the nature of active oxidant 
was not confirmed. In case of seine proteases inactivation, extensive mechanistic 
studies (oxidation of Ac-Try-OH to Ac-DOPA-OH) led to conclude that a pathway unique 
from that of an FeII/FeIV cycle involving ferryl compounds was operative. 
Overall, non-heme iron complexes, which find extensive application in oxidation 
of small organic molecules, amino acids and DNA, were shown to oxidize full proteins 
with mode of action primarily being oxidation of amino acid side chains rather than 
protein backbone cleavage where residues Cys, His, Trp, Tyr and Met were more prone 
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to oxidation and supporting the role of a metal-based oxidant responsible for inactivation 
of proteins. However, further investigation is required to unravel the exact nature of 
active oxidant. 
5.1.2. Application of non-heme cobalt complexes as biomimetic model 
systems for cobalamin 
Synthetic cobalt(III) model complexes derived from polypyridyl pentadentate non-
heme ligands (N4PyCO2Me and Bn-CDPy3), mimicking the N5 coordination 
environment around cobalt(III) center present in biologically important cofactor 
cobalamin (Cbl) or vitamin B12 were investigated (kinetic and thermodynamic analysis) 
for their reaction with glutathione (GSH) to generate glutathionylated products similar to 
glutathionylcobalamin (GSCbl), an important form of Cbl present in the cell. The Co(III) 
model complexes were synthesized, and characterized using various experimental 
techniques including UV-vis, 1H- and 13C-NMR spectroscopies, HRMS and X-ray 
crystallography. The reaction of these Co(III) model complexes with GSH followed 
second order kinetic (the order of reaction being unity with respect to each reactant). 
The rate of reaction was found to be dependent on pH where the rate increases with 
increase in pH. The second order rate constants calculated for the reaction of GSH with 
both the compounds showed that these reactions were ∼ 100 times slower than the 
reaction of GSH with aquacobalamin. Also, the observed equilibrium constants were ∼ 
1000 times weaker than the observed equilibrium constants for the formation of GSCbl 
from aquacobalamin (H2OCbl+) and GSH. The in situ generated glutathionylated 
products were further characterized using 1H-NMR and UV-vis spectroscopies, and 
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HRMS. The thiolate-ligation from GSH in glutathionylated products was confirmed by 
1H-NMR and UV-vis spectroscopies. 
Overall, synthetic Co(III) model complexes underwent facile glutathionylation 
reaction to generate thiolate-ligated glutathionylated products, though the kinetic and 
thermodynamic parameters differed from the reaction of GSH with aquacobalamin. 
Unlike aquacobalamin, these cobalt complexes reacted slower with GSH, and even the 
observed equilibrium constants were not stronger. Further work is needed to investigate 
the mechanism of this reaction to better understand the factors governing the reactivity 
of Co(III) center in these cobalamin model complexes, and render insight into the 
special reactivity of natural cobalamin. 
5.2. Conclusions and future directions 
The studies reported in this dissertation were aimed at exploring metal 
complexes derived from non-heme ligands as promising candidates for biological 
applications. In particular, inactivation of proteins using non-heme iron complexes, and 
understanding the reactivity of Co(III) center in synthetic cobalamin model complexes at 
the fundamental level via glutathionylation reaction were investigated. Both represent an 
underexplored area of research, which has not been investigated in details. 
Through our studies, we have shown that non-heme iron complexes can 
inactivate a broad range of proteins (carbonic anhydrase-I, serine proteases (trypsin 
and chymotrypsin) and 20S proteasome). These results are significant because non-
heme ligands bind tightly to iron with association constants in 1012−1015 M range and 
have the ability to mobilize FeII from ferritin, the major intracellular storage site for iron, 
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suggesting that such ligands could access iron in cells. Results from amino acid 
analysis for inactivation of serine protease under catalytic condition proved that tyrosine 
residues were selectively targeted. These results suggest that these complexes mimic 
the action of myeloperoxidases, a heme enzyme that is known to oxidize tyrosine 
residue of protein using H2O2 as the oxidant or even the tyrosine hydroxylase. This 
chemistry provides a promising future direction to target medicinally important target 
proteins that contain important tyrosine residues near the active site. Moreover, the use 
of H2O2 as an oxidant for inactivating proteins extend the scope of this study to perform 
in cellulo as H2O2 is a bioavailable oxidant, formed as a byproduct of aerobic respiration 
in cells.  Due to the fact that the tumor cells produce high levels of H2O2 as compared to 
normal cells, these can be targeted selectively.329,330 This opens up a whole new 
paradigm for developing iron complexes as potential antitumor agents. My studies also 
established that incorporating protein-binding affinity group to non-heme iron complexes 
has the potential to inactivate proteins at lower concentrations. Results from amino acid 
analysis of enzymes, oxidized by ferryls find relevance to biology, because under 
conditions of oxidative stress, ferryls such as ferrylmyoglobin can oxidize proteins. 
Inactivation of proteasome by non-heme iron complexes make them potential 
therapeutic candidates toward anticancer agent, however the potency of these 
complexes to inactivate proteasome needs to be enhanced by attaching a binding motif 
that can direct these complexes selectively toward proteasomes in cell.  
Besides the significance of non-heme ligands (as iron complexes) in protein 
oxidation, their Co(III) complexes find application as synthetic model systems for 
studying biologically important cofactor cobalamin. In this dissertation, I have reported 
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the first example of synthetic Co(III) model complexes derived from a unique polypyridyl 
non-heme ligand set, mimicking the chemistry of Cbl and undergoing glutathionylation in 
a similar fashion to aquacobalamin. However, the kinetic and thermodynamic parameter 
differs. As compared to H2OCbl+, the slower rates of reaction of model cobalt 
complexes with GSH were attributed to difference in ligand structure around Co(III) 
center. Unlike highly conjugated planner corrin rings systems found in Cbl that make the 
Co(III) center in Cbl more like Co(II), the polypyridyl rings in model cobalt complexes 
adopt conformation orthogonal to the basal plane, limiting the extent of delocalization. 
The lower values of observed equilibrium constants for the formation of glutathionylated 
products could be attributed to the weak interaction of thiolate ligands with Co(III) center 
as a result of steric hindrance of GSH with non-heme ligands on the cobalt center. 
These results signify the importance of ligand structure tuning the special reactivity of 
H2OCbl+. However, the facile glutathionylation of synthetic Co(III) model complexes 
suggest that this may represent a general reaction for cobalt complexes of this type. 
Higher abundance of GSH in cells may provide a competing reaction (glutathionylation) 
to the Co(III) complexes related to Cbl used in biological studies, especially with 
complexes containing labile ligands such as Cl- or H2O. 
Overall, my dissertation work harnesses the potential of metal complexes (iron 
and cobalt) of non-heme ligands for their applications in oxidatively inactivating proteins, 
and understanding fundamental chemistry of important biological reaction, with future 
prospect of these metal complexes as excellent tools, and in the development of novel 
therapeutic agents.  
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APPENDIX A 
A1. HRMS data for [FeIV(O)(3CG-N4Py)]3+ 
 
 
 
 
 
 
 
 
 
  
 
 
A2. HRMS of in situ generated iron complex [FeII(3CG-N4Py)Cl]2+ 
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A3. HRMS data for [FeII(3CG-N4Py)(Cl)]2+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
A4. Asp (blue) and Glu (green) residues on trypsin (left) and chymotrypsin (right) 
surface. Figures were constructed from the Protein Data Bank files 3MFJ (trypsin) and 
4CHA (chymotrypsin). 
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A5. Left Panels: LCMS chromatogram (top) and deconvoluted MS spectra (bottom) of 
trypsin (spectrum a) and after treatment with 10 (spectrum b) or 9 (c). Reactions were 
conducted at rt by incubating trypsin (1 µM) with 10 or 9 (20 µM) pulsed with H2O2 (40 
µM) every 10 min, before desalting and subjecting the samples to LCMS analysis. Right 
panels: LCMS chromatogram (top) and deconvoluted MS spectra (bottom) of 
chymotrypsin (spectrum a) and after treatment with 10 (spectrum b) or 9 (spectrum c). 
Reactions were conducted at rt by incubating chymotrypsin (1 µM) with 10 or 9 (20 µM) 
and pulsed with H2O2 (40 µM) every 10 min, before desalting and subjecting the 
samples to LCMS analysis. 
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A6. Inactivation of chymotrypsin in presence of ROS scavangers (azide, D-mannitol and 
imidazole). The reactions were conducted at pH = 6.0, in 10 mM acetate buffer 
containing 150 mM NaCl by pulsing H2O2 (40 µM) to the solution of enzyme (1 µM) with 
10 (20 µM) in presence of ROS scavengers D-Mannitol (∗), imidazole ( ), NaN3 (■) or 
control as buffer (♦) (100 µM). Enzyme activities (100% activity equal to the activity of 
the blank reaction in the absence of inhibitor) were determined by removing aliquots 
before each pulse (10 min between pulses) and plotted against the total amount of 
peroxide added. 
 
A7. Titration of 9 (0.8 mM) with NaN3. 1 mL solution of 9, in acetate buffer, was titrated 
with various concentration (0.8−16.0 mM) of NaN3 solution at room temperature. 
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A8. HPLC chromatogram from the oxidation of 13 by [FeII(CH3CN)(N4Py)](ClO4)2 and 
H2O2 shows Ac-DOPA-OH 14 as a major product 
 
 
 
 
 
 
 
 
A9. Spectral change that occurs when solution of 9 in acetate buffer (0.5 mM, red) was 
treated with H2O2 (0.25 mM, blue). 
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A10. UV-vis spectral change of 1 mM solution of 9 (red) and Ac-Tyr-OH (13) in acetate 
buffer when the solution was pulsed with 0.5 mM (blue), 1.0 mM (green) and 2.0 mM 
(pink) H2O2, respectively 
 
 
A11. Proposed site of trypsin cleavage upon treatment with ferryl 12. The residue Gly 
38, highlighted in red is located near the active site. 
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A12. Amino acid analysis of trypsin (20 µM) pulsed with H2O2 (500 µM, total addition) in 
presence of 9 and 10 (50 µM) 
 
Amino acid Theoretical 
composition 
(%) 
Experimental 
composition 
(%) 
10 9 
Ala 6.3 7.07 7.28 7.32 
Arg 0.9 1.02 1.04 1.03 
Asn/Asp 9.9 10.71 11.10 11.11 
Cys 5.4 2.66 2.37 2.55 
Gln/Glu 6.3 6.98 7.18 7.14 
Gly 11.2 12.34 12.67 12.63 
His 1.3 1.28 1.21 1.18 
Ile 6.7 6.36 6.53 6.47 
Leu 6.3 6.72 6.84 6.78 
Lys 6.3 6.96 6.99 6.98 
Met 0.9 0.62 0.64 0.67 
Phe 1.3 1.56 1.57 1.52 
Pro 3.6 4.15 4.18 4.19 
Ser 15.2 14.6 14.81 14.81 
Thr 4.5 4.53 4.65 4.63 
Trp 1.8 0.79 0.78 0.69 
Tyr 4.5 4.53 2.87 2.98 
Val 7.6 6.91 7.02 7.02 
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A13. Amino acid analysis of chymotrypsin (20 µM) pulsed with H2O2 (500 µM, total 
addition) in presence of 9 and 10 (50 µM) 
 
Amino acid  Theoretical 
composition (%) 
Experimental 
composition (%) 
10 9 
Ala 9.1 9.90 9.98 9.98 
Arg 1.2 1.42 1.41 1.41 
Asn/Asp 9.1 9.96 10.06 10.09 
Cys 4.1 1.89 1.75 1.79 
Gln/Glu 6.2 6.81 6.78 6.73 
Gly 9.5 10.24 10.30 10.36 
His 0.8 0.84 0.81 0.81 
Ile 4.1 3.96 3.97 3.98 
Leu 7.9 8.29 8.27 8.23 
Lys 5.8 6.44 6.40 6.44 
Met 0.8 0.58 0.55 0.56 
Phe 2.5 2.82 2.81 2.74 
Pro 3.7 4.24 4.33 4.30 
Ser 11.2 11.01 11.05 11.05 
Thr 9.1 9.49 9.49 9.48 
Trp 3.3 0.73 0.80 0.76 
Tyr 1.7 1.77 1.41 1.47 
Val 9.5 9.40 9.62 9.55 
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A14. Amino acid analysis of trypsin (20 µM) treated with ferryls 11 or 12 (1000 µM) 
along with the control 
 
Amino acid Theoretical 
composition (%) 
Experimental 
composition (%) 
12 11 
Ala 6.3 7.11 7.48 7.44 
Arg 0.9 1.01 0.98 1.05 
Asn/Asp 9.9 10.86 11.58 11.41 
Cys 5.4 2.57 0.54 0.81 
Gln/Glu 6.3 6.78 6.41 6.76 
Gly 11.2 11.91 12.61 12.43 
His 1.3 1.34 1.34 1.31 
Ile 6.7 6.55 6.93 6.87 
Leu 6.3 6.67 6.87 6.86 
Lys 6.3 7.14 7.21 6.71 
Met 0.9 0.38 0.37 0.41 
Phe 1.3 1.48 0.71 1.52 
Pro 3.6 4.24 4.41 4.36 
Ser 15.2 14.86 15.75 15.51 
Thr 4.5 4.52 4.788 4.69 
Trp 1.8 0.71 0.84 0.61 
Tyr 4.5 4.49 2.92 3.31 
Val 7.6 7.22 7.92 7.69 
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A15. Amino acid analysis of chymotrypsin (20 µM) treated with ferryls 11 or 12 (1000 
µM) along with control 
 
Amino acid Theoretical 
composition (%) 
Experimental 
composition (%) 
12 11 
Ala 9.1 10.05 10.21 10.17 
Arg 1.2 1.38 1.30 1.39 
Asn/Asp 9.1 9.98 10.44 10.45 
Cys 4.1 1.92 0.85 0.68 
Gln/Glu 6.2 6.65 6.36 6.09 
Gly 9.5 9.92 10.22 10.22 
His 0.8 0.86 0.83 0.83 
Ile 4.1 4.01 4.16 4.24 
Leu 7.9 8.22 8.37 8.52 
Lys 5.8 6.59 6.22 6.01 
Met 0.8 0.37 0.38 0.40 
Phe 2.5 2.65 2.66 2.75 
Pro 3.7 4.35 4.53 4.53 
Ser 11.2 11.31 11.78 12.01 
Thr 9.1 9.53 9.78 9.89 
Trp 3.3 0.67 0.56 0.57 
Tyr 1.7 1.62 1.02 1.05 
Val 9.5 9.96 10.14 10.11 
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A16. 1H-NMR spectrum for compound 6 
 
 
A17. 13C-NMR spectrum for compound 6 
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A18. 1H-NMR spectrum for compound 7 
 
A19. 13C-NMR spectrum for compound 7 
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A20. 1H-NMR (0-160 ppm) of ligand 8 (bottom), ligand 8 treated with 1 equiv. of 
FeII(ClO4)2 (middle) and ligand 8 treated with 1 equiv. of FeII(ClO4)2 and 50 equiv. of 
CH3CN (top) in D2O. Inset (middle): Peaks in 110-160 ppm 
 
 
A21. 1H-NMR (0-10 ppm) of ligand 8 (bottom), ligand 8 treated with 1 equiv. of 
FeII(ClO4)2 (middle) and ligand 8 treated with 1 equiv. of FeII(ClO4)2 followed by 50 
equiv. of CH3CN (top) in D2O 
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A22. 1H-NMR (0–160 ppm) of ligand 7 (bottom), ligand 7 treated with 1 equiv. of 
FeII(ClO4)2 (middle) and ligand 7 treated with 1 equiv. of FeII(ClO4)2 followed by 50 
equiv. of CH3CN (top) in D2O. Inset (middle): Peaks in 110-160 ppm region 
 
 
A23. 1H-NMR (0–10 ppm) of ligand 7 (bottom), ligand 7 treated with 1 equiv. of 
FeII(ClO4)2 (middle) and ligand 7 treated with 1 equiv. of FeII(ClO4)2 followed by 50 
equiv. of CH3CN (top) in D2O 
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APPENDIX B 
B1. 1H-NMR (1-4 ppm) spectra of reaction mixture containing [CoIII(N4PyCO2Me)Cl]Cl2 
(3; 10 mM) and GSH (40 mM), after a time interval of 0 h (top), 16 h (middle) and 96 h 
(bottom). The peak e (corresponding to Cys-β Hydrogen of GSH) is shifting to e' during 
the course of time showing thiolate coordination with Co(III) center in glutathionylated 
product 5 
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B2. Crystal data and structure refinement for 3·MeOH·EtOH 
Empirical Formula C28 H33Cl3CoN5O4 
Formula weight 668.87 
Crystal system Triclinic 
Space group P1 
a (Å) 9.6350(3) 
b (Å) 11.5595(4) 
c (Å) 15.6403(5) 
α (0) 97.695(2) 
β (0) 106.955(1) 
γ (0) 109.816(2) 
V (Å3) 1514.23(9) 
Z 2 
Dcalc (mg/m3) 1.467 
Absorption coefficient, µ (mm-1) 0.874 
F (000) 692 
Crystal size (mm3) 0.29 x 0.26 x 0.18 
θ-range for data collection (°) 1.94 to 28.48 
Limiting indices -12≤ h ≤12, -15≤ k ≤15 
0≤ l ≤ 20 
Unique Reflections 36734 / 7571 [R (int) = 0.0342] 
Goodness-of-fit on F02 1.033 
Final R indices [I>2σ(I)] R1 = 0.0450, wR2 = 0.1227 
R indices (all data) R1 = 0.0530, wR2 = 0.1269 
Highest peak and deepest hole (e.A-3) 1.642 and -0.388 
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B3. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 x 
103) for 3.MeOH.EtOH. U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
______________________________________________ 
 
x                  y                  z            U(eq) 
______________________________________________ 
 
Co(1)        2942(1)       9263(1)       2722(1)       14(1) 
N(1)         2305(2)        9959(2)       1690(1)       15(1) 
C(1)         2151(3)      11170(2)       2017(2)       17(1) 
C(2)         1979(3)      11239(2)       2937(2)       17(1) 
C(3)         1511(3)      12140(3)       3307(2)       23(1) 
C(4)         1405(3)      12182(3)       4170(2)       26(1) 
C(5)         1748(3)      11319(3)       4645(2)       23(1) 
C(6)         2211(3)      10446(2)       4244(2)       19(1) 
C(7)         1587(3)      11378(3)       5570(2)       28(1) 
O(1)         1009(3)      12039(3)       5865(2)       48(1) 
O(2)         2119(2)      10622(2)       6016(1)       30(1) 
C(8)         2119(4)      10729(3)       6958(2)       31(1) 
N(2)         2320(2)      10406(2)       3399(1)       16(1) 
C(9)           785(3)        8991(2)         962(2)       18(1) 
C(10)          -38(3)        7997(2)       1372(2)       18(1) 
C(11)      -1592(3)        7133(3)         897(2)       25(1) 
C(12)      -2267(3)        6217(3)       1302(2)       29(1) 
C(13)      -1409(3)        6195(3)       2174(2)       29(1) 
C(14)         133(3)        7097(2)       2626(2)       23(1) 
N(3)           810(2)        7976(2)       2222(1)       17(1) 
C(15)       3722(3)      10177(2)       1396(2)       16(1) 
C(16)       5133(3)      11010(2)       2252(2)       16(1) 
C(17)       6467(3)      11990(2)       2289(2)       21(1) 
C(18)       7675(3)      12609(3)       3143(2)       28(1) 
C(19)       7499(3)      12244(3)       3927(2)       29(1) 
C(20)       6119(3)      11255(3)       3846(2)       23(1) 
N(4)         4971(2)      10642(2)       3018(1)       16(1) 
C(21)       3805(3)        8890(2)       1228(2)       17(1) 
C(22)       4194(3)        8369(2)         535(2)       21(1) 
C(23)       4271(3)        7185(3)         507(2)       25(1) 
C(24)       3943(3)        6564(3)       1174(2)       25(1) 
C(25)       3561(3)        7142(2)       1855(2)       21(1) 
N(5)         3508(2)        8288(2)       1881(1)       17(1) 
Cl(1)        3829(1)        8473(1)       3885(1)       21(1) 
Cl(2)        4419(1)      13629(1)       1340(1)       24(1) 
Cl(3)        1886(1)        9566(1)        -982(1)       23(1) 
O(3)         9456(3)        3368(3)       1699(2)       51(1) 
C(26)       10146(4)       3945(3)       1101(3)       43(1) 
O(4)          1274(6)        4792(4)       4976(3)       37(1) 
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C(27)        1953(9)        5337(7)       4356(5)       46(2) 
C(28)        1184(2)        4951(1)       3404(8)       89(3) 
O(5)          3895(6)       4877(5)        2999(4)       49(1) 
C(29)        5216(8)       5402(6)        3643(5)       39(1) 
C(30)        5815(8)       4596(6)        3512(5)       39(1) 
_____________________________________________ 
 
B4. Bond lengths [Å] and angles [deg] for 3.MeOH.EtOH.            
_______________________________ 
 
Co(1)-N(3)                    1.930(2) 
Co(1)-N(1)                    1.933(2) 
Co(1)-N(5)                    1.933(2) 
Co(1)-N(4)                    1.933(2) 
Co(1)-N(2)                    1.938(2) 
Co(1)-Cl(1)                   2.222(6) 
N(1)-C(1)                      1.496(3) 
N(1)-C(9)                      1.506(3) 
N(1)-C(15)                    1.518(3) 
C(1)-C(2)                      1.491(3) 
C(2)-N(2)                      1.349(3) 
C(2)-C(3)                      1.390(3) 
C(3)-C(4)                      1.379(4) 
C(4)-C(5)                      1.391(4) 
C(5)-C(6)                      1.383(4) 
C(5)-C(7)                      1.494(4) 
C(6)-N(2)                      1.353(3) 
C(7)-O(1)                      1.205(4) 
C(7)-O(2)                      1.331(4) 
O(2)-C(8)                      1.462(3) 
C(9)-C(10)                    1.496(3) 
C(10)-N(3)                    1.351(3) 
C(10)-C(11)                  1.389(3) 
C(11)-C(12)                  1.378(4) 
C(12)-C(13)                  1.382(4) 
C(13)-C(14)                  1.390(4) 
C(14)-N(3)                    1.350(3) 
C(15)-C(21)                  1.508(3) 
C(15)-C(16)                  1.508(3) 
C(16)-N(4)                    1.357(3) 
C(16)-C(17)                  1.375(3) 
C(17)-C(18)                  1.387(4) 
C(18)-C(19)                   1.386(4) 
C(19)-C(20)                   1.388(4) 
C(20)-N(4)                     1.338(3) 
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C(21)-N(5)                     1.354(3) 
C(21)-C(22)                   1.377(3) 
C(22)-C(23)                   1.391(4) 
C(23)-C(24)                   1.393(4) 
C(24)-C(25)                   1.387(4) 
C(25)-N(5)                     1.339(3) 
O(3)-C(26)                     1.412(4) 
O(4)-C(27)                     1.421(9) 
C(27)-C(28)                   1.386(1) 
O(5)-C(29)                     1.252(8) 
C(29)-C(30)                   1.275(9) 
 
N(3)-Co(1)-N(1)              86.4(8) 
N(3)-Co(1)-N(5)              89.5(8) 
N(1)-Co(1)-N(5)              83.6(9) 
N(3)-Co(1)-N(4)            169.7(9) 
N(1)-Co(1)-N(4)              83.4(8) 
N(5)-Co(1)-N(4)              87.9(9) 
N(3)-Co(1)-N(2)              91.5(8) 
N(1)-Co(1)-N(2)              86.4(8) 
N(5)-Co(1)-N(2)            169.8(9) 
N(4)-Co(1)-N(2)              89.4(8) 
N(3)-Co(1)-Cl(1)             96.3(6) 
N(1)-Co(1)-Cl(1)           175.8(6) 
N(5)-Co(1)-Cl(1)             93.3(6) 
N(4)-Co(1)-Cl(1)             93.8(6) 
N(2)-Co(1)-Cl(1)             96.7(6) 
C(1)-N(1)-C(9)              111.7(2) 
C(1)-N(1)-C(15)            112.7(2) 
C(9)-N(1)-C(15)            112.9(2) 
C(1)-N(1)-Co(1)            110.1(1) 
C(9)-N(1)-Co(1)            109.9(1) 
C(15)-N(1)-Co(1)            98.9(1) 
C(2)-C(1)-N(1)              110.1(2) 
N(2)-C(2)-C(3)              121.7(2) 
N(2)-C(2)-C(1)              117.2(2) 
C(3)-C(2)-C(1)              121.1(2) 
C(4)-C(3)-C(2)              118.8(2) 
C(3)-C(4)-C(5)              119.7(2) 
C(6)-C(5)-C(4)              119.0(2) 
C(6)-C(5)-C(7)              122.9(2) 
C(4)-C(5)-C(7)              118.0(2) 
N(2)-C(6)-C(5)              121.4(2) 
O(1)-C(7)-O(2)               124.2(3) 
O(1)-C(7)-C(5)               122.3(3) 
O(2)-C(7)-C(5)               113.4(2) 
C(7)-O(2)-C(8)               115.5(2) 
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C(2)-N(2)-C(6)               119.4(2) 
C(2)-N(2)-Co(1)             112.9(2) 
C(6)-N(2)-Co(1)             127.7(2) 
C(10)-C(9)-N(1)             110.1(2) 
N(3)-C(10)-C(11)           121.9(2) 
N(3)-C(10)-C(9)             116.6(2) 
C(11)-C(10)-C(9)           121.5(2) 
C(12)-C(11)-C(10)         118.6(3) 
C(11)-C(12)-C(13)         119.8(3) 
C(12)-C(13)-C(14)         119.2(3) 
N(3)-C(14)-C(13)           121.1(3) 
C(14)-N(3)-C(10)           119.3(2) 
C(14)-N(3)-Co(1)           127.1(2) 
C(10)-N(3)-Co(1)           113.6(2) 
C(21)-C(15)-C(16)         106.4(2) 
C(21)-C(15)-N(1)           104.4(2) 
C(16)-C(15)-N(1)           104.8(2) 
N(4)-C(16)-C(17)           122.2(2) 
N(4)-C(16)-C(15)           111.1(2) 
C(17)-C(16)-C(15)         126.7(2) 
C(16)-C(17)-C(18)         118.1(2) 
C(19)-C(18)-C(17)         119.8(2) 
C(18)-C(19)-C(20)         119.5(3) 
N(4)-C(20)-C(19)           120.5(2) 
C(20)-N(4)-C(16)           120.0(2) 
C(20)-N(4)-Co(1)           128.6(2) 
C(16)-N(4)-Co(1)           111.3(2) 
N(5)-C(21)-C(22)           121.9(2) 
N(5)-C(21)-C(15)           111.6(2) 
C(22)-C(21)-C(15)         126.4(2) 
C(21)-C(22)-C(23)         118.5(2) 
C(22)-C(23)-C(24)         119.2(2) 
C(25)-C(24)-C(23)         119.4(2) 
N(5)-C(25)-C(24)           120.8(2) 
C(25)-N(5)-C(21)           120.1(2) 
C(25)-N(5)-Co(1)           128.9(2) 
C(21)-N(5)-Co(1)           110.9(1) 
C(28)-C(27)-O(4)           123.2(8) 
O(5)-C(29)-C(30)           100.6(6) 
__________________________________ 
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B5. Anisotropic displacement parameters (A2 x 103) for 3.MeOH.EtOH. The anisotropic 
displacement factor exponent takes the form: -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________ 
 
U11       U22       U33        U23       U13       U12 
______________________________________________________ 
 
Co(1)   13(1)      17(1)      13(1)       7(1)       6(1)       7(1) 
N(1)     12(1)      20(1)      14(1)       7(1)       6(1)       7(1) 
C(1)     18(1)      19(1)      19(1)       8(1)       9(1)     10(1) 
C(2)     14(1)      20(1)      18(1)       5(1)       6(1)       6(1) 
C(3)     25(1)      25(1)      26(1)       9(1)     11(1)     14(1) 
C(4)     29(1)      28(1)      25(1)       4(1)     12(1)     15(1) 
C(5)     22(1)      28(1)      19(1)       4(1)     10(1)     11(1) 
C(6)     19(1)      24(1)      15(1)       7(1)       7(1)       8(1) 
C(7)     28(1)      35(1)      23(1)       6(1)     13(1)     13(1) 
O(1)     72(2)      67(2)      35(1)     20(1)     35(1)     49(2) 
O(2)     33(1)      42(1)      22(1)     11(1)     16(1)     19(1) 
C(8)     29(1)      48(2)      20(1)     11(1)     14(1)     17(1) 
N(2)     15(1)      19(1)      16(1)       6(1)       7(1)       7(1) 
C(9)     15(1)      23(1)      15(1)       5(1)       4(1)       6(1) 
C(10)   16(1)      20(1)      20(1)       5(1)       8(1)       9(1) 
C(11)   18(1)      26(1)      26(1)       3(1)       6(1)       7(1) 
C(12)   18(1)      25(1)      40(2)       4(1)     11(1)       4(1) 
C(13)   25(1)      25(1)      39(2)      12(1)    19(1)       6(1) 
C(14)   23(1)      25(1)      28(1)      12(1)    15(1)     10(1) 
N(3)     17(1)      18(1)      20(1)       7(1)     10(1)       8(1) 
C(15)   13(1)      23(1)      16(1)       8(1)       8(1)       9(1) 
C(16)   15(1)      21(1)      18(1)       8(1)       7(1)     10(1) 
C(17)   19(1)      23(1)      27(1)     11(1)     12(1)     11(1) 
C(18)   17(1)      27(1)      35(2)     11(1)       8(1)       3(1) 
C(19)   18(1)      32(1)      27(1)       5(1)       0(1)       5(1) 
C(20)   19(1)      29(1)      19(1)       8(1)       4(1)     10(1) 
N(4)     14(1)      19(1)      16(1)       6(1)       7(1)       8(1) 
C(21)   16(1)      21(1)      17(1)       6(1)       6(1)       8(1) 
C(22)   18(1)      26(1)      20(1)       7(1)      10(1)    10(1) 
C(23)   25(1)      27(1)      25(1)       4(1)      12(1)    12(1) 
C(24)   25(1)      22(1)      31(1)       7(1)      12(1)    12(1) 
C(25)   19(1)      21(1)      25(1)       8(1)       9(1)       9(1) 
N(5)     15(1)      20(1)      16(1)       6(1)       7(1)       7(1) 
Cl(1)    24(1)      26(1)      18(1)     12(1)       9(1)     13(1) 
Cl(2)    24(1)      25(1)      29(1)     15(1)     12(1)     12(1) 
Cl(3)    18(1)      33(1)      20(1)       9(1)       7(1)     13(1) 
O(3)     59(2)      37(1)      61(2)       8(1)     41(1)     10(1) 
C(26)   39(2)      34(2)      58(2)     13(2)     28(2)     10(1) 
_____________________________________________________ 
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B6. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for 
3.MeOH.EtOH. 
_____________________________________________ 
 
x                 y                z           U(eq) 
____________________-_________________________ 
 
H(1A)        3099         11906          2065         20 
H(1B)         1214         11208          1564         20 
H(3)            1269         12717          2971         28 
H(4)            1099         12797          4438         31 
H(6)            2457           9861          4569         23 
H(8A)         2847         11586          7345         37 
H(8B)         2461         10099          7212         37 
H(8C)         1049         10574          6948         37 
H(9A)             89           9420            703         22 
H(9B)         1016           8586            452         22 
H(11)        -2177           7172            304         30 
H(12)        -3319           5603            984         35 
H(13)        -1867           5571          2461         34 
H(14)           720           7094          3230         28 
H(15)         3653         10545            849         19 
H(17)         6559         12236          1745         25 
H(18)         8619         13281          3191         34 
H(19)         8319         12667          4515         35 
H(20)         5987         11011          4383         27 
H(22)         4405           8808              85         25 
H(23)         4544           6804              39         30 
H(24)         3982           5752          1162         30 
H(25)         3333           6719          2309         25 
H(103)       8930           2440          1440         54 
H(26A)    10474           4869          1294         51 
H(26B)      9372           3613            466         51 
H(26C)    11072           3755          1126         51 
H(104)        434           4899          4914          45 
H(27A)     2223           6263          4543          55 
H(27B)     2968           5237          4482          55 
H(28A)       404           4071          3225        106 
H(28B)     1958           5002          3104        106 
H(28C)       645           5506          3209        106 
H(105)      4025           4790          2489          59 
H(29A)     5108           5503          4256          46 
H(29B)       5848          6242          3583         46 
H(30A)       5316          3846          3713         46 
H(30B)       6955          4981          3869         46 
H(30C)       5635          4339          2853         46 
______________________________________________ 
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B7.  Torsion angles [deg] for 3.MeOH.EtOH 
______________________________________________ 
 
N(3)-Co(1)-N(1)-C(1)                                107.6(2) 
N(5)-Co(1)-N(1)-C(1)                               -162.5(2) 
N(4)-Co(1)-N(1)-C(1)                                 -73.9(2) 
N(2)-Co(1)-N(1)-C(1)                                  15.9(2) 
Cl(1)-Co(1)-N(1)-C(1)                              -121.3(8) 
N(3)-Co(1)-N(1)-C(9)                                 -15.8(2) 
N(5)-Co(1)-N(1)-C(9)                                  74.1(2) 
N(4)-Co(1)-N(1)-C(9)                                162.6(2) 
N(2)-Co(1)-N(1)-C(9)                               -107.6(2) 
Cl(1)-Co(1)-N(1)-C(9)                               115.3(8) 
N(3)-Co(1)-N(1)-C(15)                             -134.2(1) 
N(5)-Co(1)-N(1)-C(15)                               -44.3(1) 
N(4)-Co(1)-N(1)-C(15)                                44.3(1) 
N(2)-Co(1)-N(1)-C(15)                              134.1(1) 
Cl(1)-Co(1)-N(1)-C(15)                                -3.1(1) 
C(9)-N(1)-C(1)-C(2)                                   102.9(2) 
C(15)-N(1)-C(1)-C(2)                                -128.8(2) 
Co(1)-N(1)-C(1)-C(2)                                  -19.6(2) 
N(1)-C(1)-C(2)-N(2)                                     13.7(3) 
N(1)-C(1)-C(2)-C(3)                                  -167.3(2) 
N(2)-C(2)-C(3)-C(4)                                       0.4(4) 
C(1)-C(2)-C(3)-C(4)                                  -178.6(2) 
C(2)-C(3)-C(4)-C(5)                                      -0.7(4) 
C(3)-C(4)-C(5)-C(6)                                       0.9(4) 
C(3)-C(4)-C(5)-C(7)                                  -178.8(3) 
C(4)-C(5)-C(6)-N(2)                                      -0.7(4) 
C(7)-C(5)-C(6)-N(2)                                    178.9(2) 
C(6)-C(5)-C(7)-O(1)                                  -171.2(3) 
C(4)-C(5)-C(7)-O(1)                                       8.5(4) 
C(6)-C(5)-C(7)-O(2)                                       7.9(4) 
C(4)-C(5)-C(7)-O(2)                                  -172.4(2) 
O(1)-C(7)-O(2)-C(8)                                      -6.2(4) 
C(5)-C(7)-O(2)-C(8)                                   174.8(2) 
C(3)-C(2)-N(2)-C(6)                                      -0.2(3) 
C(1)-C(2)-N(2)-C(6)                                   178.8(2) 
C(3)-C(2)-N(2)-Co(1)                               -179.9(2) 
C(1)-C(2)-N(2)-Co(1)                                   -0.9(3) 
C(5)-C(6)-N(2)-C(2)                                      0.3(4) 
C(5)-C(6)-N(2)-Co(1)                               -179.9(1) 
N(3)-Co(1)-N(2)-C(2)                                 -95.0(2) 
N(1)-Co(1)-N(2)-C(2)                                   -8.8(2) 
N(5)-Co(1)-N(2)-C(2)                                    0.6(6) 
N(4)-Co(1)-N(2)-C(2)                                  74.7(2) 
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Cl(1)-Co(1)-N(2)-C(2)                               168.4(2) 
N(3)-Co(1)-N(2)-C(6)                                  85.3(2) 
N(1)-Co(1)-N(2)-C(6)                                171.5(2) 
N(5)-Co(1)-N(2)-C(6)                               -179.1(4) 
N(4)-Co(1)-N(2)-C(6)                               -105.1(2) 
Cl(1)-Co(1)-N(2)-C(6)                                -11.3(2) 
C(1)-N(1)-C(9)-C(10)                               -103.5(2) 
C(15)-N(1)-C(9)-C(10)                              128.4(2) 
Co(1)-N(1)-C(9)-C(10)                                19.0(2) 
N(1)-C(9)-C(10)-N(3)                                 -12.7(3) 
N(1)-C(9)-C(10)-C(11)                               168.0(2) 
N(3)-C(10)-C(11)-C(12)                               -1.2(4) 
C(9)-C(10)-C(11)-C(12)                             178.2(2) 
C(10)-C(11)-C(12)-C(13)                               1.5(4) 
C(11)-C(12)-C(13)-C(14)                              -0.4(4) 
C(12)-C(13)-C(14)-N(3)                                -1.2(4) 
C(13)-C(14)-N(3)-C(10)                                 1.5(4) 
C(13)-C(14)-N(3)-Co(1)                            -178.1(2) 
C(11)-C(10)-N(3)-C(14)                                -0.4(4) 
C(9)-C(10)-N(3)-C(14)                              -179.7(2) 
C(11)-C(10)-N(3)-Co(1)                             179.3(2) 
C(9)-C(10)-N(3)-Co(1)                                  -0.1(3) 
N(1)-Co(1)-N(3)-C(14)                              -171.0(2) 
N(5)-Co(1)-N(3)-C(14)                               105.4(2) 
N(4)-Co(1)-N(3)-C(14)                              -179.5(4) 
N(2)-Co(1)-N(3)-C(14)                                -84.8(2) 
Cl(1)-Co(1)-N(3)-C(14)                                12.1(2) 
N(1)-Co(1)-N(3)-C(10)                                   9.3(2) 
N(5)-Co(1)-N(3)-C(10)                                -74.2(2) 
N(4)-Co(1)-N(3)-C(10)                                   0.9(6) 
N(2)-Co(1)-N(3)-C(10)                                 95.6(2) 
Cl(1)-Co(1)-N(3)-C(10)                             -167.5(2) 
C(1)-N(1)-C(15)-C(21)                               172.0(2) 
C(9)-N(1)-C(15)-C(21)                                -60.3(2) 
Co(1)-N(1)-C(15)-C(21)                               55.8(2) 
C(1)-N(1)-C(15)-C(16)                                 60.4(2) 
C(9)-N(1)-C(15)-C(16)                              -171.9(2) 
Co(1)-N(1)-C(15)-C(16)                              -55.8(2) 
C(21)-C(15)-C(16)-N(4)                             -69.9(2) 
N(1)-C(15)-C(16)-N(4)                                40.3(2) 
C(21)-C(15)-C(16)-C(17)                           107.6(3) 
N(1)-C(15)-C(16)-C(17)                           -142.2(2) 
N(4)-C(16)-C(17)-C(18)                                0.2(4) 
C(15)-C(16)-C(17)-C(18)                         -177.1(2) 
C(16)-C(17)-C(18)-C(19)                             -1.0(4) 
C(17)-C(18)-C(19)-C(20)                              0.4(4) 
C(18)-C(19)-C(20)-N(4)                                1.0(4) 
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C(19)-C(20)-N(4)-C(16)                               -1.9(4) 
C(19)-C(20)-N(4)-Co(1)                           -179.0(2) 
C(17)-C(16)-N(4)-C(20)                                1.3(4) 
C(15)-C(16)-N(4)-C(20)                            178.9(2) 
C(17)-C(16)-N(4)-Co(1)                            178.9(2) 
C(15)-C(16)-N(4)-Co(1)                               -3.5(2) 
N(3)-Co(1)-N(4)-C(20)                              160.7(4) 
N(1)-Co(1)-N(4)-C(20)                              152.2(2) 
N(5)-Co(1)-N(4)-C(20)                             -124.0(2) 
N(2)-Co(1)-N(4)-C(20)                                65.8(2) 
Cl(1)-Co(1)-N(4)-C(20)                              -30.8(2) 
N(3)-Co(1)-N(4)-C(16)                               -16.6(6) 
N(1)-Co(1)-N(4)-C(16)                               -25.2(2) 
N(5)-Co(1)-N(4)-C(16)                                58.6(2) 
N(2)-Co(1)-N(4)-C(16)                             -111.6(2) 
Cl(1)-Co(1)-N(4)-C(16)                             151.8(2) 
C(16)-C(15)-C(21)-N(5)                              69.6(2) 
N(1)-C(15)-C(21)-N(5)                               -40.9(2) 
C(16)-C(15)-C(21)-C(22)                          -107.7(3) 
N(1)-C(15)-C(21)-C(22)                             141.7(2) 
N(5)-C(21)-C(22)-C(23)                                 0.4(4) 
C(15)-C(21)-C(22)-C(23)                           177.5(2) 
C(21)-C(22)-C(23)-C(24)                               0.4(4) 
C(22)-C(23)-C(24)-C(25)                              -0.5(4) 
C(23)-C(24)-C(25)-N(5)                                -0.2(4) 
C(24)-C(25)-N(5)-C(21)                                 1.1(4) 
C(24)-C(25)-N(5)-Co(1)                             177.7(2) 
C(22)-C(21)-N(5)-C(25)                                -1.2(4) 
C(15)-C(21)-N(5)-C(25)                            -178.7(2) 
C(22)-C(21)-N(5)-Co(1)                            -178.3(2) 
C(15)-C(21)-N(5)-Co(1)                                 4.2(2) 
N(3)-Co(1)-N(5)-C(25)                                -65.7(2) 
N(1)-Co(1)-N(5)-C(25)                              -152.1(2) 
N(4)-Co(1)-N(5)-C(25)                               124.3(2) 
N(2)-Co(1)-N(5)-C(25)                              -161.5(4) 
Cl(1)-Co(1)-N(5)-C(25)                                30.6(2) 
N(3)-Co(1)-N(5)-C(21)                               111.1(2) 
N(1)-Co(1)-N(5)-C(21)                                24.7(2) 
N(4)-Co(1)-N(5)-C(21)                               -58.9(2) 
N(2)-Co(1)-N(5)-C(21)                                15.3(6) 
Cl(1)-Co(1)-N(5)-C(21)                            -152.6(2) 
______________________________________________ 
 
Symmetry transformations used to generate equivalent atoms 
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 Oxidative inactivation of proteins (carbonic anhydrase-I, trypsin, chymotrypsin 
and 20S proteasome) by non-heme iron complexes, and glutathionylation of non-heme 
cobalt complexes mimicking the N5 coordination environment like that of biologically 
important cofactor cobalamin or B12 (Cbl) are reported. Different non-heme ligand sets 
or inhibitors were used to inactivate different proteins. Carbonic anhydrase-I (CA-I) and 
20S proteasome were inactivated by iron complexes in the presence of O2 and a 
reductant (DTT), consistent with a pathway involving the reductive activation of O2, 
whereas serine proteases trypsin and chymotrypsin were inactivated by ferryls (single 
turnover), and by an iron complex in presence of biologically relevant oxidant, H2O2 
(catalytic conditions). Analysis of the CA-I inactivation products by SDS-PAGE, ESI-MS 
and LC/MS/MS confirmed that the protein is inactivated by oxidation of amino acid side 
chains (His, Trp and Met) rather than fragmentation of the protein backbone. On the 
other hand, amino acid analysis of serine proteases inactivation products confirmed that 
residues Cys, Tyr, and Trp were oxidized under single turnover condition while the 
residue tyrosine was oxidized selectively under catalytic conditions. Control experiments 
preclude the role of ROS, and supported the role of a metal-based oxidant responsible 
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for protein inactivation in all the cases. 
A low spin Co(III) cobalamin model complex derived from a polypyridyl 
pentadentate N5 non-heme ligand was synthesized and characterized fully by X-ray 
crystallography, UV−vis, IR, 1H-NMR and 13C-NMR spectroscopies, and mass 
spectrometry (HRMS). Kinetic and thermodynamic studies on the reaction of this cobalt 
complex along with another related congener with glutathione were performed in 
aqueous buffer to generate biomimetic species of glutathionylcobalamin, an important 
form of cobalamin found in nature. The reaction follows second order kinetic, with both 
the rate constants and the observed equilibrium constants smaller than the rate 
constants and equilibrium constant of the reaction of aquacobalamin and GSH to give 
glutathionylcobalamin. Glutathionylation showed significant pH dependence, where 
rates increased with pH. Taken together, these results suggest that glutathionylation is 
a general reaction for Co(III) complexes related to Cbl. 
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